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Abstract
The primary aim of this research was to investigate safety and potency of an aroA mutant 
of Pasteurella multocida serotype B;2 (JRMT12) as a live vaccine candidate in cattle 
against experimental haemonhagic septicaemia (HS). To do this, three different 
experiments were set up to study the responses of calves to vaccination with the aroA 
strain and their response to challenge with the parent wild type 85020 strain one week after 
vaccination: 1) Different routes of vaccination, intranasal (IN) and intramuscular (IM) 
using two doses of 10  ^ CFU of the aroA strain with a 4-week interval; 2) Different doses 
(10^, 10  ^and 10  ^CFU) injected twice IM; 3) A single IM vaccination with 10  ^CFU.
Safety of JRMT12 was assessed by determination of clinical responses (rectal temperature 
and demeanour) and changes in serum amyloid A (SAA) and haptoblobin (Hp), taken as 
indicators of the progress and severity of infection. IN injection of calves with c,10^ CFU 
of the mutant did not cause any clinical signs of HS. IM injection of a  10  ^ CFU of the 
mutant caused some typical clinical signs of the disease such as dullness and there was a 
clinical response manifested by a rise in rectal temperature and SAA levels. IM injection of 
calves with lower doses (c.10^ andalO^ CFU) of JRMT12 did not cause disease symptoms 
but significantly increased the concentrations of SAA levels at 3 hours after both the 
primary and booster IM vaccinations. Our results showed that the mutant could be safely 
administered to calves.
Potency was assessed by measurement of serum antibodies (IgG and IgM) to P. multocida 
B:2 and by survival rate after subcutaneous challenge with the wild type strain. 
Vaccination with JRMT12 was able to induce a strong antibody response only after a 
second IM dose. Lower IgG titres were detected after the second vaccination with 10  ^ or 
10  ^ CFU. A similar pattern of response was seen with IgM titres. IN-vaccinated calves 
showed no detectable antibody response to one or two doses of vaccine. All of the animals 
vaccinated twice IM with JRMT12 at doses of 10 ,^ 10  ^and 10  ^CFU were solidly immune 
to challenge with 10  ^ CFU of P. multocida B:2 wild type. A single IM vaccination of 
calves with 10  ^ CFU of JRMT12 did not confer protection against challenge. IM 
vaccination twice with 10  ^ CFU was considered an optimum dose that fully protected 
calves but showed no obvious reactogenicity.
Immunogenic components of P. multocida to which antibody was raised during different 
stages of vaccination and challenge were detected by SDS-PAGE and immunoblotting. 
Antibody staining of the bands of 51, 37, 30, 26 and 16 kDa, only appeared with sera taken 
one week after the second vaccination. These 5 bands were thus identified as potentially
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immunogenic components with roles in protection against challenge. For further 
identification of immunogenic components, outer-membrane proteins (OMPs) of the 
bacterium were prepared and two of them (37 and 30 kDa bands) were subjected to 
identification by mass spectrometry (MS). The 30 kDa was identified as OmpH and the 37 
kDa band was identified as OmpA of P. multocida by MASCOT analysis of the data.
A possible contributory role of cellular immunity against HS was investigated in calves 
given a single IM dose of 10  ^ CFU and in control calves after challenge. A lymphocyte 
stimulation assay was used to assess the effects of a CFE of P. multocida on peripheral 
blood mononuclear cells (PBMCs) isolated from calves at different times after challenge. 
The results were indicative of a possible immunosuppressive effect of challenge with P. 
multocida B:2 on calf PBMCs. Such an effect does not appear to have been reported 
previously, was in keeping with the lack of response to CFE observed with PBMCs from 
the in vivo experiment. The suppressive effect was further investigated by in vitro 
experiments. Calf PBMCs obtained from a normal calf were treated with CFE for 1 h 
before adding ConA. Addition of CFE at 50 pg/ml caused a 3-5 fold decrease in the 
proliferative response to ConA. The suppressive effect was only observed with CFE from 
two other P. multocida strains, a P. multocida serotype D strain (a causative agent of 
atrophic rhinitis in pigs) and, with lower suppressive activity, P. multocida serotype A3 (a 
causative agent of pneumonia in cattle). The active part of the suppressive agent(s) was 
likely to be protein. Heating at 80°C for 5 min completely destroyed the suppressive 
properties and an OMP preparation of P. multocida B:2 markedly suppressed the 
proliferative response of PBMCs to ConA. Dialysis of CFE with a cut off 10,000 Da did 
not alter its suppressive effects.
B cell and T cell subpopulations (CD4^, CD8  ^ and yd"^ ) in normal calf PBMCs were 
identified and the changes in their relative proportions after different treatments was 
investigated using FACS analysis. The ratio of proliferating and non-proliferating fractions 
was also determined, to assess the proliferative status of each population. CD4^ and CD8  ^
T cells were the principal cells which proliferated in response to ConA and whose 
proliferation was suppressed by a CFE of F. multocida. The suppression of CD4^ T cells 
was not due to an adverse toxic effect of CFE on the cells, as CFE alone did not decrease 
the number of these cells. ConA increased the percentage of proliferating CDd'^ T cells by 
10-fold compared to the control cells, but CFE treatment before addition of ConA allowed 
only a 3-fold increase. Our in vitro experiments showed that P. multocida contains a 
component(s) with the potential to inhibit the proliferative réponse of CD4^ and CD8  ^T 
cells.
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IFNy = interferon gamma
Ig = immunoglobulinIHA = indirect haemagglutination
IL-(X) = interleukin-(number)
IM = intramuscular
IN = intranasal
IROMP -  iron-dependent OMP
lU = international units
XVII
= litres/millilitres/microlitres
LAL = Limulus amoebocyte lysate
LB = Luria-Bertani broth
LD50 = lethal dose 50%
LPS = lipopolysaccharide (endotoxin)
MHC = major histocompatibility complex
M/mM//xM = molar/millimolar/micromolar
min = minute(s)
mRNA = messenger RNA
Mw -  molecular weight
NaCl = sodium chloride
NB = nutrient broth
NK = natural killer
NO = nitric oxide
NOD = nucleotide-binding oligomerisation domain
NSAID = nonsteroidal ant-iinflamatory drug
OAV = oil adjuvant vaccine
ODx nm = optical density at wavelength X nm
OMP = outer-membrane protein
PABA = paia-aminobenzoic acid
PAGE = polyacrilamide gel electrophoresis
PAR = progressive atrophic rhinitis
PBMC = peripheral blood mononuclear cell
PBS = phosphate-buffered saline
PHA = phytohaemagglutinin
PGR = polymerase chain reaction
Pm = Pasteurella multocida
PMN -  polymorphonuclear
PMPT = passive mouse protection test
PMT = Pasteurella multocida toxin
PRR = pattem-recognition receptor
p.s.i. = pound per square inch
PWM = pokeweed mitogen
RNA = ribonucleic acid
rpm = revolutions per minute
RPMI = Roswell Park Memorial Institute
rRNA = ribosomal RNA
RT = room temperature
SAA = serum amyloid A
SBA = sheep blood agar
sec -  second(s)
SDS = sodium dodecyl sulphate
SIR = subcutaneous inflammatory response
TOR = T cell receptor
TEMED = tetramethylethylenediamine
Th (1/2) = helper T cell (1/2)
TLR = toll-like receptor
TNF-a = tumor necrosis factor alpha
tRNA = transfer RNA
Tris = Tris (hydroxymethyl) aminoethane
v/v = volume by volume
w/v = weight by volume
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Chapter 1 
INTRODUCTION
1.1 History and taxonomy of the family Pasteurellaceae
Members of bacterial family Pasteurellaceae are small (0.2-2 pm), Gram-negative, 
chemoorganotrophic, non-motile facultatively anaerobic coccobacilli or rods. They are, 
with few exceptions, fermentative and oxidase- and catalase-positive (Bisgaard, 1994). 
Organisms belonging to the family Pasteurellaceae can colonize mucosal surfaces of the 
respiratory, alimentary, genital tracts and cause diseases in different mammals, birds, and 
reptiles (Jacques, 2002). For a long time it was believed that the family consisted only of 
three genera: Pasteurella described by Trevisan 1887, Actinobacillus by Brumpt 1910, and 
Haemophilus by Winslow et a l 1917, but several other groups of organisms that exhibit 
complex phenotypic and genotypic relationships with these genera were also included 
(Boot & Bisgaard, 1995; De Alwis, 1999). After the redesignation of the organisms 
formely known as [Pasteurella] haemolytica into the new genus Mannheimia in 1999 
(Angen et a l, 1999), substantial reclassification was made amongst the bovine 
Pasteurellaceae. Since then, researchers have added some new genera, such as Histophilus 
(Angen et a l, 2003), Gallibacterium (Christensen et a l, 2003; Christensen et a l, 2004a), 
Actinobacillus (Christensen & Bisgaard, 2004), Volucribacter (Christensen et a l, 2004b), 
Nicoletella (Kuhnert et a l, 2004), m à Avibacterium (Blackall et a l, 2005) into the family. 
Pasteurellaceae now includes 11 genera {Pasteurella, Actinobacillus, Haemophilus, 
Lonepinella, Mannheimia, Phocoenobacter, Gallibacterium, Histophilus, Volucribacter, 
Avibacterium, Nicoletella) and 62 species. At least four genera and several more species 
are expected to be named soon (Olsen et a l, 2005).
1.1.1 Diseases caused by Pasteurellaceae
The Pasteurellaceae include a large number of important human pathogens, such as 
Haemophilus influenzae, H.ducreyi and Actinobacillus actinomycetemcomitans, and 
animal pathogens such as Pasteurella multocida, Mannheimia haemolytica, Haemophilus 
paragallinarum, H. parasuis, H. somnus, Actinobacillus equuli, A. pleuropneumoniae, and 
A. suis. Some of these pathogens are distributed widely, causing economically significant 
diseases in a variety of hosts (Jacques, 2002).
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1.1.2 The genus Pasteurella
Classification of the genus Pasteurella is based on genetic relationships, determined by 
DNA:DNA hybridisation, rRNA:DNA hybridisation and 16S rRNA sequencing (De 
Alwis, 1999). On the basis of these methods, this genus consists of 11 species. Pasteurella 
, sensu stricto, includes Pasteurella multocida with 3 subspecies {multocida, septica, and 
gallicida), P. dagmatis, P. gallinarum, P. voluntium, P. stomatis, P. avium, P. langaa, P. 
anatis and Pasteurella subspecies A and B (Boot & Bisgaard, 1995; Kawamoto et a l, 
1990; Ki’ause et al., 1989).
1.1.3 The species Pasteurella multocida
Pasteurella multocida has been recognised as an important veterinary pathogen for over a 
century. Its importance as a human pathogen, causing respiratory diseases and infections of 
the central nervous system (Berge et a l, 2002; Capitini, 2002), has been increasingly 
recognised in the last 50 years (Johnson, 1994; Johnson et a l, 2000; Sheikli et a l, 1996). 
These result largely from animal bite wounds.
1.1.3.1 Cell morphology
P. multocida is a Gram-negative, non-motile, non-spore-forming, short rod or 
coccobacillus, 0.2-0.4 by 0.6-2.5 pm in size (De Alwis, 1999). Cells can occur singly, in 
pairs and occasionally as a chain or filaments, especially after repeated laboratory 
subcultures of old cultures or cultures grown under unfavourable conditions. In young 
cultures and animal tissues it shows the typical bipolar staining (safety pin shape), 
particularly with Leishman or methylene blue stain (Solano et a l, 1983). Virulent strains 
are usually capsulated and their capsules can be seen in organisms isolated from hosts and 
laboratory cultures supplemented with serum or hlood (De Alwis, 1999).
1.1.3.2 Colonial characters
The organism grows on most of the common nutrient media. Special media such as brain- 
heart infusion (BHI) and dextrose-starch agar (DSA) provide relatively complete resources 
and result in better growth. Supplementing media with serum or blood enriches the 
medium and also supports good growth (OIE, 2000). Colonies from 18-24 hour cultures 
grown aerobically at 35-37°C on solid media are 1-3 mm in diameter. Freshly isolated 
colonies on tryptose agar or CSY (Casein, Sucrose, Yeast) agar enriched with blood are
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approximately 2 mm in diameter after 24 hours at 37°C (Wijewardana, 1986). Colonies on 
blood agar are of approximately 1 mm in diameter and on plain unenriched media may be 
smaller (OIE, 2004). The moiphology of colonies is mainly related to capsular type 
(Wijewardana, 1986). Colonies may vary in size, depending on the degree of capsulation. 
When freshly isolated or grown on media containing serum, they vary from larger greyish 
to smaller ones that give a yellowish-green or bluish-green iridescence when viewed in 
transmitted light. Rough colonies, that are generally the smallest, may be produced as 
result of loss of capsular material, due to long term storage or after several passages in 
synthetic media. This process is called dissociation and is associated with reduction of 
virulence and loss of antigenicity (Heddleston, 1966; Pemi & Nagy, 1976). Capsule 
production, iridescence and virulence sometimes can be regained or enhanced by animal 
passage (Rimler & Rhoades, 1989).
1.1.3.3 The serotypes of Pasteurella multocida
A classification system (or typing) for host and disease specificity has been made based on 
antigenic differences in capsular polysaccharides and also differences in antigenic variety 
of lipopolysaccharides (LPS, also called O antigen). Based on capsular typing there are 5 
different capsular types named A, B, D, E, and, F (Rimler et a l, 1989). The other method 
is “somatic typing” based on O antigen of the organism in which 16 different somatie types 
(numbered 1 to 16) have been distinguished (Heddleston et a l, 1972; Namioka & Murata, 
1964). It is generally accepted that designation of serotypes should be based on a 
somatic:capsular combination. Among different systems, two systems commonly in use are 
the Namioka-Carter and the Carter-Heddleston systems. Asian and African haemorrhagic 
septicaemia-causing serotypes (Section 1.5.1) are designated 6:B and 6:E, respectively, in 
the former system, while in the latter system they are designated B:2 and E:2, respectively 
(OIE, 2000).
Generally, type A capsular Pasteurella are mainly associated with fowl cholera, rabbit 
snuffles (also called recurrent purulent rhinitis), and respiratory diseases of animals. Type 
D is the predominant type in atrophic rhinitis of pigs and occasionally has been isolated 
from the lungs of ruminants or other species. Type F is mainly isolated from turkeys. 
Types B and E are usually associated with haemorrhagic septicaemia of cattle and 
buffaloes.
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1.2 Diseases in animals
Specific serotypes of P. multocida are associated with different diseases in cattle, buffalo, 
sheep, goats, camels, pigs, poultry and other animals.
1.2.1 Haemorrhagic septicaemia (HS)
HS is the most economically important disease of the group of diseases caused by different 
Pasteurella. The disease, unlike some other pasteurelloses where the agent plays a 
secondary role, is a primary pasteurellosis. It is an acute, fatal septicaemic disease of cattle, 
buffaloes, camels, feral ruminants and pigs (De Alwis, 1999). It is dealt with in more detail 
in section 1.5.
1.2.2 Fowl cholera (FC)
Fowl cholera is a primary pasteurellosis that in acute form results in septicaemia and death. 
Chronic forms of the disease are the predominant form in industrial poultry husbandry. FC 
is a noticeable cause of economic loss in the developed poultry industry and in traditional 
poultry husbandry (Rimler, 1997). Capsular serogroups A, B, D, E, and F have been 
reported; all but serogroup E have been isolated from avian hosts. A very wide range of 
birds including wild birds are susceptible to this disease. Serotypes A :l, A:3 and A:4 are 
the common cause of the FC in most countries, although all of the 16 somatic serotypes of 
the group A, and some types of group D have also been reported (Brogden et a l, 1978; De 
Alwis, 1993; OIE, 2004).
The records of FC date back to 1600. Many of the earliest studies on understanding the 
role of microorganisms in infectious diseases were with this disease. The use of attenuated 
agents as vaccine, for immunisation against diseases was invented by Louis Pasteur one 
hundred years ago, for this disease (De Alwis, 1999).
1.2.3 Atrophic rhinitis (AR)
Atrophic rhinitis or progressive atrophic rhinitis (PAR) is an infectious disease of swine 
characterised by purulent nasal discharge, shortening or twisting of the snout, atrophy of 
the turbinate (conchal) bones and reduced productivity. The most severe progressive form 
is caused by infection with toxigenic strains of Pasteurella multocida alone or in 
combination with Bordetella bronchiseptica (OIE, 2004). AR is an important disease in
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intensive pig breeding. Pasteurella multocida type D and toxigenic strains of type A are 
associated with the disease (Davies et a l, 2003; Pijoan, 1988). Bordetella bronchiseptica 
as a normal inhabitant of the upper respiratory tract of the animal, is believed also to play a 
role in pathogenesis of the disease. Production of a dermonecrotic toxin is the main cause 
of the atrophy in turbinates. Concurrent infection with B. bronchiseptica or the action of 
certain iiiitants like aerial pollution creates favourable conditions for the proliferation of P. 
multocida (Chanter et a l, 1989; De Alwis, 1999; Hamilton-Miller & Shah, 1996).
1.2.4 Bovine pasteurellosis
Bovine pasteurellosis or pneumonic pasteurellosis is a pneumonia of mainly beef cattle that 
is caused by different viruses or stress as predisposing factors and P. multocida capsular 
serogroup A or Mannheimia (Pasteurella) haemolytica type A1 as secondary pathogen. 
There is no consistency in the somatic types involved. This is unlike haemorrhagic 
septicaemia, which is a primary pasteurellosis caused by specific serotypes (B:2 or E:2) of 
the P. multocida.
The disease has some other synonyms such as bovine enzootic pneumonia, shipping fever, 
transit fever, and bovine respiratory disease (BRD) complex that show the conditions that 
are relevant in specific circumstances. It is economically the most important disease of the 
beef and dairy industry of the United States, as it is believed that losses due to this disease 
are greater than those due to all other diseases put together. A challenge model has been 
developed, whereby challenged calves developed progressive pneumonic disease similar to 
that seen in natural cases of disease (Dowling et a l, 2002). The pasteurellae that cause 
pneumonic pasteurellosis are canied in the upper respiratory tract (URT) of calves. In the 
case of Mannheimia (Pasteurella) haemolytica type A l, the bacterium is not easily 
detected in the URT of healthy calves, but is shed and can be easily isolated in calves that 
are stressed in some way or affected with another concurrent infection. The URTs of 
stressed or otherwise diseased calves can be easily colonised by Mannheimia (Pasteurella) 
haemolytica A l. In the case of P. multocida, no such relationship between stress and 
ability to colonise has been observed (De Alwis, 1999).
1.2.5 Pasteurellosis in sheep and goats
Pasteurellosis of sheep and goats is a pneumonia in all ages of these animals, and a distinct 
septicaemic syndrome involving pleurisy and pericarditis in young lambs. The 
predominant organism that causes disease in sheep and goats is Mannheimia (Pasteurella)
Saeed Ataei Kachooei, 2007 6 INTRODUCTION
haemolytica biotype A (Porter et a l, 1995). Experimental disease indicates an association 
between the incidence and severity of the disease and LPS chemotype and suggests an 
important role for LPS chemotype in determining host-species susceptibility to lung 
infection (Hodgson et a l, 2003). This is probably the most economically important 
bacterial disease of sheep and goats (De Alwis, 1999).
1.3 Molecular biology of Pasteurella multocida
Over a century has passed since the isolation of pasteureilae from birds by Pasteur in 1880 
and from cattle by Kitt in 1885. During this time, considerable research has been done on 
members of the family but this has resulted in only very limited understanding of the 
organism. Substantial progress towards a better understanding has been made recently, 
with a number of groups studying different aspects of the molecular biology of P. 
multocida (Hunt et al.  ^2000).
1.3.1 Non-protein cellular components
1.3.1.1 Capsule
Many strains express a polysaccharide capsule on their surface, and isolates can be 
differentiated serologically by capsular antigens into serogroups A, B, D, E, and F (Carter, 
1967; Rimler & Rlioades, 1987). The capsule is composed of polysaccharides, 
lipopolysaccharides (LPS) and a variety of proteins. The capsule antigen of P. multocida 
responsible for serotype specificity is intimately associated with lipopolysaccharide (LPS) 
material. Both LPS and polysaccharides are absorbed onto erythrocytes and are believed to 
play a role in passive haemagglutination (Rimler & Rhoades, 1989). Both the capsule- 
specific antigen and LPS can be adsorbed onto erythrocytes from crude cell extracts. 
However, passive haemagglutination tests, with serum containing antibodies against the 
capsule-specific antigen and LPS, usually show a reaction only with the capsule-specific 
antigen (Rimler & Rlioades, 1989). Capsular antigens of P. midtocida serotypes B and E 
have been shown to be immunogenic and protective in cattle against serotype E challenge 
(Nagy & Penn, 1976). However, non-capsulate and capsulate organisms of serotype A, 
strain X-73, were reported to be equally effective in immunising birds against fowl cholera 
(Heddleston, 1966). The capsule of serotype A strain is composed of hyaluronic acid and is 
believed to be an important virulence factor (Watt et al., 2003). Acapsular mutants of 
serotype B:2 have also been prepared and shown to be avirulent and protective as a live 
vaccine (Boyce & Adler, 2000; Boyce & Adler, 2001).
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The genes related to capsule synthesis have been identified in avian and bovine isolates 
(Boyce et a l, 2000a; Boyce et a l, 2000b; Chung et a l, 1998). The capsule biosynthetic 
locus of P, multocida B:2 consists of 15 genes, which can be grouped into three functional 
regions. Regions 1 and 3 contain genes proposed to encode proteins involved in capsule 
export, and region 2 contains genes proposed to encode proteins involved in 
polysaccharide biosynthesis (Boyce & Adler, 2000).
1.3.1.2 Lipopolysaccharide (LPS)
P. multocida LPS has chemical and biological properties such as endotoxic properties 
which are similar to those found in many species of Gram-negative bacteria. As antigens, 
LPSs have been associated with immune protection of animals and are believed to be the 
chemical basis for the specificity of the somatic typing system (Brogden & Rebers, 1978). 
LPSs have been purified from many different strains of P. multocida. In common with LPS 
from bacteria of the family Enterobacteriaceae, chemical analysis has shown that they 
contain lipid A, 2-keto-deoxyoctonate, L-glycero-D-mannoheptose, glucose and 
glucosamine. Other sugars encountered amongst LPSs from different strains were 
galactose, rhamnose, D-glycero-D-mannoheptose and galactosamine (Rimler et a l, 1984). 
Although in LPS isolated from two serotype A strains of P. multocida, a possible structure 
for the heptose region has been described, in which a triheptose unit linked to a 2-keto-3- 
deoxyoctulosonic acid residue the complete structure of P. multocida LPS has not been 
determined. A heptosyltransferase (an enzyme required for the addition of heptose to LPS) 
mutant of PC-associated P. multocida was prepared and shown to be attenuated in chicken 
(Haiper et a l, 2003). Further studies showed that the predominant LPS glycoforms 
isolated from this mutant were severly truncated (Harper et a l, 2004).
LPS is believed to play an important role in the pathogenesis of diseases caused by 
different serotypes of P. multocida. In the HS-associated serotype B LPS is thought to be 
responsible for toxicity and to play an important role in the pathogenesis of the disease 
(Horadagoda et a l, 2002). Turkeys were relatively resistant to the lethal effects of LPS 
obtained from FC-related P. multocida serotype A (Rlioades & Rimler, 1987). Crude 
preparations of LPS have been associated with protection in experimental models but it has 
been shown that purified preparations are not immunogenic (Muniandy et a l, 1998).
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1.3.2 Protein cellular components
It is generally believed that certain proteins may play an important role in protective 
mechanisms (Bosch et a l, 2004; Grossmann et a l, 1998; Lugtenberg et a l, 1986). With 
the exception of some strains in serotypes A and D, the protein components of P. 
multocida are non-toxic (De Alwis, 1999).
1.3.2.1 Outer-membrane proteins (OMPs)
The outer membrane of Gram-negative bacteria plays an important role in interaction of 
the organism with the environment. It is composed of phospholipids, LPS and OMPs. The 
LPS and phospholipids together compose a permeability bander to hydrophobic 
compounds, and OMPs mainly function in transport of various molecules in and out of the 
organism and also participate in maintenance of outer membrane stability (Nikaido, 2003). 
It is generally believed that many virulence factors are surface located and many of them 
may play important roles in colonization and invasion. OMPs can also act as immunogenic 
components as they are in direct contact with host immune system during the process of 
infection (Greenwood et a l, 2002). Thus, OMPs have attracted major attention in the 
studies of host pathogen interactions. The sarcosine-insoluble membrane fraction (Sarkosyl 
extract) from different bacteria has been extensively used as an OMP preparation since it 
has been shown that it is highly enriched in OMPs (Davies et a l, 1990; Morton et a l, 
1996; Ravaoarinoro et a l,  1994; Zhao et a l, 1995).
In P. multocida seven proteins have been shown to be present in outer membrane: OmpH-1 
(Luo et a l, 1997), OmpA (Pm0786) (Gatto et a l, 2002), Omp87 (Pm1992) (Ruffolo & 
Adler, 1996), Ompl6 (P6-like protein, Pm0966) (Kasten et a l, 1995), PlpB (Cooney & Lo,
1993), Lpp and GlpQ (Lo et a l, 2004). OmpW and Omp47 are possible orthologues of 
characterised OMPs in other species (Boyce et a l, 2006). Most of the recent studies on 
identification and characterization of OMPs of P. multocida has been focused on serotype 
A (causative agent of fowl cholera in chicken), since the whole genome of this serotype 
has been sequenced.
Whole-cell protein profiles of a wide range of HS-causing strains showed a high degree of 
homogeneity. B:2 strains showed a major protein band at 32 kDa while E:2 strains showed 
a major band at 37 kDa. Other bands at 27, 45 and 47 kDa were shared by all strains, 
iiTespective of serotype (Johnson et a l, 1991). Proteins of 29 and 36 kDa in the
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cytoplasmic and periplasmic fractions and a protein of 42 kDa in the membrane fraction 
were only partially protective in mice (Ramdani & Adler, 1994).
Certain outer membrane proteins have been reported to be immunogens for P. multocida 
serogroups B and E (Dawkins et a l, 1991a; Srivastava, 1998; Tomer et a l, 2002). In both 
A and B serotypes an 87 kDa OMP has been identified as an immunogenic component 
(Chaudhuri & Goswami, 2001; Ruffolo & Adler, 1996). An oil adjuvant vaccine, prepared 
from the OMP extract of P. multocida B:2, showed complete protection in buffalo calves. 
Immunoblotts indicated that the 44, 37 and 30 kDa fractions were major immunogens (Pati 
et a l,  1996). About 20 polypeptide bands ranging from 16 to 90 kDa were identified by 
SDS-PAGE profiles of OMP preparation from P. multocida serotype B:2. Three of them 
with molecular weight of 31, 33 and 37 kDa were considered to be the major OMPs, based 
on band thickness and intensity of staining. By immunoblotting studies, using whole-cell 
hyperimmune serum raised in rabbits as well as buffalo immune sera, it became evident 
that the polypeptide of 37 kDa was the most antigenic OMP in the profiles of all the 
isolates (Tomer et a l, 2002). Iron-dependent outer-membrane proteins (IROMPs) 
produced by both P. multocida and M. haemolytica are specific receptors for iron-binding 
host molecules, such as transferrin, lactofemn, haemoglobin or haem, and are expressed in 
the absence of free iron. They play an important role in bacterial pathogenesis and are 
potential vaccine candidate antigens (Bosch et a l, 2004). The rapid spread and 
multiplication of invasive bacteria like P. multocida, requires efficient mechanisms for 
scavenging iron for growth (Veken et a l,  1996). Very low levels of free iron are available 
inside the host, due to the presence of iron-binding glycoproteins such as haptoglobin, 
transferrin, and lactoferrin. Generally two mechanisms of iron sequestering systems have 
been identified in bacteria. The first one is by secretion of siderophores to remove iron 
from the host iron-binding proteins. Then, the iron-siderophore complex can be captured 
and internalised by special receptors that are located in the outer membrane. P. multocida 
is able to secret a siderophore called multocidin (Subramaniam et a l, 1997). The second 
mechanism is through iron-binding proteins expressed on the outer membrane of the 
bacterium, which are able to bind to transfemn and lactofemn. In the Asian HS-associated 
serotype of P. multocida an 82-kDa iron-regulated OMP has been found which specifically 
binds bovine transfemn. In contrast, P. multocida serotype B;3,4 that is associated with HS 
in feral ruminants, did not express transfemn-binding proteins (Veken et a l, 1996). It was 
found that convalescent-phase sera from buffaloes reacted against some iron-restricted and 
other proteins, indicating that these proteins were produced in vivo (Veken et a l, 1996). In 
addition to these mechanisms, some bacterial proteins have the ability to bind 
haemoglobin. This enables them to use heme as an iron source for their growth. HgbA is a
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haemoglobin binding protein identified in P. multocida serogroup D from pig (Bosch et a l, 
2002b) and HgbB was identified in a P. multocida A:1 fowl cholera-associated strain (Cox 
et a l, 2003). It has been shown, in a study on different HS-causing serotypes of P. 
multocida, that all tliree investigated serotypes, B:2, E:2 and B:3,4, bound haemoglobin 
while none of them bound lactoferrin. Transferrin binding was restricted to strain B:2 
(Veken et a l, 1996). However, although almost all of these receptors from P. multocida 
were immunogenic, none of them protected mice against infection when used alone as a 
vaccine antigen (Bosch et a l, 2004).
The gene psl (P6-like protein product) was shown to be present in all 16 somatic serotypes 
(Kasten et a l, 1995). However, immunization of turkeys with recombinant P6 OMP failed 
to protect them against challenge despite the production of high titres of antibody to this 
protein (Kasten et a l, 1997b).
The ompH gene, encoding a porin that is a major structural protein of the outer membrane 
of P. multocida, is negatively regulated by iron and glucose (Bosch et a l, 2001; Luo et a l, 
1997; Luo et a l, 1999). OmpH is a homologue of the P2 porin of H. influenzae and a 
monoclonal antibody against OmpH of P. multocida was passively able to protect mice 
against infection (Marandi & Mittal, 1996). OMP87 (oma87, Pml992) has high similarity 
to the D15 OMP of H, influenzae (Ruffolo & Adler, 1996). This OMP from H. influenza 
was protective (Loosmore et a l, 1997). Recombinant OMP87 protein from P. multocida 
B:2 reacted with serum of vaccinated animals (Chaudhuri & Goswami, 2001).
OmpA is the major OMP of P. multocida. OmpA (35 kDa) is a homologue of Omp5 in H. 
influenzae and may be involved in adherence to host cells via heparin and/or fibronectin 
bridging (Dabo et a l, 2003). OmpA has significant identity to E. coli OmpA which 
functions as porin and plays important role in outer membrane stability (Nikaido, 2003). 
An ompA-likc gene has been characterized in P. multocida serotype A3 that is associated 
with bovine pneumonic pasteurellosis (Dabo et a l, 2003).
A 39 kDa protein from P. multocida serotypes A:1 and A:3 induces active and passive 
protection in chicken or turkeys (Ibrahim et a l, 2000; Rimler, 2001). CoiTelation has been 
found between the amount of the 39 kDa protein in crude capsular extract (CCE) and 
pathogenicity and capsule thickness (Borrathybay et a l, 2003b). The 39 kDa molecule has 
recently been characterized as a lipoprotein and named Pip B {Pasteurella lipoprotein B) 
(Tabatabai & Zelir, 2004).
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The omplô  gene, encoding a 16 kDa OMP has been found among different serotypes of P. 
multocida (Goswami et a l, 2004). A 39 kDa protein is associated with capsulai' 
preparations and has been characterised as an adhesion factor (Ali et a l, 2004; 
Borrathybay et a l, 2003a).
1.3.2.2 Enzymes
P. multocida produces a number of enzymes, which are believed to play an important role 
in the pathogenesis of the diseases caused by this species.
Hyaluronidases are enzymes that are generally associated with invasive mechanisms in 
bacteria, helminths and snake venoms. Several Gram-positive bacteria produce the enzyme 
and it has been associated with their virulence (Rimler et a l, 1984; Rimler & Rhoades,
1994). Several studies documented that serogroup B strains isolated from cases of HS 
produced hyaluronidase (Carter & Chengappa, 1980; Rimler & Rhoades, 1994; Rimler, 
2000). The role of the enzyme produced by type B strain in pathogenesis is uncertain, 
especially in view of the fact that it has not been demonstrated in serogroup E strains (De 
Alwis, 1995). Hyaluronidase production has been examined with different isolates from 
different hosts in different countries. These studies showed that all B:2 strains had activity 
against hyaluronic acid (Rimler & Rlioades, 1994).
Neuraminidase has been associated with virulence in other microorganisms but the 
association of P. multocida neuraminidase with a specific disease process or its role as a 
virulence factor is inconclusive as it was shown there was no conelation between virulence 
and activity of the enzyme in a mouse model (Drzeniek et a l, 1972). Serogroups A, B, D 
and E produce this enzyme (Drzeniek et a l, 1972; Muller & Krasemanu, 1974; Scharmarm 
& Blobel, 1972). Its activity is found to be highest in strains of serogroups of A and D 
(Drzeniek et a l, 1972).
1.3.2.4. Toxins
HS-causing B serotypes have not been shown to produce characterised exotoxins. 
However, cytotoxic effects of serotype B:2,5 on macrophages have been shown by in vivo 
and in vitro tests, and HS-associated strains were reported to produce a vacuolating 
cytotoxin (Shah et a l, 1996). No further reports on this toxin have been appeared.
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Dermonecrotic toxin, also known as P. multocida toxin (PMT), is produced by P. 
multocida serotype D and is the principle virulence factor involved in the pathogenesis of 
swine progressive atrophic rhinitis (PAR) (Foged, 1991). PMT induces localised osteolysis 
in nasal turbinates through increased osteoclastic bone resorption (Hunt et a l, 2000). No 
coiTelation has been found between production of toxin and somatic serotype (Rimler & 
Brogden, 1986). Antiserum, made against the toxin from a swine serogroup D strain, 
showed neutralising activities against the lethal effects of the toxin from rabbit serogroup 
D and swine serogroup A and D strains from different geographic origins (Rimler et a l, 
1989; Rimler & Rhoades, 1989).
The toxA gene has been cloned in E. coli and it has also been shown that the cloned gene is 
able to express functional PMT (Petersen et a l, 1991). Toxin related sequences, have not 
been characterised in other P. multocida serogroups (Hunt et a l, 2000). Attempts were 
made to express a protective epitope of PMT in B. bronchiseptica to create a single­
component mucosal vaccine. This study showed that vaccination of mice with this live 
recombinant strain was not able to raise antibodies against PMT, although an antibody 
response to B. bronchiseptica was detected (Rajeev et a l, 2003). Intranasal challenge of 
mouse and pig with toxigenic strain of P. multocida serotype D causes suppression of 
antibody response to immunization with ovalbumin. Challenge with non-toxigenic strains 
did not cause this immunosuppressive effect. The study also showed that a CFE of the 
toxigenic strains, was also able to cause the suppression (Jordan et a l, 2003).
1.3.2.5 Bacteriocins
Bacteriocins are proteins produced by many species of bacteria and show bactericidal 
properties that are active against their own species or closely-related species (De Alwis, 
1999). Some bovine and avian isolates of P. multocida are able to produce bacteriocins 
(Chengappa & Carter, 1977; Lee et a l, 1988; Lee et a l, 1991). In a study on serotypes A, 
B, and D, about half of the species were found to produce bacteriocins. The importance of 
bacteriocins in pathogenesis of the disease is not clear (De Alwis, 1999).
1.3.3 Common antigens
P. multocida contains some antigens which also can be found in other related Gram- 
negative bacteria. Antigenic relationships with Haemophilus, Actinobacillus, Escherichia, 
Mannheimia and Neisseria have been recorded (Bain & Knox, 1961; Prince & Smith, 
1966; Schryvers et a l, 1986).
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Both PfhBl and PfhB2 (filamentous haemagglutinins) have been recognised as two new 
potential virulence factors in the genome sequence of the avian isolate P. multocida 
(Pm70). In particular, P, multocida has two genes pfhBl (7845 bp) and pfhB2 (11757 bp) 
with significant homology (Figure 1) to the filamentous hemagglutinin gene in Bordetella 
pertussis (May et a l, 2001). They contain domains with strong homology to FhaB of 
Bordetella pertussis. FhaB governs the adherence of B. pertussis to host cells and is a 
major component of acellular vaccines for prevention of human whooping cough (see also
1.4.4). Similar proteins have also been described in several other pathogens, including 
Haemophilus ducreyi (LspAl and LspA2), Neisseria meningitidis, Serratia marcescens, 
Proteus mirabilis, ^nà Pseudomonas aeruginosa (May et a l, 2001).
Figure 1 Homology of PfhB domains between P. multocida, H. ducreyi, and B. 
pertussis
Homology comparisons among PfhBl, PfhB2, from P. multocida, LspAl, LspA2, firam H. 
ducreyi, FhaB from B. pertussis, and P76 from Haemophilus somnus are presented. 
Homologous domains are represented with the same coloured boxes and the direct repeats 
in p76 and PfhA2 are patterned in blue. The N(P/Q)NG(I/M) extracellular processing motif 
is indicated and the integrin-binding protein motifs are shown as dark puiple lines (May et 
a l, 2001).
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1.4 Genetics of P. multocida
The complete genome sequence of P. multocida serotype A:3 (Pm70), a common avian 
clone, has been published (May et a l, 2001). The genome of Pm70 is a single chromosome 
of 2,257,487 base pairs and contains 2,014 predicted coding regions, 6 ribosomal RNA 
opérons, and 57 tRNAs (May et a l, 2001). The function of about half of the Pasteurella 
mutocida coding regions has been determined.
1.4.1 Virulence and virulence-associated genes
Identifying virulence genes has constituted a considerable proportion of studies on P. 
multocida in order to understand pathogenesis at the molecular level and also because of 
the potential for vaccine development. Despite considerable reseaich, only a small number 
of virulence-associated genes have been definitively identified. These include those 
involved in the production of toxin, capsules, haemagglutinins and those involved in amino 
acid, nucleotide, and iron transport and metabolism (Boyce et a l,  2002).
Using signature-tagged mutagenesis, different genes have been identified that, when 
inactivated, cause a reduction in virulence. In serotypes of P. multocida associated with 
fowl cholera, 25 genes have been identified by this method in a mouse intraperitoneal 
model (Fuller et a l, 2000). In a similar study, 15 mutants have also been identified to be 
attenuated for chickens, 5 of which were also attenuated in the mouse. Some of the 
attenuated mutants were due to alterations in metabolic genes (Harper et a l, 2003).
The P. multocida dam gene, encoding DNA adenine methylase, has been cloned and 
sequenced in fowl cholera associated serotypes. Similar to other Gram-negative species, 
this enzyme regulates the expression of virulence genes. In other bacterial species. Dam is 
important in regulating and coordinating several cell functions, including initiation of 
chromosome replication, DNA repair, and gene transcription. As a result of the role of 
Dam in DNA repair, bacteria with altered Dam activity have increased mutability. Its role 
in regulation of gene transcription, particularly of genes involved in pathogenicity, causes 
strains with altered Dam activity to be attenuated. It has been shown that alteration of Dam 
activity in P. multocida causes increased spontaneous mutation frequency and attenuation 
in mice (Chen et a l, 2003).
Several genes that may be involved in virulence and immunity in P. multocida and other 
bacterial pathogens were noted from the genome sequence, such as the type IV fimbrial
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subunit gene ptfA, capsule biosynthesis genes, genes involved in iron acquisition, the skp 
gene and those encoding outer membrane porin ompH and the omp%l OMP. Thus, 
although the molecular basis for pathogenicity of P. multocida is not well understood, 
genomic analysis has identified 104 genes (about 7% of the coding density of the genome) 
that may be virulence-associated (Figure 2) (May et a i, 2001). However, the mechanisms 
that control expression of these potential virulence factors have not been precisely 
determined (Chen et a i, 2003).
Figure 2 A comprehensive view of the biochemical processes involved in P. 
multocida pathogenicity
Orthologues previously identified as virulence factors in other organisms are represented. 
Principal functional categories are shown in bold. Potential coding sequences related to 
these functions are arranged within each correspondingly coloured category (May et a i, 
2001 ).
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1.4.2 Iron-related genes
More than 2.5% of the P. multocida genome is devoted to genes encoding proteins 
homologous to known proteins involved in iron uptake or acquisition (May et a l, 2001). It 
has been shown that the expression of these genes increases under iron-limiting conditions 
(Faustian et a l, 2001). The /h r  gene of P. multocida, which encodes a predicted protein of 
147 amino acids, has been cloned. The Fur protein, which exhibits Fe^’^ -dependent DNA- 
binding activity, is the major regulator of genes encoding haem- or haemoglobin-binding 
proteins (Bosch et a l, 2001; Ekins & Niven, 2002). A/hr-knockout mutant of P. multocida 
showed constitutive expression of high-molecular-mass proteins that have been associated 
with iron-uptake processes (Bosch et a l, 2001).
Expression of the hgbA gene produced two outer-membrane proteins, of 40 and 60 kDa in 
iron-depleted cultures using 2,2'-dipyridyl (DPD) as an iron chelator (Garrido et a l, 
2003a). It is believed that hgbA is widespread in P. multocida strains regardless of their 
serotype or the animal from which they were isolated (Bosch et a l, 2002b). Although 
antibodies against the 40 and 60 kDa molecules were present in the serum of infected mice, 
they were not able to cause protection against challenge. It has been demonstrated that the 
hbpA gene is negatively regulated by iron, manganese and haemin through a fur- 
independent pathway (Gamdo et a l, 2003a).
The hgbB gene from a fowl cholera-associated P. multocida strain, has been cloned and 
characterized. HgbB is an outer-membrane protein which shai'es 68 and 69% similarity to 
the haemoglobin/haemoglobin-haptoglobin binding protein HI0712 from Haemophilus 
influenzae Rd and HgpC from H. influenzae B, respectively. Inactivation of hgbB did not 
affect the ability of P. multocida to bind hemoglobin, nor its ability to produce disease in a 
mouse model. In addition, recombinant HgbB did not confer any protection against 
homologous or heterologous challenge (Cox et a l, 2003).
After iron has been captured, its transport into the cell requires the activity of the exbB, 
exbD and tonB gene products which supply the energy necessary for this process (Ganido 
et a l, 2003a). The expression of these genes in P. multocida is under iron control. It has 
been suggested that in fowl cholera-associated serotypes each of these three genes is 
necessary for virulence (Bosch et a l, 2002a).
The P. multocida znuACB genes encode a high-affinity zinc-uptake system. Contrary to 
that determined so far for all other znuACB bacterial systems known, P. multocida znuACB
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genes are not under the control of the zur gene, which is absent in this bacterium, but rather 
aie controlled by the iron-uptake regulator (fur) (Garrido et ah, 2003b).
1.4.3 Metabolic genes
There have been few metabolic genes cloned or characterized from P. multocida. A gene 
encoding the P. multocida adenylate cyclase has been described. It was very similar to its 
E. coli homologue with the deduced protein sequences indicating N-terminal catalytic and 
C-terminal regulatory domains (Mock et al., 1991). The beta-subunit of the P. multocida 
tryptophan synthase has been cloned, with high level of similarity to homologues from 
other Gram-negative bacteria (Jablonski et a l, 1996). A galE mutant of P. multocida 
prepared by allelic exchange showed attenuation in the mouse. galE encodes an enzyme 
required for the epimerization of UDP-glucose to UDP-galactose prior to LPS assembly, 
and this mutant probably expresses an altered LPS (Harper et a l, 2004). The galE gene of 
P, multocida is able to complement a galE mutant of Salmonella (Fernandez de 
Flenestrosa, 1997). The GalE protein is most closely related to a H. influenzae homologue 
with 85% identity. A transposon mutant deficient in heptosyl transferase III was shown to 
be attenuated in mice and chickens (Harper et a l,  2003). waaQpM , encoding a putative 
enzyme, is required for the addition of heptose to LPS. It was shown that the predominant 
LPS glycoforms of a waaQpM mutant strain were severely truncated and the strain was 
attenuated. It was also noted that the attenuation was not due to increased semm sensitivity 
(Haiper et a l, 2004).The gene firA  encodes a glucosamine transferase which appears to be 
involved in the biosynthesis of Lipid A (Dieker & Seetharam, 1991).The skp gene has been 
cloned but its function is not very well understood. The skp and firA  genes are believed to 
be a part of an operon governing the first steps of lipid A synthesis (Delamarche et a l, 
1995; Manoha et a l, 1994).
Transposon insertion in the purN  gene of a fowl cholera-associated P. multocida caused 
attenuation for both chickens and mice. This gene encodes the enzyme 5'- 
phosphoribosylglycinamide transformalase N, which catalyzes the fourth step of de j î o v o  
purine biosynthesis (Harper et a l, 2003). The ability to synthesize purine nucleotides from 
simple precursors has been identified as being important for bacterial growth in vivo, and it 
has been reported recently that several of the genes involved in purine biosynthesis in P. 
multocida are up-regulated in bacteria harvested from the blood of infected chickens 
(Boyce et a l, 2002).
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The gene encoding the P. multocida AroA (5-enolpyruvylshikimate-3-phosphate synthase) 
enzyme has been exploited to produce different attenuated mutants of avian and bovine 
serogroups. The enzyme catalyses the step in the shikimate pathway for the biosynthesis 
of aromatic amino acids (L-phenylalanine, L-tyrosine and L-tryptophan). A defective aroA 
sequence creates a dependence for growth on aromatic compounds. Different deletion 
mutants of the aroA gene of P. multocida strains have been prepared (see also 1.12.4) 
using allelic exchange and shown to be attenuated for virulence in chicken or mouse 
(Homchampa et a l, 1992; Homchampa et a l, 1994; Homchampa et a l, 1997; Scott et a l, 
1999; Tabatabaei, 2000; Tabatabaei et a l, 2002).
1.4.4. Genomic diversity and homology
The genetic map o f P. multocida Pm70 represents the only P. multocida genome to have 
been sequenced. However genomic heterogeneity within P. multocida has been studied 
using different methods of molecular epidemiology such as repetitive sequence-based PCR 
(rep-PCR) and amplified fragment length polymorphism (AFLP) (Amonsin et a l, 2002), 
ribotyping (Blackall et a l, 1998), rRNA gene restriction site polymorphism analysis 
(ribotyping) and restriction endonuclease analysis (REA) (Amonsin et a l, 2002; Blackall 
et a l, 1998; Dabo et a l, 1999; Wang et a l, 2007). Avian strains showed considerable 
genomic diversity (Blackall et a l, 1998; Blackaiu et a l, 2001). The generation of genetic 
maps of other serotypes of P. multocida to compare their organisation could help to 
understand whether the restriction polymoiphism relates to a distinct association between 
the genome architecture and properties such as virulence, host specificity and other 
metabolic or pathological phenotypic aspects (Hunt et a l, 2000).
1.4.5 Gene regulation
To survive and multiply inside and outside the host, bacterial pathogens require the 
coordinated expression of a range of genes. By gene transcription experiments, it has been 
proved that genes are differentially regulated under different in vitro conditions and during 
different in vivo stages. It is likely that pathogens continually alter their gene expression 
profiles in response to the innate immune system and to the environment of their host, as 
they move from one host niche to another (Boyce et a l, 2002) or under different cultural 
conditions like low iron, different temperatures, different pHs, and different media (Xia et 
a l, 2002). Whole-genome microanays of P. multocida serotype A (Pm70) have been 
utilized to compare levels of gene expression during growth in rich and minimal media. It 
has been shown that the expression of a total of 669 genes (one third of the genome) was
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detectably altered over the eourse of the experiment. A large number (n = 439) of genes, 
including those involved in energy metabolism, transport, protein synthesis, and binding, 
were expressed at higher levels in rich medium. Genes with increased expression in 
minimal medium (n = 230) included those encoding amino acid biosynthesis and transport 
systems, outer membrane proteins, and heat shock proteins (Faustian et a l, 2002).
There are only a very limited amount of data available on how expression of bacterial 
virulence genes changes during stages within the host. A comparison has been made 
between gene expression profiles of P. mutocida harvested from the blood of septicaemic 
chickens in the last stages of fowl cholera and those from bacteria grown in rich medium. 
It was shown that 40 genes were differently expressed in all of three chickens. The 
majority of the up-regulated genes were involved in amino acid transport and metabolism 
and energy production pathways to cope with the host environment. Interestingly, bacteria 
from only two of the three infected animals had a gene expression profile highly similar to 
that observed during growth under iron-limiting conditions, suggesting that severe iron 
starvation may not always occur during P. multocida infection (Boyce et a l, 2002).
1.5 Distribution and importance of haemorrhagic 
septicaemia (HS)
1.5.1 Definition
HS, also called septicaemic pasteurellosis or barbone, is an acute septicaemic disease that 
occurs in cattle, yaks, camel, and water buffalo, and to a much smaller extent, pigs and 
horses. HS principally affects cattle and buffaloes. It is a primai'y pasteurellosis caused by 
serotypes B:2 or E:2 o îPasteurella multocida (Radostits et a l, 2000).
1.5.2 Global distribution
HS has been recorded in Asia, Africa, America and Europe. It has never occuiTed in 
Oceania (De Alwis, 1999). According to FAQ (1991), some southern European states have 
recorded a low occuiTence whilst low sporadic or endemic status has been reported in 
many south American states. According to Animal Health Yearbook 1994, there have been 
some reports of the disease from southern and eastern European countries but they were 
not confirmed by serotyping. In Africa, HS occurs in a number of countries in all regions 
of this continent (De Alwis, 1992).
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HS is endemic in some areas of Asia and is the classical disease of southern Asia 
(Radostits et a l, 2000). It has also been reported to be endemic in the Near and Middle 
East. The disease was reported from Iran in 1930s, and a serious study of the disease was 
made at the Razi Vaccine and Serum Research Institute in 1935. This resulted in the 
introduction of a saponin-adjuvanted vaccine in 1938 using a native isolated strain (Delpy 
& Rastegar, 1938; Kaweh et a l, 1960). HS occurs in South and Southeast Asia, including 
Indonesia, Myanmar, Laos, Cambodia, the Philippines, Thailand and Malaysia. The 
disease was first reported in 1880 in Malaysia (Benkirane, 2002). In Sri Lanka, it was 
reported in 1911 for the first time. Routine vaccination was introduced in 1957 after the 
epidemics in the mid-1950s (Wijewardana, 1986). HS is believed to have been introduced 
into the Philippines in buffaloes imported from Hong Kong in 1902 and in a shipment of 
cattle imported from Shanghai in 1903. In Japan the disease was reported in 1923 for the 
first time but there is no report of HS after 1954 (De Alwis, 1999).
In North America, HS is not endemic although there have been some reports of the disease 
in bison. Some cases of sporadic outbreaks have been recorded in dairy and beef cattle in 
different areas of the USA (Chengappa et a l, 1982; Heddleston et a l, 1967). In Canada, an 
outbreak was reported in beef calves in 1994 (Rimler & Wilson, 1994). In some South 
American countries HS is likely to occur due to the significant population of water buffalo 
and conditions similar to those in tropical areas of Asia.
1.5.3 Economic importance
The actual economic losses due to HS are difficult to determine. The problem is that many 
factors need to be considered in computing economic losses (De Alwis, 1999). HS is a 
disease that is most prevalent in situations where husbandry practices are poor and, 
concuiTently, disease surveillance systems are often not well developed. Reported losses, 
therefore, merely reflect the trend whereas actual losses may be considerably higher. Very 
few countries have made actual estimates of economic losses (De Alwis, 1992). Sudden 
epidemics do occur occasionally in non-endemic areas, causing heavy losses in all age 
groups of animals. In endemic areas, most adult animals have acquired natural immunity, 
and the disease is prevalent among young animals in the 6 months to 2 years age group. 
Such losses, though insidious in nature and difficult to estimate, are economically 
significant (De Alwis, 1992).
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1.5.3.1 Losses in Asia
HS is economically the most important disease of cattle and buffaloes, particularly in Asia 
and to a lesser extend in Africa (Benkirane, 2002). According to FAQ reports, Asia 
harbours 447 million cattle and 161 million buffaloes, 33% and 95% of the world’s 
populations of these species, respectively (FAO, 2003). The high population of buffaloes 
in Asia and the higher susceptibility of this species to HS, have made more significant the 
economic losses due to HS in Asia. 37% of the milk in Asia is produced by buffaloes but, 
in India, where the production of milk is the highest, this amount is 50%. It was estimated 
that, in India, during the past four deeades 46-55% of all bovine deaths were due to HS 
(Dutta et a l, 1990). In Myanmar about 50% of the governmental measures in animal 
disease control is spent on HS (Johnson et a l, 1989). According to an FAO report in 1979 
in Pakistan 34.1% of all deaths in susceptible animals were caused by HS and economic 
losses in 1978 were estimated at US$189 million (De Alwis, 1999). In most of the Asian 
countries, cattle and buffaloes are used for draft power mainly in the rice fields. ConcuiTcnt 
seasonal outbreaks of the disease in farms, during the harvest season, highlight the 
significance of the economic losses caused by HS in these countries. In most estimates of 
losses, only direct losses, i.e. value of animals that die of HS, has been taken into account. 
A true estimate of losses should cover all of the factors, which also constitute the above 
mentioned indirect losses (Benkirane, 2002).
1.5.3.2 Losses in Africa
Africa has less of the world’s cattle and buffalo populations, with only 15% and 2% for 
cattle and buffaloes, respectively. As a result, the disease is of less economic importance in 
Africa than in Asia. There are some other diseases that are economically more important 
than HS, These include the African endemic diseases, such as trypanosomiasis, theilleriosis 
and contagious bovine pleuropneumonia; and also rinderpest and FMD (Foot and Mouth 
Disease), which are common in both Africa and Asia (De Alwis, 1999).
1.6 Haemorrhagic septicaemia: clinical aspects
1.6.1 The disease
Haemonhagic septicaemia is an acute, highly fatal disease characterised by terminal 
septicaemia, principally affecting cattle and buffaloes. It is caused by two serotypes of the 
bacterium Pasteurella multocida known as the Asian and African serotypes, designated
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6:B and 6:E by the Namioka-Carter system and more recently B:2 and E:2 by the Carter- 
Heddleston system, respectively (OIE, 2004).
Using modem techniques of serotyping, it has been indicated that type B strains of P. 
multocida, other than serotype B:2, have also been involved in some cases of HS (Rimler 
& Wilson, 1994). In view of the wider spectrum of serotypes of the B and E groups, and 
the involvement of species of animals other than cattle and buffaloes it may be more 
appropriate to give the disease a broader definition as: an acute, fatal, septicaemic disease 
caused by strains of P. multocida belonging to the serogroups B or E, commonly in cattle 
and buffaloes and also in pigs and feral ruminants (De Alwis, 1999).
Unlike other pasteurelloses, where the pasteurella plays a secondary role, HS is a primary 
pasteurellosis. The disease is experimentally reproducible using pure cultures of the 
causative organism alone and is preventable by vaccines incorporating the specific 
serotypes. Thus, HS is a specific form of pasteurellosis, occurring mainly in cattle and 
buffaloes. This is similar to the situation of typhoid in humans, and pollorum in poultry, 
which are both caused by a specific strain of Salmonella in a specific host species (De 
Alwis, 1992).
1.6.2 Source of infection
Pasteurella multocida dose not survive for a long time in the environmental conditions 
outside the host. Thus, the environment could not be the major source of infection although 
the organism survives for relatively longer in moist conditions (De Alwis, 1999). It has 
been shown that the organism survives in sterilised soil for 2-3 weeks but in the natural 
mud where animals live this survival period is not more than 24 hours (De Alwis, 1999). It 
is believed that pasteureilae can survive in animal tissues and perhaps in carcases for a few 
days. Thus, carcases dumped into rivers are likely to be a method of spreading the 
infection. However, no pei*manent source of infection has been established outside the host 
(De Alwis, 1999).
Outbreaks of HS are more likely to occur when clinically affected or carrier animals are 
introduced into the herd. In experimental development of the disease, 10  ^ to 10^  ^ colony 
forming units (CPU) are required to produce the infection by the natural routes (De Alwis 
et a l, 1990). In the natural transmission of the infection it is not clearly understood if or 
how such a large dose of the bacterium is transmitted to an animal. It has been suggested 
that unknown circumstances may alter the susceptibility of animals so that a smaller
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number of bacteria can cause the disease. Alternatively, it can be speculated that bacteria 
grown in vitro are not as virulent as those multiplied in the host (De Alwis, 1999). Isolates 
from clinical cases and from latent canier animals showed no difference in virulence for 
mice (Wijewardana, 1986) but, as the presence of host-specific virulence factors has been 
shown (Harper et a l, 2003), this remains to be investigated in the natural hosts.
1.6.3 Route of infection
Natural routes of infection are by inhalation and/or ingestion of contaminated materials. 
The disease is reproducible using oral drenching or aerosol sprays, although experimental 
infections have shown that large numbers of organisms are required to set up an infection 
by the intra-nasal or the oral route. However, the dose required to produce clinical disease 
is not always reproducibly the same and also results with a given dose are not always the 
same (De Alwis, 1994).
Artificial routes of infection are used in most experiments because they are more 
reproducible. Subcutaneous injection of 10"^  to 10  ^ CFU is able to cause the disease. 
Different routes of experimental infection are loosely related to the course of the disease, 
clinical syndrome and the extent of pathological lesions. Generally, intranasal and oral 
infections result in a longer course of the disease and more profound lesions. On the other 
hand subcutaneous inoculation of the agent results in a rapid onset of disease, a shorter 
course and less marked pathological lesions (De Alwis, 1999).
1.6.4 Clinical signs
Haemonhagic septicaemia is usually manifest by a rapid course, sudden onset of fever, 
profuse salivation, severe depression and death in about 24 hours. These are the usual 
symptoms observed in the disease. Oedema in the submandibular region is common and in 
later stages the affected animal may show severe dyspnoea and alimentary tract disorders. 
In outbreaks, sudden death without any previous signs is usually reported (Horadagoda et 
a l, 2002).
The disease is more acute and has a shorter course in buffaloes than cattle (De Alwis, 
1994). Generally as a syndrome, during the progression of the disease, three phases can be 
distinguished. In the first phase which is the phase of temperature elevation (often 
unnoticed) loss of appetite, depression, general apathy and increased temperature are 
dominant signs. The fever (41-42°C) lasts throughout the course, but the temperature drops
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to subnormal levels during the terminal phase, a few hours before death. In the second 
phase respiratory signs such as increased respiratory rate, laboured breathing, clear nasal 
discharge and salivation are dominant. Submandibular oedema may appear in this stage. 
Nasal discharges become mucopurulent with increased severity of the disease. In the third 
phase recumbency is the most obvious sign and terminal septicaemia occurs and death 
follows in almost all of the cases (OIE, 2004). The incubation period is usually 1-3 days, 
and the course of the disease may range from sudden death, with no observable clinical 
signs, to a protracted course extending up to 5 days (Radostits et a l, 2000).
At post-mortem examination, the first obvious lesion is subcutaneous oedema, particularly 
in the submandibular and brisket region. Other lesions include petechial to ecchymotic 
haemoiThages, congestion and/or consolidation of lungs, fibrinous pneumonia, pleurisy and 
pericarditis (OIE, 2004).
1.6.5 Pathogenesis of HS
It appears that after entry into an unexposed susceptible animal, the initial site of 
multiplication is the tonsillar region. The host defence mechanisms, both specific and non­
specific, will interact with the pathogen which will lead either to clinical disease or 
arrested infection in which the animal becomes an immune earner. The dose of infecting 
organisms, amongst other factors, is an important determinant of outcome, at least in 
experimental infection (De Alwis, 1999; Horadagoda et a l, 2001; Radostits et a l, 2000).
There is little evidence that HS-causing strains of P. multocida produce specific exotoxins 
that are required for pathogenesis. However, it has been shown that sera from buffaloes 
recovering from HS are able to inhibit the vacuolating cytotoxic activity of the organism 
and of culture supernatants known to contain free toxin (Shah et a l, 1996). The production 
of hyaluronidase by HS-causing strains of serotype B:2 has been implicated in 
pathogenesis (Carter & Chengappa, 1980), but other B type strains sueh as B:3,4, which 
are able to produce a syndrome similar to HS, are not able to produce hyaluronidase. 
Therefore, the importance of this enzyme is not clear (De Alwis, 1999; Rimler & Rhoades, 
1994). An 82-kDa iron-regulated OMP, has been detected in serotype B:2 which 
specifically binds bovine transferrin, but the protein has not been detected in serotype 
B:3,4. (Veken et a l, 1996).
The role of endotoxin of P. multocida in the pathogenesis of the disease is important 
(Heddleston & Rebers, 1975; Horadagoda et a l, 2002; Musa et a l, 1972). It has been
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shown that administration of endotoxin to buffalo calves produces a clinical syndrome 
similar to HS. Endotoxin can also promote an acute phase response (APR) including 
production of tumour necrosis factor-a (TNFa). The APR is a non-specific, systemic host 
response that is cytokine-mediated. It results from tissue injury or infection and is an 
integral part of the host defence mechanism (Horadagoda et a l, 2002). Therefore, LPS can 
facilitate the multiplication and spread of the bacterium in the host, and further reinforces 
the role of the capsule in virulence mechanism (Boyce & Adler, 2000; De Alwis, 1999). 
Many of the putative virulence-associated components were identified in P. multocida 
serotype A chicken isolates such as fimbriae and filamentous hemagglutinin (Fuller et a l, 
2000; Harper et a l, 2003) and it is not clear in many cases whether they are also present in 
the HS-associated strains (Section 1.4.1).
1.6.6 Bacteriology
Tonsillar tissues are believed to be the initial site of multiplication after the entry of the 
pasteurella organisms into the host. Pasteurella can be isolated from blood only during the 
terminal stages of the disease. At the time of death, around 10^-10^ CFU/ml appear in the 
blood. Multiplication of the bacterium occurs in the carcass. Under tropical conditions, 
bacterial counts in the carcass’s blood can reach to lO^ -^lO^  ^CFU/ml (De Alwis, 1999).
1.7 Epidemiology
HS, in most countries of Asia and sub-Saharan Africa is an endemic disease. According to 
the incidence and distribution of the disease, Asian countries have been classified into 
three categories; countries where the disease is endemic or sporadic, countries with 
clinically suspected but not confirmed cases of the disease, or countries free of the disease 
(Benkirane, 2002).
1.7.1 Seasonal distribution
The distribution of HS is related to climatic conditions, husbandry practices, and the type 
of animals reared. HS is generally associated with wet, humid weather conditions and most 
outbreaks occur during the wet seasons. Outbreaks can occur at all times of the year but 
those occurring during wet seasons tend to spread, presumably due to the longer survival 
of the organism under moist conditions (Radostits et a l, 2000). In the endemic areas, 
outbreaks usually coincide with onset of rains which is normally preceded by a long dry 
period (Francis et a l, 1980). The conelation with wet weather conditions has been proved
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by studies in India and Pakistan. Seasonal occuiTence has been well documented in India, 
with the majority of the outbreaks occuning during wet seasons from July to September, 
with the peak in August. Seasonal occurrence has also been confirmed in Pakistan (Sheikh 
et a l, 1996). In India, the disease occurred more frequently in states that received a higher 
annual mean rainfall (Dutta et a l,  1990).
1.7.2 Serotype and strain distribution
The Asian serotypes belong to capsular type B only whereas the African serotypes are 
types B and E (OIE, 2004). Egypt and Sudan have reported the presence of both E and B 
serotypes (Hassanin et a l, 1995; Shigidi & Mustafa, 1979) and from Cameroon there is 
one record of an outbreak caused by the B strain (Martrenchar & Njanpop, 1994). There 
are indications that serotype B may be present in some East African countries (De Alwis, 
1999).
North American isolates are recorded as B:2 serotypes. Re-examination of these isolates 
using serotyping and fingeiprinting methods revealed that a bison strain isolated from 
Montana in 1965 was serotype B:3,4, not B:2 as earlier reported (Rimler & Wilson, 1994). 
Other serotypes associated with sporadic septicaemic pasteurellosis resembling HS in feral 
ruminants include serotype B:1 isolated from antelope in the United States, and B;4 from 
bison in Canada. Cenetic fingerprinting has established that the North American B:2 
strains possesses a DNA profile different from that of the Asian B:2 strains (De Alwis,
1999).
HS has not been reported from United Kingdom. However, from deer with a septicaemic 
disease a strain has been isolated which has been identified as serotype B:3,4. This strain 
has been used as a live vaccine in a large-scale trial (Section 1.12.2) (Jones & Hussaini, 
1982; Myint et a l, 1987).
From an epidemiological standpoint, DNA fingeiprinting serves as an additional tool to 
serotyping methods in strain identification (Wilson et a l, 1992). Recently, a global 
collection of over 200 isolates associated with classical HS disease has been examined 
using DNA fingerprinting along with other serotyping methods. According to this, a large 
number of DNA fingerprint profiles have been identified amongst HS-associated group B 
isolates (Rimler, 2000).
Saeed Ataei Kachooei, 2007 27 INTRODUCTION
1.7.3 Host susceptibility
Buffaloes are generally believed to be more susceptible to HS than cattle, and in this 
species, the disease course is shorter. The overall mean case-fatality rate for buffaloes is 
nearly three times as high as in cattle (Radostits et a l, 2000). In Sri Lanka it has been 
shown that whilst the herd infection rate was not significantly different in cattle and 
buffalo herds, the morbidity rates within affected buffalo herds was considerably higher 
(De Alwis et a l, 1990; Wijewardana, 1986). The buffalo is highly sensitive to circulatory 
LPS and this may be the reason for higher mortality rate in buffalo than in cattle 
(Horadagoda et a l, 2002). Reports are available on the association of HS serotypes with 
disease in other species. Sporadic outbreaks of HS have been reported among pigs caused 
by the Asian B:2 serotype (Verma, 1988). It has been shown in Sri Lanka that goats kept in 
close contact with buffaloes clinically affected with HS developed neither disease nor 
immune carrier status. In fact, experimentally, large doses of organism (10"^  to 10*^  CFU) 
were able to cause disease only in 10% of goats (Wijewardana, 1986). Infection with B:2 
serotype has been recorded among elephants associated with outbreaks in cattle and 
buffaloes in Sri Lanka (de Alwis & Sumanadasa, 1982). HS has been reported among 
camels in Sudan (De Alwis, 1999; Hassanin et a l, 1995). In the United States, septicaemic 
disease caused by serotype B:1 has been recorded in antelopes and that caused by B:3,4 in 
elks. In Canada, the disease caused by B:4 has been recorded in bison (Rimler & Wilson, 
1994).
1.7.4 Morbidity and mortality rate
Both morbidity and mortality rates vary between 50 and 100% and animals that recover 
require a long convalescence. Morbidity and mortality are influenced by a variety of 
factors and their interactions. These factors are 1) host species and age; 2) immunological 
factors; 3) endemic and non-endemic areas; 4) husbandry methods (Radostits et a l, 2000). 
Relatively higher morbidity rates have been recognised among young animals aged 6 
months to two years. In Sri Lanka for example, 65% and 77% of all HS death among cattle 
and buffaloes, respectively, were in animals under 2 years of age (Wijewardana, 1986).
When clinical disease is established, case fatality approaches 100% if treatment is not 
earned out sufficiently early (in the pyrexic stage). Morbidity is high in non-endemic areas 
when HS occurs as sporadic outbreaks and also when it is first introduced in clean areas. 
Morbidity in endemic areas is related to herd immunity status, the greater the percentage of 
immune to non-immune animals, the lower will be the morbidity (Radostits et a l, 2000).
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1.7.5 Carrier animais
The presence of the HS organisms in the nasopharynx of healthy cattle and buffaloes is 
well documented (De Alwis et a l,  1990; Wijewardana, 1986). Further investigations 
showed that the presence of nasopharyngeal earner animals was related to recent outbreaks 
of the disease, indicating that the percentage of nasopharyngeal earners is related to recent 
exposure to disease. Approximately 45% of healthy cattle in herds associated with the 
disease harbour the organism in comparison to 3-5% in cattle from herds unassociated with 
the disease (Radostits et a l, 2000).
Pasteureilae are not confined to the nasopharynx and associated lymph nodes of animals 
could harbour the organism (Wijewardana, 1986). It has been observed that some animals 
display a positive status, then negative, and subsequently positive again, indicating an 
intermittent appearance of the organism in the nasopharynx. It has been concluded that two 
types of earner status exist - latent and active. In the active carriers the bacterium is present 
in the nasopharynx and from this site is shed in nasal secretions. Latent earners harbour the 
organism in tonsils in which the bacterium is believed to multiply and intermittently spill 
over into the nasophai’ynx (De Alwis et a l, 1990). It has been shown by immunochemical 
techniques that the exact place in which Pasteurella is localized is the crypt of the tonsil 
and not the tonsilar tissue (Horadagoda & Belak, 1990). The mechanisms involved in 
converting a latent carrier to active earner have not been revealed yet (De Alwis, 1999).
1.7.6 Epidemiological cycle
A presumptive epidemiological cycle (Figure 3) for haemorrhagic septicaemia has been 
suggested (De Alwis, 1994). The old theory that, under stress, carrier animals break down 
into clinical cases does not appear to hold, since all earner animals also have high antibody 
levels believed to be protective (De Alwis, 1999). In an endemic area, after one outbreak of 
HS, a large number of surviving animals become latent earners. They inteiTnittently shed 
the organisms, the frequency diminishing with time. Since the herd immunity is high, there 
would be no new clinical cases. The first clinical case occurs when a shedder comes into 
contact with a susceptible animal, which is a new animal to a herd, such as a newborn after 
the previous outbreak, or as an introduced animal from elsewhere (De Alwis, 1994).
Movement of animals has frequently been associated with epidemics. Movements can 
precipitate disease in two ways. Firstly, the animals being moved may be earners and able 
to infect susceptible stock. Secondly, the animals being moved may be susceptible and
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then may be infected from native immune earners. In either case explosive outbreaks could 
result (De Alwis, 1999).
1.8 Diagnosis of HS
1.8.1 Clinical diagnosis
A clinical diagnosis can be made on the basis of characteristic signs, gross pathological 
lesions, herd history, morbidity and mortality patterns, species susceptibility, and age 
group affected. A tentative clinical diagnosis is generally important because the immediate 
investigation of control measures to prevent spread of disease is based on a field diagnosis 
(OIE, 2004). As HS occurs mostly under poor husbandry conditions, no clinical signs 
whatever may be observed in the first case of an outbreak (Radostits et a l, 2000). Since 
morbidity and mortality rates are highly variable and are dependent on a number of factors, 
such as the presence of susceptible animals, the previous occuiTence of HS in the herd and 
climatic conditions, whether it is an enzootic area, the age group and species affected, 
whether the animals had been vaccinated, and finally their interactions, they must be 
viewed against the background of these surrounding circumstances (De Alwis, 1994).
1.8.2 Laboratory diagnosis
Laboratory confirmation of diagnosis is by isolation in culture or in mice and identification 
of the agent by biochemical and serological methods as type B or E. An outline of a 
scheme for routine laboratory tests for diagnosis of HS from test materials (De Alwis, 
1994), is shown in Figure 4. Laboratories in countries where HS is endemic receive a 
variety of specimen types and quality for diagnosis. A wide range of laboratory diagnostic 
tests have been developed which mainly include: 1) culture on specific media for isolation; 
2) biochemical and serological tests for identification and serotyping; 3) nonserological 
tests to complement presumptive identification of serotype; 4) molecular methods for 
strain identification of serotypes (OIE, 2000).
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Figure 3 Presumptive epidemiological cycle for haemorrhagic septicaemia 
(De Alwis, 1994)
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Figure 4 Scheme for routine laboratory diagnisis of haemorrhagic septicaemia 
(De Alwis, 1994)
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1.8.2.1 Microbiological tests
The conventional method of laboratory diagnosis is based on isolation of the organism 
from animal tissues and identification by biochemical and serological methods. The 
organism can be cultured from blood or nasal swab from an animal within a few hours of 
death. From older carcasses, a long bone is used for culture from the bone marrow 
(Radostits et a l, 2000). Pasteurellae grow on ordinary media such as nutrient agar, or 
enriched media such as tryptose agar and CSY agar (Casein Sucrose Yeast), with or 
without 5% sterile blood. Direct cultuie yields results only with fresh material. 
Contaminants and post-mortem invaders, when present, overgrow the pasteurellae (OIE, 
2004). Biological screening (mouse inoculation) is used to isolate P. multocida from 
contaminated samples. In this method a saline suspension of the sample (0.2 ml of eluted 
blood swabs or a portion of bone maiTow in saline) is used for subcutaneous inoculation of 
a mouse. If P. multocida types that cause HS are present, the mouse will die within 24-36 
hours. Smears of the heart blood of the infected mouse will show an abundance of bipolar 
staining coccobacilli when stained with Gram, Leishman or methylene blue stains. The 
blood of the mouse can also be cultured, and will yield pure cultures (De Alwis, 1994).
Cultures are oxidase and catalase positive, produce indole and reduce nitrates, but fail to 
produce urease, utilise citrate, grow on McConkey agar medium or liquify gelatine. 
Growth on triple sugar iron (TSI) agar helps to differentiate pasteurellae from the common 
Gram-negative enteric bacteria. Pasteurella gives a slow acid reaction with no gas, and no 
detectable production of hydrogen sulphide in this medium (OIE, 2004).
1.8.2.2 Serological tests
Different serological methods have been used for identification of pasteurellae which are 
principally based on the detection of the capsular and somatic antigens. Conventional 
serological tests which are eurrently in use in diagnostic laboratories include: rapid slide 
agglutination test, indirect haemagglutination test (IHAT) and agar gel precipitation test 
(AGPT). Several other serological tests have been developed which are mainly used in 
research programmes. These include AGPT for capsular typing, counter- 
immunoelectrophoresis for somatic typing, coagglutination test for differentiation between 
type B and E, agglutination test for somatic typing and enzyme-linked immunosorbent 
assay for identification of P, multocida that cause HS (OIE, 2004).
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The rapid slide agglutination test is a simple method for capsular typing of pasteurellae 
using fresh cultures. A single colony is mixed with a drop of saline on a slide, a drop of 
antiserum is added, and the slide is wanned gently. A coarse, floccular agglutination within 
30 seconds, is indicative of a positive reaction (Namioka & Murata, 1961).
The indirect haemagglutination test (IHA) is also a method for capsular typing of 
pasteurellae. The capsular extract, which is also called polysaccharide capsule, (see section
2.3.4), of the unknown strain is used to coat (sensitise) red blood cells (RBCs). 
Agglutination of the coated erythrocytes (haemagglutination) by hyper-immune antisera 
specific for capsular types A, B, D, E and F is considered positive for the corresponding 
type (OIE, 2000). The original method was described by Carter and modified by Sawada 
(Carter, 1955; Sawada gf (^7, 1982).
The agar gel precipitation test (AGPT) is a method for somatic typing of pasteurellae (De 
Alwis, 1999). The somatic antigen is a heat-treated extraction of pasteurella grown on a 
solid medium. In the double diffusion technique, wells are punched in the solid agar in a 
circular pattern with one centre well sunounded by six peripheral wells. The test antigen is 
placed in the centre well and antisera which are prepared in chickens against 16 different 
types are placed in the peripheral wells. All HS-associated serotypes will react with type 2 
antiserum. Cross reactions may occur with type 5 (OIE, 2000). The test was invented by 
Heddleston and modified by Wijewardena (Heddleston et a l, 1972; Wijewardana, 1982).
1.8.2.3 Non-serological tests
Several non-immunological tests have been developed for the rapid identification of the P. 
mutocida strains. These include the acriflavine flocculation test described by Carter and 
Subronto (Carter & Subronto, 1973) for identification of type D strains, the hyaluronidase 
decapsulation test for type A strains (CaiTer & Rundell, 1975) and the hyaluronidase 
production test for the rapid identification of HS-related type B strains (Caiter & 
Chengappa, 1980). Two methods have been used to assess the production of hyaluronidase 
by Pasteurella. In one method, a hyaluronic acid producing culture of Streptococcus equi 
or a capsulated mucoid P. multocida type A is streaked across an appropriate solid 
medium. Pasteurella cultures to be tested are streaked across at right angles. The plates are 
then incubated for 18 hours at 37° C. Hyaluronidase production is indicated by reduction in 
size of hyaluronic acid producer colonies which are located adjacent to the Pasteurella 
colonies (OIE, 2004).
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1.8.2.4 Molecular methods
In recent years, identification and characterisation has favoured analyses that reflect one of 
the most fundamental properties of an organism, its genomic information. Molecular 
approaches such as DNA hybridisation and nucleic acid amplification have allowed 
bacterial detection directly from clinical samples, di'amatically reducing the time required 
for identification. Molecular technology has significantly influenced the identification and 
characterisation of P, multocida (Hunt et a l, 2000). These nucleic acid recognition 
methods not only differentiate the serotypes that cause HS but also help in differentiation 
of strains within serotypes (Wilson et a l, 1992).
Polymerase chain reaction (PCR) tests have been developed for the diagnosis of P. 
multocida and HS-causing pasteurellae (Brickell et a l, 1998; Kasten et a l, 1997a; 
Townsend et a l, 1998a). In a PCR test, primer sequences are designed to enable 
identification of the pathogen at any level of specificity such as strain, serotype, species 
etc.. The P. multocida-s^Qciftc PCR described by Townsend (1998) identifies all 
subspecies of P. multocida', subsp. Multocida, subsp. Gallicida, and subsp. Septica through 
specific amplification of a 460 bp DNA fragment. Type B cultures with the predominant 
somatic antigen being either type 2 or 5 are identified by the amplification of a 620 bp 
fragment (OIE, 2004). It has also been indicated that the putative transcriptional regulator 
genes Pm0762 and Pml231 are species-specific, and that PCR methods targeting these 
genes provide a useful means of rapidly and precisely differentiating P. . multocida from 
other bacteria (Liu et a l, 2004). HS-causing type-B-specific PCR primers can also be used 
in a multiplex PCR with the P. multocida-s^&cific primers and confinn the identity and 
provide a presumptive serotype within 3-4 hours, in comparison with biochemical analysis 
and conventional serotyping, which can take up to 2 weeks (OIE, 2004). HS-causing 
isolates of P. multocida have also been analysed by a PCR-based fingerprinting method 
known as repetitive extragenic palindromic (REP) PCR. The analysis of HS-causing P. 
multocida strains provided evidence of a disease-associated REP profile with a high degree 
of homogeneity observed among the strains regardless of whether the capsular serotype 
was B or E (Townsend et a l, 1997). These profiles were clearly distinct from serologically 
similar strains that do not cause HS, but exhibited a degree of relatedness to strains that 
cause clinically similar septicaemic disease such as B:l, B:2, B:3, B;4. These findings have 
shown the possibility of a disease-specific test rather than a serotype-specific test (De 
Alwis, 1999).
S a eed  Ataei Kachooei, 2 007  35 INTRODUCTION
Once identification has been made, further differentiation of isolates is possible, by 
genotypic fingerprinting methods. Restriction endonuclease analysis (REA), has been 
carried out on a wide range of HS causing strains. Hhal and Hpall have been used to digest 
the DNA. The resulting images of band patterns (DNA fingerprint profiles) may be 
analysed by computer. Using Hhal, 13 unique fingerprint profiles were characterised 
among 54 serotype 2 isolates. In contrast, while a single Hhal profile was observed among 
13 serogroup E isolates, differentiation of these strains was possible following Hpall 
digestion (Rimler, 2000; Wilson et a l, 1992). Ribotyping and field alteration gel 
electrophoresis (PAGE) have been used to analyse the DNA of strains of P. multocida that 
cause HS, after digestion with restriction enzymes (Blackall et a l, 1995; Townsend et a l, 
1998b). PAGE has displayed a greater degree of discrimination between strains, compared 
with ribotyping. Both of these methods are useful tools for differentiation between HS- 
causing and avirulent strains (OIE, 2000). Random amplified polymorphic DNA (RAPD) 
analysis and arbitrarily primed PCR (AP-PCR), have been shown to be useful for 
epidemiological studies of P. multocida isolates from rabbits and for differentiating post­
vaccination isolates of P. multocida obtained from turkeys, respectively. However, RAPD 
and AP-PCR analysis of HS-causing P. multocida isolates have not been described (OIE,
2000). Using repetitive sequence PCR, all HS-causing strains that were analysed 
demonstrated similar profiles, although this method provided a useful discrimination of 
avian and swine isolates (Townsend et a l, 1997; Townsend et a l, 1998b).
1.8.2.5 Antibody detection in host
Antibody detection is not used for routine diagnosis of HS. The epidemiological finding 
that most exposed but clinically unaffected animals develop high antibody titre 
unattainable by vaccination, is of diagnostic value in situations where deaths have occuiTed 
in a very short time and no carcasses are available for collection of material for laboratory 
tests. In other circumstances, disease-reporting systems may be poorly developed and 
consequently reporting is delayed and no material is available for culture and isolation at 
the time of investigation. In these situations, antibody levels in surviving animals can be 
assayed as an indicator of HS infection (De Alwis, 1994).
Numerous serological tests have been described for the detection of antibodies in naturally 
immune, infected and vaccinated animals. These include the indirect haemagglutination 
(IHA) test (Carter, 1964; Nagy & Penn, 1976; Verma & Jaiswal, 1997), immunoblotting 
teehniques (Johnson et a l, 1989; Pati et a l, 1996; Tomer et a l, 2002), passive mouse 
protection (PMP) test (Carter, 1964; Chandrasekaran et a l, 1994a), and enzyme-linked
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immunosorbent assay (ELISA) test (Carter, 1964; Nagy & Penn, 1976; Verma & Jaiswal,
1997).
The original IHA test (Carter, 1955) was later modified by him, using formalinised human 
‘O’ cells (Carter, 1962), then by Wijewardana et al. (1976) using sheep erythrocytes 
(Wijewardana, 1986), and later by Sawada using glutaraldehyde-treated sheep erythrocytes 
(Sawada et a l, 1985). This test can be used for diagnostic purposes because it is generally 
believed that high titres (1/160 up to 1/1280 or higher) detected by the IPIA test among in­
contact animals surviving in affected herds are indicative of recent exposure to HS. In 
different experiments on buffaloes and cattle, the IHA test has been used to assess potency 
of different kind of vaccines.
The application of an ELISA technique has been described for the detection of HS 
antibodies (Chandrasekaran et a l, 1994a; Dawkins et a l, 1991b; Johnson et a l, 1989; 
Muneer et a l, 1994). Chandrasekaran et a l  used three different kinds of antigens in an 
ELISA test to measure antibody titres after vaccination of buffaloes (Chandrasekaran et a l , 
1994a) and Pati et a l used a sonicated preparation of P. multocida. Antibody titres 
detectable in vaccinated buffalo calves using an IHA test were lower than the ELISA titres 
but the pattern of the antibody response was similar (Pati et a l, 1996). In another study on 
vaccinated calves, humoral immune responses were measured by the IHA test and the 
ELISA. Statistically, ELISA values were found to be superior to IHA values because of the 
small coefficient of variance (Verma & Jaiswal, 1997). In another study, it was shown that 
there was no relationship between PMP and IHA, and protection of buffaloes against 
challenge (Chandrasekaran et a l, 1994a).
Immunoblotting has been used to detect the immunogenic proteins, especially outer 
membrane proteins (OMP) of P. multocida, along with other serological procedures. In a 
study by Johnson et al. (1989), antibodies from vaceinated cattle strongly labelled five to 
six of the 40 protein bands in P. multocida, in addition to the response to 
lipopolysaccharide. In another study, Pati et al. (1996) observed ten major polypeptide 
bands in OMP of 88 to 25 kDa. Immunoblotting suggested that the polypeptides of MW 
44, 37 and 30 kDa were the major immunogens, of which two (37 and 30 kDa ) were type- 
specific to serotype B:2 (Pati et a l, 1996). Recently, it has been shown by Tomer et al 
(2002) that a polypeptide of 37 kDa was the most antigenic OMP in the profiles of all the 
investigated P. multocida B:2 isolates.
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1.9 Treatment and prevention
The rapid onset of HS and its short course leaves little opportunity for treatment, which is 
effective only if carried out in the early stages of the disease. For this reason, vaccination is 
generally accepted as a means of disease control.
1.9.1. Treatment
Once visible signs appear, treatment is of little value. Antibiotic therapy can only be used 
as a practical approach in an outbreak by checking the rectal temperatures of all in-contact 
animals in a diseased herd and using the drug immediately. The oldest therapy 
recommended was intravenous treatment with sulphonamides. Intravenous infusion of 
sulfadimidin sodium at a dosage of 1 ml per 2.3 kg body weight has been recommended. 
The large volume required in this treatment procedure has made the use of sulphonamides 
difficult (De Alwis, 1992). Other antibiotics have been tested and found to be effective 
against HS and penicillin, ampicillin and oxytetracycline appear to be the most useful. 
However the sensitivity patterns are likely to vary from one country to another depending 
on the prevailing drug usage practices (Radostits et a l, 2000).
Treatment with hyperimmune serum (serum therapy) has been attempted experimentally 
but appears to have no practical value (De Alwis, 1999).
1.9.2 Prevention
In all countries where HS occurs, vaccination is adopted as the method of control. There 
are three categories of measures for prevention and control of HS. 1. Measures to be 
adopted in endemic countries on a prophylactic basis. 2. Measures to be taken in the event 
of an outbreak. 3. Measures necessary for prevention of spread across regional or national 
borders. In all of these measures vaccination is the most important component (De Alwis, 
1999).
1.10 HS vaccines
1.10.1 History
The work of Louis Pasteur on chicken cholera opened the way to vaccine development in 
the laboratory. In April 1880, Pasteur reported to the French Academy of Science that
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“ ...chicken choiera is produced by a microscopic parasite [now known as Pasteurella 
multocida], that there exists an attenuated virus [Pasteur was using “virus” in the ancient 
sense of the word] of that disease, and that one or more inoculations of this attenuated 
virus can preserve the animals from the mortal effects of a later inoculation...let me be 
permitted to use the word ‘vaccinate’ to express the act of inoculating a chicken with the 
attenuated virus” (Plotkin, 2003).
Historically, Baldrey in 1907 prepared a killed vaccine (0.25% lysol-inactivated broth 
culture) for HS (De Alwis, 1999). This first attempt of vaccination offered immunity 
against HS for 6 weeks. Delpy and Rastegar in 1938 prepared a vaccine that consisted of a 
suspension of lysed bacteria in 5% saponin. Dhana in 1959 prepared a vaccine from 
capsular extract of the organism. Chengappa and Carter in 1979 introdueed a streptomycin- 
dependent (Str^) mutant of the agent as a live vaccine. Myint in 1987 used a strain isolated 
from deer for vaccination as a live vaccine. Muniandy in 1993 used an OMP preparation of 
the organism as subunit vaccine. Tabatabaei et al. in 2000 prepared an aroA mutant of the 
agent and showed its attenuation and protection in mouse.
1.10.2 Available HS vaccines
CuiTently there are four different types of HS vaccines. These vaccines are commercially 
available and are being used in different countries and under different regimens.
1.10.2.1 Plain bacterins
Bacterins which consist of a suspension of killed whole cells are the simplest foim of 
vaccine. To provide sufficient immunity with bacterins, repeated vaccination is required. 
Inactivated broth culture is the commonest type of bacterin, also called broth bacterins, but 
may cause shock reactions in a small percentage of animals. These reactions are 
presumably due to free endotoxin present in the preparation and are more probable with 
dense formalinised bacterial suspensions. Another disadvantage with plain bacterins is that 
the antibody response to them is poor and only provides immunity for about six weeks 
(OIE, 2004). Due to the shock encountered in some animals vaecinated with broth 
bacterins, an agar-wash formalin-killed vaccine (harvested from surface of solid medium). 
Some of these vaccines with higher concentration of cells are able to provide immunity for 
up to 4 months (Verma & Jaiswal, 1998).
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1.10.2.2 Alum-precipitated vaccine (APV)
APV appears to be the most popular vaccine used in Asia and Africa (Verma & Jaiswal,
1998). It consists of a bacterin to which potash alum has been added to give a final 
concentration of 1% (w/v) alum. Again, the disadvantages of such vaccines are short 
duration of immunity, which is only 3-4 months, and shock reactions can occur. They tend 
to precipitate during storage so it is important to mix them thoroughly before use. If this 
precaution is not taken, animals receiving vaccine from the bottom of the bottle will 
receive a large dose of bacteria and the chances of shock will be increased (OIE, 2004).
1.10.2.3 Aluminium hydroxide gel vaccine
In Thailand and Laos, an aluminium hydroxide gel vaccine is used extensively (Verma & 
Jaiswal, 1998). This vaccine has common properties with the alum-precipitated vaccine. 
Immunity up to 6 months is claimed and vaccination is practised twice a year (De Alwis,
1999). Further vaccination did not confer a substantial immunity of more than 90 days 
even using Vitamin E and levamisole as immunomodulators (Verma & Jaiswal, 1998).
1.10.2.4 Oil adjuvant vaccine (OAV)
An oil adjuvant vaccine for HS was first developed in 1955. It consists of a water in oil 
emulsion, where the aqueous phase consists of a dense broth culture and the oil phase a 
light mineral oil (OIE, 2004). The choice of emulsifying agent is very important in 
influencing the type of emulsion that results (Verma & Jaiswal, 1998). The longest 
duration of immunity, which is 6-9 months, is conferred by OAV. Two initial doses 
followed by annual revaccination is reckoned to provide adequate immunity. This vaccine 
is the one recommended for general use. The optimum age for primary vaccination is 4-6 
months as it has been found that the response of younger animals is poor (OIE, 2004). The 
OAV possesses a thick viscosity, and it is therefore difficult to administer, sometimes 
causing swelling at the site of inoculation (Verma & Jaiswal, 1998).
1.10.3 Deficiencies of available vaccines
It has been over 100 years since the discovery of prophylactic vaccination of cattle against 
HS with killed vaccines and around 60 years since the first uses of different kinds of 
adjuvanted vaccines. During this long period it has been proved that using these vaccines 
provide some control of HS. On the other hand deficiencies of these vaccines have been
S a eed  Ataei Kachooei, 2007  40  INTRODUCTION
recorded including, short duration of immunity, high viscosity, reactogenicity, short shelf 
time. Broth bacterins confer only an immunity of very short duration, and dense bacterin 
may cause an endotoxic shock. The alum precipitated and aluminium hydroxide gel 
vaccines are believed to confer immunity for only 3-4 months and need to be given twice 
yearly. Oil adjuvant vaccines suffer from limited duration of stability and high viscosity 
(Verma & Jaiswal, 1998).
1.11 Experimental vaccines
Although several new vaccines have been prepared, none of them has become established 
as a practical vaccine in the field. Some of these vaccine trials have focused on use of other 
adjuvants especially with low viscosity, like the production of double emulsions. Most of 
the vaccine trials relating to improvement of the vaccine can be categorised under two 
main headings: 1) Development of media to provide growth conditions that would cause 
the fullest expression of antigenic components that play an important role in protection; 2) 
Development of live vaccine by production of suitable avirulent, protective mutants using 
genetic manipulation. Such organisms, that can be administered by any route, should serve 
as ideal vaccine candidates as they will mimic the normal routes of infection and promote 
similar immune responses, at least initially, as the native strain.
1.11.1 The ideal vaccine
It is generally believed that an ideal HS vaccine should have the following characteristics 
(De Alwis, 1999):
-High level of immunity with minimum delay after vaccination and lasting for at least a 
year
-No adverse reaction
-Easy to handle in the field with a consistency that makes it easy to administer 
-Stable for use in the tropics 
-Easy and economical to produce
None of the vaccines developed so far attain all these requirements. Although different 
types of new vaccines have been developed by different groups of researchers, none of 
them has been able to replace any of the routine vaccines in the field.
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1.11.2 OMP-enriched vaccine
It has been shown that vaccines made from P. multocida serotype B:2 grown on iron- 
restricted media (containing the iron chelator 2.2-dipyridyl) give better protection than 
those grown in iron-replete media (containing 0.1 M FeCls). This superior protection has 
been attributed to a high molecular mass protein of over 84 kDa, which is expressed in 
abundance under iron-restricted conditions. Another protein (116 kDa) was found to be 
produced in vivo and when grown under iron-restricted conditions in vitro but was absent 
from cultures grown in normal media. Protein profiles by SDS-PAGE and immunoblotting, 
using serum from buffaloes naturally immune as a result of experimental exposure to a 
virulent B:2 strain, recognised the 116 kDa, whereas sera from buffaloes immunised with 
the inactivated oil adjuvant vaccine failed to do so (De Alwis, 1999). Convalescent-phase 
sera from buffaloes reacted against some iron-restricted and other proteins, indicating that 
these proteins were produced in vivo (Veken et al., 1996),
Although much work has been done on the characterisation of high molecular mass OMPs 
produced in vivo, and in iron-restricted media in vitro, by type A strains of P. multocida 
associated with avian pasteurellosis and bovine pneumonia, the experiments have not 
resulted in the production of a commercial vaccine for these strains (Bosch et a l, 2004). A 
commercial ovine pasteurellosis vaccine against Mannheimia {Pasteurella) haemolytica 
(Ovipast Plus^, Intervet), is prepared by growing the organism in iron-restricted media and 
causes strong protection in sheep (Gilmour e ta l,  1991; Porter e ta l,  1995).
1.11.3 Subunit vaccines
In order to generate a vaccine of superior quality, several studies have been done on 
different cellular components of Pasteurella multocida, including outer-membrane proteins 
(OMPs), lipopolysaccharides (EPS), polysaccharide capsules and proteins to evaluate their 
potential as protective immunogens (Chaudhuri & Goswami, 2001; Dawkins et a l, 1991b; 
Nagy & Penn, 1976; Ramdani & Adler, 1991). It has been concluded that no single 
component is totally responsible for immunity. All fractions, EPS, proteins and 
polysaccharides evidently contribute towards immunity. The complete set of immunogens 
would be present in whole bacterial cells grown in vivo or cultivated in vitro in a medium 
that provides all essential in vivo conditions for the full expression of relevant 
immunogenic components. It appeal's that there are many common components in the 
different types of P. multocida that play a role in protection (Frost & Adler, 2000; Hunt et 
a l, 2000).
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1.11.3.1 OMP vaccines
Since OMPs of P. multocida have been identified as major immunogens (Chevalier et a l, 
1992; Lu et a l, 1988; Lu et a l, 1991a; Lu et a l, 1991b), a number of reports have focused 
on the role of OMPs in eliciting protective immune responses (Vasfi Marandi et a l, 1996; 
Vasfi Marandi & Mittal, 1997). OMP extracts from P. multocida strain P52 (the Indian 
vaccine strain of serotype B:2) have been investigated for their use as subunit vaccines. 
Using SDS-PAGE, 10 major polypeptide bands of molecular weight ranging from 88 to 25 
kDa have been detected. Using immunoblots, it has been indicated that the 44, 37 and 30 
kDa fractions were major immunogens. Buffalo calves in two groups were vaccinated 
using a whole-cell, oil-adjuvanted vaccine and an oil adjuvant vaccine prepared from the 
OMP extract. Antibody responses were tested, by IHA, ELISA and passive mouse 
protection (PMP) tests. Following challenge, all the five OMP vaccinated animals survived 
whereas only 2 out of the tliree HS oil adjuvant vaccinated animals withstood the 
challenge. It was suggested that this OMP preparation could be useful as a vaccine against 
HS (Pati et a l, 1996). Although administration of an OMP-enriched crude preparation 
from P.multocida B:2 was protective in buffalo calves (Pati et a l, 1996), none of the 
purified OMPs was identified as a protective antigen. The 37 kDa OMP appeared to be one 
of the most antigenic components and was common between vaccine and field isolates 
(Tomer a l, 2002).
1.11.3.2 Lipopolysaccharides (LPS)
Lipopolysaccharide (LPS) preparations of Pasteurella multocida type B:2 were shown to 
be protective against experimentally-induced pasteurellosis in mice (Ramdani & Adler, 
1991). However, the observed protection was abrogated if such LPS was digested with 
proteinase K prior to use in immunization, indicating that the protectivity of LPS extracts 
prepared by the Westphal method was actually due to contaminating OMPs in the 
preparation (Muniandy et a l, 1998). The role of LPS in immunity has been studied using 
monoclonal antibodies and active immunisation experiments. Both procedures confered 
only partial passive protection in mice, indicating that LPS plays a partial role in immunity 
to infection (Adler et a l, 1996). The 0-antigen polysaccharide side-chain (OS) of LPS did 
not appear to contribute to the observed protection as judged by the fact that immunisation 
of mice with purified OS or OS-protein conjugates, failed to confer full protection against 
challenge with homologous virulent organisms. This was despite generation of significant 
levels of OS-specific antibodies, predominantly either of the IgM or IgG isotypes, in 
immunised mice (Muniandy et a l, 1998). Although LPS possesses antigenic properties, it
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has not been accepted as a vaccine candidate for cattle due to strong toxicity and 
anaphylactic effects.
1.11.3.3 Capsular polysaccharides
Capsular preparations have been used for experimental vaccination of cattle (Dhanda, 
1959) but have not resulted in a practical vaccine. In a later study, aluminium hydroxide 
adjuvanted capsular preparations of types B and E were used to immunise cattle. All 
animals which received the highest vaccine dose survived and all unimmunised control 
animals died after intravenous challenge by a virulent type E strain and a vaccine dose- 
response relationship was obtained. Do se-dependent serological responses were observed 
which were similar for both antigens. The results of PMP and IHA tests (type E) on the 
sera of immunised cattle conesponded with the degree of protection against challenge 
(Nagy & Penn, 1976). Oil-adjuvanted capsular extracts prepared by solvent precipitation 
from the supernatant fluid of fermenter-grown type B has been used for vaccination of 
cattle but did not yield any encouraging results (Nagy, 1979; Verma & Jaiswal, 1998). The 
differences in protection conferred by different capsular preparations might be due to the 
contamination of capsular extracts with other cellular components.
1.11.3.4 Protein vaccines
Proteins are generally likely to play an important role in protective mechanism against HS. 
Soluble cytoplasmic or periplasmic proteins of serogroups B and E are non-toxic. These 
fractions that were able to cause 25-60% protection in a mouse model (Ramdani & Adler,
1994).
1.12 Live vaccines
It is generally accepted that natural exposure to live organisms (such as in actual infection) 
produces greater irnmunity than immunisation through inactivated vaccines. This has been 
specially shown in HS, where the naturally-acquired immunity in exposed animals that 
results from aivested infection has been found to be superior to vaccinal immunity (De 
Alwis, 1982). If we can find an organism that has all the properties of the field strains, 
including all the antigen components, but has lost its virulence, it will constitute the basis 
for an ideal live vaccine. An ideal live vaccine should have the following characteristics: 1) 
it must have all, or at least most of the protective antigens present in the field strains; 2) it 
must grow readily in ordinary culture media; 3) it should be avirulent for cattle and
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buffaloes, or it may have low vimlence (the lethal dose must be considerably higher than 
immunising dose); 4) it should be able to multiply sufficiently in vivo following 
vaccination, producing a full complement of the important immunogens, thereby 
stimulating an adequate immune response (De Alwis, 1999).
Strains satisfying these criteria may occur in nature, or may be produced in the laboratory 
by exposure to mutagenic agents or by gene manipulation techniques.
1.12.1 Streptomycin-dependent (Str*^ ) mutant
Using N-methyl-N nitro-N-nitrosoguanidine (NMG), an HS-causing type B strain of P. 
multocida (strain R-473) was mutagenised to produce a streptomycin-dependent (Str^) 
mutant. This mutant was used for vaccination of the mouse and rabbit as animal models. It 
was shown that single vaccination was only fully protective in rabbit against a homologous 
challenge 21 days after vaccination (Wei & Carter, 1978).
A number of Str° mutants have been obtained from Sri Lankan strains of HS-causing P. 
multocida serotype B:2. These mutants were avirulent to mice, when inoculated alone, but 
some mutants killed mice when inoculated with streptomycin. Although most of the 
mutants were stable, some of them produced streptomycin-independent revertants. It was 
shown that the rate of reversion varied between different mutants and most of them were 
highly virulent for mice (De Alwis et a l, 1980). One of these mutants has been used to 
immunise calves subcutaneously or intramuscularly with one or two doses in Sri Lanka. 
No adverse reactions were observed in any of the vaccinated animals. It was shown that a 
single dose of vaccine conferred immunity in 66.6% to 83.3% of cattle and 100% of 
buffalo calves, and a booster dose given three weeks later enhanced the immunity in cattle. 
One of the disadvantages of the vaccine was the large number of cells of this mutant strain 
that was needed to produce a protective response. The absence of in vivo multiplication of 
the organism in the absence of streptomycin was suggested as one possible reason (De 
Alwis & Carter, 1980). The Str° mutants have not led to the development of a practical 
vaccine but they have revealed that live strains of P. multocida can be used for vaccination.
1.12.2 Deer strain live vaccine
A P. multocida serotype B:3,4 was isolated from a fallow deer {Dama dama) in England 
after an outbreak of septicaemic disease (Jones & Hussaini, 1982). It was reported to have 
a low virulence for cattle possibly due to the lack of transferrin-binding proteins (Veken et
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a l, 1996). It lias also been used as an experimental live vaccine, containing 2 x 10  ^viable 
organisms per dose, in cattle and buffaloes. The strain was able to raise antibodies in cattle 
that protected mice against serotype B:2 infection. Six months after vaccination, five of six 
calves were protected against serotype B:2 challenge. It protected calves for up to 9 
months after vaccination against a challenge with serotype B:2. The live vaccine was 
reported to be more efficacious than an alum-precipitated vaccine in protecting calves 
against B:2 challenge (Myint et a l, 1987). A lyophilised form of the vaccine induced 
protection in three of five subcutaneously-vaccinated and three of four intradermally- 
vaccinated young cattle after 12 months, when challenged with the B:2 serotype. Eleven 
buffaloes vaccinated subcutaneously and two vaccinated intradermally survived the same 
challenge 13 months after vaccination (Myint & Carter, 1989). In a field experiment, 1415 
cattle and 303 buffaloes were vaccinated subcutaneously. No disease was recorded in the 
cattle after vaccination but three buffaloes died soon after vaccination (Myint, 1990). It 
was shown that the strain was able to cause death in a small proportion of young animals 
when administered subcutaneously. The effect of the route of vaccination was evaluated in 
a field study by subcutaneous vaccination of 8231 cattle and buffaloes and intranasal 
vaccination of 674 animals (Carter et a l, 1991). The intranasal route of vaccination was 
not protective against the standard subcutaneous challenge. Therefore, after field 
experiments, the safety of this vaccine has been questioned for primary vaccination of 
young buffalo calves (Carter et a l, 1991; Myint, 1990). But, encouraging results have been 
obtained when the deer strain was administered intranasally as an aerosol spray (possibly 
due to access to lower parts of respiratory tract) in a population of cattle and buffaloes over 
six months of age in Myanmar (Myint et a l, 2005). However, there is some doubt about 
efficacy of vaccine, as the study did not include non-vaccinated animals as a control group. 
The vaccine should only be administered intranasally and for animals over six months of 
age. In Denmark, P. multocida serotype B:3,4 was isolated from Danish fallow deer 
{Dama dama) with haemorrhagic septicaemia. Restriction endonuclease analysis using 
Hhal as restriction endonuclease, showed that all isolates had a profile identieal to that of 
the fallow deer isolate from the United Kingdom. Cultures from the palatine tonsils of 
apparently healthy fallow deer from the same area showed a carrier rate of 27% (isolated 
from 6 animals) among apparently normal animals from the same population (Aalbaek et 
a l, 1999). This report showed that the deer strain vaccine is a potential pathogen, thus 
vaccination sould be done only under controlled conditions to prevent the spread of the 
organism.
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1.12.3 Acapsular mutants
A cexA (gene involved in the export of capsule) mutant (PBA875) of P. multocida serotype 
B:2 has been constructed by allelic replacement (Boyce & Adler, 2000). It was shown that 
immunisation with high, but not low, doses of the mutant confered significant protection 
against wild-type challenge in a mouse model (Boyce & Adler, 2001).
Another acapsular mutant (AL18) of P. multocida serotype B:2 has been constructed by 
inactivation of the bcbH gene (a gene predicted to be involved in polysaccharide 
biosynthesis). Immunisation of mice with the mutant was able to confer significant 
protection against wild-type challenge, while immunisation with similar doses of either 
killed wild-type or killed mutant failed to confer protection (Boyce & Adler, 2001).
The protection afforded both of these acapsular vaccines was less than 100% and it has 
been suggested that this is due to the rapid removal of acapsular bacteria from the blood, a 
view which has been supported by the strong dependence of the level of protection on 
vaccine dose (Boyce & Adler, 2001).
1.12.4 aroA mutant vaccine
In 1950, for the first time it was demonstrated that attenuated auxotrophs of Salmonella 
typhi that required aromatic compounds for growth were avirulent in a mouse model 
(Brown et a l, 1987; Li et a t, 1999). Mutants in aroD or aroA genes are attenuated by a 
blockage in biosynthesis of aromatic metabolites such as chorismic acid, a precursor of p- 
aminobenzoic acid (PABA). This metabolite is required for the biosynthesis of 
tetrahydrofolate, and is a precursor of L-tyrosine, L-phenylalanine and L-tryptophan. Since 
mammals acquire the folic acid precursors and aromatic amino acids through dietary 
nutrients, intermediary metabolism does not include a PABA biosynthetic pathway. 
Salmonella cannot assimilate the folic acid that is available in the mammalian cytoplasm, 
and aromatic amino acids are in short supply. Multiplication of intracellular aro mutants is 
therefore limited (Hale, 1995). After the first attempt to introduce aroA Salmonella 
typhimurium as a vaccine candidate (Brown et a l, 1987), the capacity of live salmonella 
vaccines to elicit immune responses to guest antigens from viruses, bacteria and parasites 
was demonstrated. Also, they may be used as delivery systems for other substances such as 
interleukins, by oral administration (Hormaeche, 1995).
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AroA mutants of a wide range of pathogenic bacteria have now been created to be 
exploited as live vaccines. Some of these mutants aie: Aeromonas hydrophila (Hernanz 
Moral et a l, 1998; Vivas et a l, 2004; Vivas et a l, 2005), Aeromonas salmonicida 
(Marsden et a l, 1996), Shigella flexneri (Kotloff et a l, 1996; Noriega et a l, 1994; Verma 
& Lindberg, 1991), Shigella dysenteriae (Walker & Verma, 1997), Yersinia pestis (Oyston 
et a l, 1996), Yersinia enterocolitica (Bowe et a l, 1989; O'Gaora et a l, 1990), Neisseria 
gonorrhoeae (Chamberlain et a l, 1993), Pseudomonas aeruginosa (Priebe & Schwarz, 
2003). Following exposure to aerosols of aroA mutants of Bordetella bronchiseptica, mice 
developed a limited lung infection and were subsequently protected against respiratory 
challenge with the virulent parental strain (Kabay et a l, 1992),
An aroA mutant of Mannheimia (Pasteurella) haemolytica biotype A, serotype 1 has been 
constructed. This mutant was highly attenuated in a mouse septicaemic model. Mice 
immunized intraperitoneally with two doses of the mutant were protected against a lethal 
parental strain challenge (Homchampa et a l, 1994).
aroA mutants from a fowl cholera-associated Pasteurella multocida, serotype A:1 (X-73) 
and serotype A:3 (P-1059) have also been constructed and designated PMPl and PMP3, 
respectively. In a mouse model, PMPl and PMP3 showed high attenuation and were able 
to protect against lethal challenge. One of the mutants, PMP3, was able to confer immunity 
against heterologous challenge with serotype A:1 or A:4 (Homchampa et a l, 1992; 
Homchampa et a l, 1997). These mutants also protected chickens against intratracheal 
challenge with wild type. At least 10  ^CPU of PMPl and 10  ^CPU of PMP3 were required 
to provide complete protection against challenge. Doses of 10  ^CPU of the mutants caused 
endotoxin reactions. Both vaccine strains provided cross-protection with a heterologous 
challenge strain serotype 4 (Scott et a l, 1999).
aroA mutants of HS-associated P. multocida serotype B:2 strains have also been 
constructed by allelic exchange in our laboratory (Tabatabaei et a l, 2002). These dérivâtes 
have been confirmed as highly attenuated for virulence in a mouse model of HS. 
Intraperitoneal injection of mice with 1 CPU/mouse with P. multocida 85020 parent strain 
(Section 2.1.1) killed 2 of 3 injected mice, but intraperitoneal injection with 2.6 x 10^  
CPU/mouse of the mutant did not kill any of 5 injected mice. It was shown by mouse 
challenge experiments that intraperitoneal or intranasal vaccination of an aro A strain was 
able to create complete protection against homologous challenge. All of the 5 mice injected 
intraperitoneally with 2.6 x lo^ CFU/mouse survived the intraperitoneal challenge with 
1000 LDsos with parent strain two weeks after vaccination. The experiments also showed
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that one intranasal inoculation of mice with 3.8 x 10  ^ CFU/mouse was protective against 
intraperitoneal challenge in 2 of 4 mice (Tabatabaei, 2000). The virulence and protection 
experiments and investigation of immune responses in natural host, form part of this thesis 
(Section 1.14).
1 . 1 3  I m m u n i t y  t o  H S
Immunity against pathogens is a consequence of activation of the immune system, which is 
an organization of cells and molecules with specialized functions (Roitt et a l, 1998). The 
physiological function of the immune system is defence against infectious microbes 
(Abbas & Lichtman, 2003). The immune system is composed of two inteiTelated parts, the 
innate and adaptive systems, whose response depends on the type of microbial invader 
(Kaufmann et a l, 2002). Innate immunity (also called natural or native immunity) consists 
of cellular and biochemical defence mechanisms that are in place even before infections 
and respond rapidly. These mechanisms, which react only to microbes and not to non- 
infectious agents, essentially respond in the same way to repeated infections (Abbas & 
Lichtman, 2003). Adaptive immunity (also called specific or acquired immunity) develops 
as a response to infection and increases in magnitude and defensive capabilities with each 
successive exposure to a particular microbe. The adaptive immune response has the ability 
to recognize and react to a large number of microbial and non-microbial substances. The 
components of adaptive immunity are lymphocytes and their products (Abbas & Lichtman, 
2003).
Recognition of the microbial pathogen is the first step of immune response. To achieve 
this, innate immunity has evolved a set of germ line-encoded proteins, named pattem- 
recognition receptors (PRRs), which are either free in the plasma (including collectins, 
pentraxins, and complement) or membrane bound (such as Toll-like receptors [TLRs] and 
nucleotide-binding oligomerisation domain [NOD] receptors), and are capable of 
recognizing conserved microbial molecules, termed pathogen-associated microbial patterns 
(PAMPs). In bacterial pathogens, these molecules include lipopolysaccharide (LPS) of the 
Gram-negative bacteria and lipoteichoic acid of Gram-positive baeteria (Kaufmann et a l ,
2002), Although innate and adaptive immunity are two distinguishable components of the 
immune system, there are two important links between them, First, the innate immune 
response to microbes stimulates the adaptive immune response and influences the nature of 
the adaptive response. Second, the adaptive immune responses uses many of the effector 
mechanisms of innate immunity to eliminate microbes, and they often function by
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enhancing the antimicrobial activities of the defence mechanisms of innate immunity 
(Abbas & Lichtman, 2003). The successful elimination of most pathogens requires 
interaction between these two arms of the immune system. The initial inflammatory 
reaction to infection, which is a part of the non-specific response, sets a suitable 
environment for mounting an adaptive response, by increasing blood flow and recmitment 
of polymoiphonuclear leukocytes ([PMNs], also called neutrophils), 
monocytes/macrophages and lymphocytes to the site of infection. IL-2 secreted by 
activated CD4'*’ T cells recruit the anti gen-presenting cells (APCs) (Section 1.13.2) in 
phagocytosing and processing the pathogen (Hodgson, 2001). These are examples of 
active interaction between innate and adaptive immunity.
Significant gaps exist in the cuiTcnt understanding of the nature of immunity against HS. 
Further information, especially related to vaccine development, would be helpful in the 
control of the disease (De Alwis, 1999). Most of the cuiTcnt knowledge has been obtained 
through studies on immune responses against different vaccines, mostly on the basis of 
data on morbidity/survival (Verma & Jaiswal, 1998).
1.13.1 Innate immunity
Innate immunity uses different cellular and molecular components in defences against 
pathogens (Abbas & Lichtman, 2003). In order to control the replication and spread of 
microbes, the innate immunity must be able to recognize and respond to infection rapidly, 
since most microbial pathogens can proliferate far more quickly than the host can mount an 
adaptive response (Kaufmann et a l, 2002). This is more prominent in acute diseases. The 
innate immune response to intracellular bacteria is mainly cellular, while both molecular 
and cellular mechanisms are involved in innate immunity against extracellular bacteria 
(Abbas & Lichtman, 2003). Cellular defences consist of phagocytic cells (PMNs, 
monocytes, and macrophages), and natural killer cells (NK). Some of the molecular 
components of innate immunity are blood proteins, including members of the complement 
system, acute phase proteins (APPs), and other mediators of inflammation. Another group 
of molecules is the cytokines, which regulate and coordinate many of the activities of the 
cells of innate immunity. Innate immunity also uses other mechanisms such as physical 
and chemical barriers, such as epithelia and antimicrobial substances produced at epithelial 
surfaces to prevent the entrance or spread of pathogens through body (Abbas & Lichtman,
2003).
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Mice infected intraperitoneally with as few as 20 CPUs of HS-associated P. multocida B:2 
showed an overwhelming septieaemia in less than 30 hours. The kinetics of infection 
demonstrated a very rapid in vivo multiplication rate. There was no evidence of inhibition 
of bacterial cell growth by natural host defence mechanisms, even with the very small 
inocula used (Ramdani et a l, 1990). Similar experiments on mice showed that the LD50 
varied according to the different routes of challenge. The LD50 dose (dose which kills 50% 
of inoculated animals) of P. multocida 85020 (an HS-causing strain isolated in Sri Lanka) 
inoculated by the IP and SC routes was <20 CFU/mouse, whereas when delivered by the 
IN route the LD50 was c^  10^  CFU/mouse (Tabatabaei et a l, 2002). Generally, oral and IN 
inoculation of the agent causes a longer course of the disease (Section 1.6.3). In natural 
hosts SC injection of 10"^  to 10  ^ CFU causes the disease but, using the oral or IN route, 
high doses of inoculum are required (De Alwis, 1999). After intranasal infection of eight 
buffaloes with 2.5-3.4 x 10  ^CFU only three animals succumbed to the disease 26-30 hours 
later and five survived (Horadagoda et a l, 2001). This is also suggestive that the dose 
required to cause the disease varied individually and results with a given dose may not be 
consistent. These demonstrations indicate that innate immunity may play an important role 
in natural infection (by oral or IN routes) in natural hosts.
1.13.1.1 Complement
The complement system, when it was identified more than hundred years ago, was known 
as part of the antibody response that destroys bacteria by lysis. The system is composed of 
about twenty serum proteins which interact with each other or with other cellular 
components of immune system such as phagocytes and T cells (Kemper & Atkinson, 
2007). Complement, along with other plasma derived PRRs, coats the microbes 
(opsonisation), allowing recognition and binding by opsonic receptors on host phagocytes 
(Kaufmann et a l, 2002). The complement system can be activated through three different 
pathways: the classical pathway, which is triggered directly by pathogen or indirectly by 
antibody binding to the pathogen surface; the lectin pathway; and the alternative pathway. 
All three pathways can be initiated independently of antibody as part of innate immunity. 
Finally, all three pathways culminate in the formation of the C3 and C5 convertases that, in 
turn, generate the anaphylatoxins C3a and C5a, the membrane-attack complex (MAC; 
C5b-C9) and the opsonin C3b (Maiion et a l, 1984). Activation of the complement system 
in response to extracellular bacteria may be through the alternative pathway when the 
opsonin C3b binds to the surface of the microbe (Abbas & Lichtman, 2003). The 
complement system can also affect T-cell responses through the direct modulation of T-
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cells or indirectly through the alteration of immunomodulatory cells, particularly APCs 
(Kemper & Atkinson, 2007).
The destructive effects of fresh serum on Gram-negative bacteria is assumed to be one of 
the consequences of the activity of complement (Taylor, 1983). In P. multocida serotype 
A, the causative agent of fowl cholera, it has been shown that a virulent strain was resistant 
to turkey serum while an avirulent strain was serum-susceptible (Hansen & Hirsh, 1989; 
Lee et a l, 1988). Similar results have been reported by other studies and serum resistance 
has been considered as a tool to assess the virulence in PC-associated strains (Morishita et 
a l, 1990). However, lesions have also been reported in chickens infected by serum- 
sensitive strains (Muhairwa et a l, 2002) and the relationship between virulence and serum 
resistance is complicated in the chicken (Diallo & Frost, 2000). Different monoclonal 
antibodies reacting with the LPS of the bacterium could opsonise P. multocida for 
phagocytosis by mouse macrophages, but were not bactericidal in the presence of 
complement (Adler et a l, 1996; Ramdani & Adler, 1991). Experiments on sensitivity of P. 
multocida B:2 to naïve calf serum show that the organism is quite resistant to complement- 
mediated killing. This study showed that both the wild type and an acapsular mutant grew 
rapidly in either fresh or heat-treated calf serum. It was concluded that capsule does not 
play any role in resistance to complement. Similar results were obtained for growth in 
mouse serum (Boyce & Adler, 2000).
1.13.1.2 Cytokines
Cytokines are proteins secreted by the cells of innate and adaptive immunity and form a 
complex network that play crucial roles in both innate and adaptive immunity. Generally 
they can be listed under pro- and anti-inflammatory categories (Kaufmann et a l, 2002). 
Chemokines (name is a contraction of chemotactic cytokine) are a large family of 
structurally homologous cytokines that stimulate leukocyte movement and regulate the 
migration of them from the blood to tissues (Abbas & Lichtman, 2003). Since in different 
texts there is some overlap in classification of the cytokines and chemokines, all of them 
are mentioned here under one category. The main cytokines that contribute to innate 
immune reactions against bacterial infections are TNF, IL-1, IL-12, IFN-y, and IL-18. In 
infections by bacteria, macrophages respond to bacterial endotoxins and perhaps to other 
bacterial products by producing TNF (also called tumor necrosis factor-alpha [TNF-a], for 
historical reasons and to distinguish it from the closely-related TNF-(3, or lymphotoxin), 
interleukin-1 (IL-1), and chemokines. TNF-a and IL-1 are pro-inflammatory cytokines that 
mediate and regulate innate immunity. They are principal mediators of the acute
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inflammatory response to Gram-negative bacteria and responsible for many of the systemic 
complications of severe infections (Abbas & Lichtman, 2003). Macrophages also respond 
to LPS-producing bacteria and intracellular bacteria by secreting IL-12, which induces the 
local production of IFN-y from T-cells and NK cells. The IFN-y then activates the 
macrophages to destroy phagocytosed bacteria. IL-12 also stimulates the subsequent 
adaptive immune response. These actions of IL-12 are completed by IL-18. These 
cytokines secreted by macrophages, especially TNF-a, IL-1, and IL-12, are also 
responsible for the systemic manifestations of infection. IL-12 is produced by macrophages 
in response to many microbes. Large amounts of IL-12 are produced in severe Gram- 
negative sepsis, resulting in the production of TNF, the principal mediator of septic shock. 
IL-12 antagonists prevent lethality in experimental models of LPS-induced septic shock. 
TNF-a has different biological actions at different concentrations. At low concentrations, 
TNF-a acts on leukocytes and endothelium to induce acute inflammation. At moderate 
concentrations, it mediates the systemic effects of inflammation (fever, secretion of APPs 
by liver and production of leukocytes by bone maiTOw), and at high concentrations, it 
causes the pathologic abnormalities of septic shock (Abbas & Lichtman, 2003).
The toxic effects of LPS-containing antigen prepared from virulent serotype B:2 strains of 
P. multocida have been shown in laboratory animals and calves (Heddleston et a l, 1967). 
Administration of LPS has been demonstrated to induce the secretion of several cytokines 
including IL-1, TNF-a, and EL-6 (Chen et a l, 1992). It has been shown that intravenous 
injection of P. multocida LPS is capable of inducing an immediate (with a peak 1-2 hours 
post-injection) TNF response in the buffalo (Horadagoda et a l, 2002). A primary role for 
LPS in the induction of HS in the calf was indicated by the consequent development of a 
rapid and severe endotoxemia in the terminal stages of the disease. However, TNF-a was 
only detected in serum in one of the three diseased animals. The early release of TNF-a, 2- 
3 hours after exposure to LPS, and restriction of the production to local levels were 
suggested as possible reasons for the lack of detection of TNF-a (Horadagoda et a l, 2001). 
Individual animal differences, similar to those noted in calves by others following LPS 
injection, has been suggested as the possible reason (Horadagoda et a l, 2002). In this 
experiment, leukocytosis was observed only in animals that developed a severe 
endotoxaemia and eventually died of HS and not in those that survived. According to this 
observation, it was suggested that endotoxin is initially restricted within the lung lesions 
during the course of infection, only to be released into the circulation in a fatal 
overwhelming dose, perhaps after bacterial growth exeeds a certain threshold (Horadagoda 
et a l, 2001). Considerable species variation in the sensitivity to LPS has been reported, 
with ruminants and pigs being more sensitive compared to dogs and rodents (Olson et a l,
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1995). It has been concluded that buffaloes are more sensitive to circulatory LPS and this 
has been suggested as a possible explanation for the higher mortality rate in buffaloes than 
in cattle due to HS (Horadagoda et al., 2002).
1.13.1.3 Acute phase proteins (APPs)
Acute phase proteins such as C-reative protein (CRP), fibrinogen, serum amyloid A 
(SAA), haptoglobin (Hp), and ai-acid glycoprotein (ai_AGP) are proteins secreted by the 
liver into the blood plasma in the acute-phase response (Abbas & Lichtman, 2003). The 
acute-phase response, which is characterized by pyrexia, leukocytosis, endocrine changes 
and the redistribution of traee elements, plays a crucial role in containing the body damage 
and assisting the processes of healing. One of the changes in the acute-phase response 
includes changes in the concentration of APPs, some of which decrease in concentration 
(negative APPs), such as albumin or transferrin, and others of which increase in 
concentration (positive APPs), such as CRP, SAA, Hp, ai.AGP, and ceruloplasmin (Ceron 
et ah, 2005). Several APPs which were originally identified in humans have been 
identified in different animals, although there are some degrees of variation in the response 
of individual proteins between different species (Eckersall & Cornier, 1988; Murata et a l,
2004). Clinically, the measurement of plasma concentrations of APPs are used to assess 
the severity of inflammation. They are preferable to haematological assays for this puipose 
as they are more sensitive and also the APP assay can be done on frozen samples. 
Haptoglobin (Hp), the most widely studied APP in cattle, is a protein that binds free 
haemoglobin in the circulation. Hp has been identified as a reliable index to show the level 
of inflammation in both experimental and clinical investigations (Horadagoda et al., 1999). 
Serum amyloid A (SAA) is also a major APP in humans, cattle, and laboratory animals, ui- 
AGP, which like most of the APPs is a glycoprotein, has been identified as an 
inflammatory marker in cattle (Horadagoda et a l, 1993; Horadagoda et a l, 1994). ai.AGP 
is a moderate APP in both humans and cattle and its serum levels only increase two- to 
four-fold in response to tissue damage (Motoi et a l, 1992).
In a study on calves, the involvement of APPs in pathogenesis and resolution of 
pneumonia was investigated after intratracheal challenge with P. multocida A:3. Plasma 
concentrations of SAA increased rapidly between 5 and 23 hours in response to challenge 
and decreased dramatically between 72 and 96 hours after challenge. Hp concentrations 
also increased significantly compare to mean values of samples before challenge and fell 
gradually thereafter. Increases in the ai-AGP concentrations were more gradual than those 
observed for SAA or Hp. The ai-AGP response reached its highest levels at 48 hours after
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challenge and decreased thereafter with a slight recovery between 72-96 hours (Dowling et 
a l, 2002). The study indicated a role for the investigated APPs in inflammatory responses 
of cattle to infection, and was used in a further study as markers of the onset and progress 
of experimental HS in calves (Hodgson et a l, 2005).
1.13.1.4 Phagocytes
PMNs are the main phagocytic cells in blood. They are the major phagocytic cells 
controlling the growth of extracellular bacteria as well as some facultative intracellular 
pathogens. PMNs and activated macrophages utilize both oxygen-dependent (respiratory 
burst) and oxygen-independent (using proteolytic enzymes) mechanisms to kill bacteria. 
Oxygen-dependent mechanisms of respiratory burst are initiated by activators such as 
bacteria and LPS. Most bacteria are sensitive to toxic intermediates released by phagocytic 
cells but some of them show different levels of sensitivities to these mediators. The level of 
sensitivity of different species may affect the prognosis of the disease in the host.
In mammals the main phagocytic cells, PMNs, monocytes and macrophages, are also 
called professional phagocytes because of their ability to ingest a variety of particles and 
they are responsible for recognition of microbes by presenting them to T cells. 
Paraprofessional phagocytes include dendritic cells (DC) with selective phagocytic ability 
and along with macrophages, are important in inducing the adaptive response by 
presenting antigen. DCs originate from both myeloid and lymphoid precursors, the former 
are involved in the induction of the adaptive immune response (Kaufmann et a l, 2002). 
Cattle macrophages and PMNs possess a unique Fc receptor that is structurally different 
from other Fc receptors. This receptor may represent a special adaptation to the structure of 
IgG2 since bovine IgG2 has a very small hinge region (Tizard, 2000).
In atrophic rhinitis-related strains of P. multocida, the OmpH of 37.5 kDa was able to 
induce a dose-dependent increase in oxidative burst of bovine PMNs isolated from 
peripheral blood (Galdiero et a l, 1998). The major OMPs isolated from M. haemolytica 
were also able to induce alterations of the biological activity of bovine PMNs (lovane et 
a l, 1998a). Phagocytosed P. multocida serotype A:3 ( bovine pulmonary strain) was able 
to survive in bovine monocytes (Dowling et a l, 2004). An avian isolate of P. multocida 
(fowl cholera causing strain) has also been shown to persist in avian monocytes because of 
an outer membrane protein (Truscott & Hirsh, 1988). An attempt was made to investigate 
the effect of HS-related P. multocida on certain microbicidal reactive oxygen and nitrogen 
intermediates released by PMNs from vaccinated animals. The PMNs from the peripheral
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blood of both control and experimental buffaloes vaccinated against HS were isolated. 
PMNs from control animals upon activation with P. multocida LPS and live P. multocida 
cells generated higher levels of hydrogen peroxide (H2O2) and nitric oxide (NO') than the 
non-activated cells (P < 0.01). In the presence of P. multocida LPS, PMNs from animals 
vaccinated against haemon'hagic septicaemia generated significantly higher H2O2 (P < 
0.05) and NO- (P < 0.01) than the PMNs from control animals. The study suggested that 
buffalo PMNs possessed a potent oxidant defence system even in the presence of P. 
multocida (Roy et a l, 1996). However, HS-causing strains of P. multocida B:2 are 
cytotoxic for murine macrophages. Intraperitoneal injection of mice causes cytoplasmic 
vacuolation, lysis and death in peritoneal macrophages. In vitro incubation of a mouse 
macrophages cell line with HS-causing strains or with their culture supernatants was also 
able to induce vacuolation. Pre-incubation of cells with antiserum obtained from an 
infected buffalo, inhibited the vacuolation (Shah et a l, 1996). OMPs of P. multocida B:2 
are antiphagocytic. They are able to interfere with phagocytosis of opsonised Candida 
albicans by murine peritoneal cells in vivo. It has been suggested that antiphagocytic 
mechanisms induced by the OMPs enhance the virulence of the organism (Srivastava,
1998). The polysaccharide capsule of P. multocida B:2 has also been considered as an 
antiphagocytic agent, since acapsular mutants are readily taken up by mouse peritoneal 
macrophages, while there is a significant resistance to phagocytosis in wild-type strains 
(Boyce & Adler, 2000).
There is limited evidence of intracellular survival of P. multocida and mechanisms 
involved in interference with the respiratory burst (Hodgson et a l, 2006). Several studies 
have investigated the effects of pasteurellae on mononuclear phagocytes. Some pathogens 
have aquired the ability to alter killing mechanisms of macrophages. Many of the studies 
have studied the whole organisms while some others have used different components of 
the organisms for study. Opsonising antibodies against P. multocida B:2 facilitate 
phagocytosis of the bacterium. These investigations, which could also be categorised under 
adaptive immunity (Section 1.13.2), have revealed that, despite the resistance to 
complement activity and other anti-phagocytic properties, opsonisation of the organism 
with antibodies enhances the up-take of the organism (Adler et a l, 1996; Ramdani & 
Adler, 1991). P. multocida B;2 has been shown to be phagocytosed inefficiently in a 
mouse model but to survive inside macrophages without multiplication (Adler et a l,
1996). In another study using acapsular mutants of P. multocida B:2 it was shown that the 
mutants were phagocytosed more rapidly than the wild type by murine peritoneal 
macrophages. It was also reported that the internalized mutant cells survived for at least 30 
minutes in mouse macrophages (Boyce & Adler, 2000). It was reported in another study
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that P. multocida B:2 is able to survive at least for 2 hours in a murine macrophage cell 
line (J774) (Tabatabaei, 2000).
1.13.2 Adaptive immunity
There are two types of adaptive immune responses; humoral (also called antibody- 
mediated) immunity and cell-mediated (also called cellular) immunity. Humoral immunity 
is mediated by antibodies in the blood and at mucosal surfaces that are produced by B 
lymphocytes (B cells). Cell-mediated immunity is mediated by T lymphocytes (also called 
T cells). Adaptive immune responses are generated to specific antigens of pathogens that 
ai'e captured and displayed by antigen-presenting cells (APCs) (Abbas & Lichtman, 2003). 
Different types of cells function as APCs at different stages of cellular and humoral 
responses. The most highly specialized APCs are DCs, which capture microbial pathogens 
that enter from the external environment, process them to small fragments, transport them 
to adjacent lymphoid organs, and present them to T cell receptors (TCRs) on naïve T cells 
to start an immune response. TCR, which is structurally very similar to Fab fragment of an 
immunoglobulin molecule, consists of two different polypeptide chains, termed a and p, 
linked by disulphide bond. A minority of T cells bear an alternative, but structurally similar 
receptor made up of a different pair of polypeptide chains designed y and 5 (Marion et a l, 
1984). The function of yô'  ^ T cells in immune responses is not entirely clear, yô"^  T cells 
share many functions with ap^ T cells particularly in their role as inducers of inflammation 
by EFN-y production. On the other hand, they are different from ap"^  T cells in the way by 
which their receptor interacts with antigen and the types of antigens that stimulate them. 
yb'TCR is not able to recognize antigen in the form of peptide-MHC complex but they 
express receptors recognise and react with some microbial phospholipids antigen 
molecules, such as isopentenylpyrophosphate (IPP), found on Mycobacteria and other 
bacteria and parasites. The specifity of these receptors for different non-peptide molecules 
on different pathogens shows variation between different species, suggesting that the yô 
response may be directed against pathogens commonly encountered by a given species 
(Goldsby et a l, 2003; Herzig et a l, 2006). In young ruminants yô^ T cells predominate 
(45-50% of peripheral blood T cells) over aP"^  T cells (5-30% of peripheral T cells) 
(Tizard, 2000), but this proportion decreases by adulthood (to 5% of total PBMCs) (Herzig 
et a l, 2006). TCRs (here the term TCR is used as aP-TCR as this is the only TCR capable 
of recognizing antigen) only recognize the antigen as peptide fragments bound to a MHC 
(major histocompatibility complex) molecule displayed on the surface of APC that is 
called peptide-MHC complex. There are two classes of MHC molecule (named MHC class 
I and MHC class II), which differ in their structure and expression pattern on body tissues.
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MHC class I molecules are expressed by most of the somatic cells but MHC class II 
molecules are normally expressed by APCs (Goldsby et a/., 2003).
Mature T cells express either CD4 or CDS molecules and, together with CD3, they 
form an essential part of the TCR complex. CD4'*' T cells usually act as helper T cells and 
recognize antigen presented by MHC class II molecules on APCs (as macrophages, DCs, 
and B cells). By contrast, CDS^ T cells are usually cytotoxic and recognize antigen-derived 
peptides presented by MHC class I molecules on somatic cells (Marion et a l, 1984). Foi- 
an efficient stimulation of T cells, activated DCs also express co-stimulatory molecules 
called B7-1, B7-2 (also called CD80 and CD86, respectively), and CD40. The co­
stimulatory molecules B7 and CD40 boost the stimulation when bound to corresponding T 
cells receptors CD28 and CD154, respectively (Roitt et a l, 1998). After activation, CD8^ 
T cells, acquire cytotoxic activity and aie called cytolytic T lymphocytes (CTLs), which 
are able to destroy host cells that are infected. Activated CD4^ T cells can be divided into 
two major sub-populations, called type 1 helper (Thl) and type 2 helper (Tli2) T cells. Thl 
T cells, which mainly function against intracellular pathogens, are activated by antigen 
and, in the presence of IFN-y and/or IL-12, express IL-2 and IFN-y. Th2 T cells, which 
function against some helminth parasites and stimulate allergic reactions, are activated by 
antigen, IL-4 or IL-10 and express IL-4 and IL-6 (Hodgson, 2001).
These two different CD4^ T cell-mediated responses, have been identified in mouse and 
humans and it is believed that the type of response influences the outcome of infection- 
resolution or exacerbation. However, this model of CD4'*' T cell activation is different in 
the bovine as it was shown that the T cell response can not be categorized under this model 
(Brown et a l, 1998). It was also suggested that, the Thl/Tli2 paradigm might be different 
from mouse and human. For instance, in sheep and cattle, at the site of intracellular 
microbes (with the possible exception of the skin) and helminth parasite infections, T cells 
produce cytokines related to both Thl and Th2 profiles (Hodgson, 2001). A high 
proportion of peripheral blood lymphocytes (15-30%), in young ruminants do not show 
any of the CD4 or CD8 markers (called CD4'CD8‘ T cells) and in newborn calves this 
proportion is very high (up to 80%). Thus the circulating T cells in ruminants (yô'*', CD4‘, 
CD8', WCH [cattle species-specific cell-surface antigen found on a major subset of yô'*' T 
cells with no homologue in human or mouse]) are very different from T cells found in 
blood of human and mouse (ap'*', WCF, CD4'*', CDS') (Tizard, 2000).
In chicken and turkeys infected with P. multocida, both humoral and cellular immune 
mechanisms are involved in protection (Baba et a l, 1978; Baba, 1984; Maheswaran et a l.
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1976). Although in HS, humoral immunity is believed to be the main component of the 
immunity, the contributory role of cell-mediated immunity cannot be discounted (De Alwis
1999).
1.13.2.1 Humoral immunity
Humoral immunity is the principal protective immunity against extracellular bacteria. 
Antibody produced in response to extracellular bacteria is mainly directed against 
antigenic components of the bacterial cell wall and secreted or cell-associated toxins, 
which maybe proteins or polysaccharides. Protection against polysaccharide-rich 
encapsulated bacteria is a major function of humoral immunity. Neutralisation, 
opsonisation and phagocytosis, and complement activation through the classical pathway, 
are effector mechanisms of antibodies to fight these infections. Antigenic proteins of 
extracellular bacteria are also able to activate CD4^ helper T cells. Activated CD4^ cells 
produce cytokines that stimulate antibody production by B cells, induce local inflammation 
(by secretion of TNF), and enhance the phagocytic activity of macrophages (by secretion 
of fFN-y). Activated macrophages produce cytokines which causes inflammation and in 
the some severe cases result in septic shock. Septic shock is the most severe cytokine- 
induced pathological consequence of infection by Gram-negative and some Gram-positive 
bacteria in which TNF is the principal mediator (Abbas & Lichtman, 2003).
It is generally believed that immunity to HS is predominantly humoral and it can be 
transferred with serum of immune animals to naïve animals. Although very little is known 
about what constitutes a protective response, measuring the antibody levels has been used 
as a tool to measure immunity in vaccinated animals (Verma & Jaiswal, 1998). The tests 
that have been mainly used for this puipose include the passive mouse protection test 
(PMPT), indirect haemagglutination (IHA) test, immunoblotting technique, and antibody 
enzyme-linked immunosorbent assay (ELISA), but studies on buffaloes have revealed no 
strong relationship between PMPT, IHA (Section 1.8.2.5) and protection (Chandrasekaran 
e ta l ,  1994a; Chandrasekaran ef a/., 1994b).
ELISA and immunoblotting tests have been used to examine the antibody responses of 
cattle vaccinated against HS-causing strains of P. multocida. The study revealed that, in 
addition to the response to lipopolysaccharide, antibodies from the vaccinated animals 
reacted strongly with five to six of the 40 protein bands in this organism (Johnson et a l, 
1989). Monoclonal antibodies against EPS could opsonise P. multocida serotype B:2 for
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phagocytosis by mouse macrophages, but were not bactericidal in the presence of 
complement (Adler et a l, 1996).
The humoral responses of buffaloes was characterized after immunization with four 
different killed HS vaccines including; non-adjuvanted broth bacterin, alum-precipitated, 
oil adjuvant and a double emulsion. There appeared to be a relationship between ELISA 
antibody titres and active protection of animals. Three different preparations of P. 
multocida B:2 including formalin killed and boiled whole cells, and LPS were used as 
antigens in the ELISA system. Regardless of the different kinds of antigen used, the mean 
antibody levels rose significantly over a 3-month period in buffaloes immunised with the 
adjuvanted vaccines (Chandrasekaran et a l, 1994b). Generally, bovine IgG consists of 
thiee subclasses: IgGl, IgG2a, and IgG2b. IgGl constitutes about 50% of the serum IgG 
and is remarkable for being the predominant immunoglobulin in cow’s milk rather than 
IgA (Tizard, 2000). Preliminary analysis of the antibody isotype in the pre-challenge sera 
of the buffaloes in the above study at 6 months post-immunisation revealed the 
predominant isotypes to be IgGl and IgG2 with the percentage of 48% and 42%, with IgM 
and IgA at 7% and 3% respectively (Chandrasekaran et a l, 1994b). It was not possible to 
assign any relative protective role to these immunoglobulins isolated from immune animals 
because of the lack of a reliable and reproducible data from the passive mouse protection 
test. Because of the lack of complete protection in some of the vaccinated buffaloes, it was 
suggested that there may be a minimum threshold of antibody level necessary for 
protection against challenge (Chandrasekaran e ta l,  1994b).
No minimum level of antibody necessary for protection has been distinguished by other 
studies. One reason for this is the differences in the methods of antigen preparation used in 
the ELISA. Another reason could be the individual differences between animals, especially 
between cross-bred animals due to genetic differences, in mounting an immune response 
(Verma & Jaiswal, 1998), as it has been shown in cattle that serum IgG2 concentrations 
vary greatly among different individuals and IgG2 levels are highly heritable (Tizard, 
2000). A strong relationship between IgG but not IgM antibody levels and resistance to 
challenge was revealed in another study on vaccinated buffaloes using different HS 
vaccines. It was shown that animals immunised with an oil-adjuvanted vaccine developed 
a high level of IgG and IgM as compared to the other groups of animals vaccinated with 
bacterin or non-vaccinated animals. The IgG class was detected as the principal antibody 
response with only mild IgM responses. It was shown that the response increased gradually 
until day 75, then dropped slightly and maintained its level for about one year. At the time 
of challenge (250 days post-vaccination) the level of IgM class antibodies had decreased
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considerably while the IgG class response was still at a high level (Shah & de Graaf,
1997). In both of the above-mentioned studies, the increase in antibody titre after 
vaccination was only gradual and did not reach maximum until 2-3 months after 
vaccination.
In another study, passive immune cross-protection in mice produced by rabbit antisera was 
used to determine the immunological relationship between strains associated with HS and 
fowl cholera (FC). Various degrees of cross-protection were seen among the strains. 
Antiserum against a serotype B:3,4 strain protected against strains capable of causing HS 
(serotypes B:l, B;2, B:3,4, B:4 and E:2) and FC (serotypes A :l, A:3 and A:5). Antiserum 
against an FC strain (serotype A:5) similarly protected against strains capable of causing 
HS and FC. Interestingly, antigenic analyses indicated that cross-protection was not 
necessarily induced by serotype-specific capsular or somatic antigens or major porin 
proteins. SDS-PAGE and immunoblots of whole cell lysates of the different HS and FC 
strains using the various antisera showed many protein-staining bands with similar 
mobilities and antigenic activity. These cross-reactive antigenic bands occurred in the 20- 
to 120-kDa range. Furthermore, it was shown that adsorption of antiserum with a 
heterologous serotype removed its reactivity with most of these bands, as well as its ability 
to cross-protect (Rimler, 1996).
1.13.2.2 Cell-mediated immunity (CMI)
Cell-mediated immunity is the major adaptive immune response against intracellular 
bacteria. CMI mainly consists of two types of reactions: lysis of infected cells and 
macrophage activation. The lysis of infected cells is earned out by CTLs. Macrophage 
activation, which results in killing of phagocytosed bacteria, is through T cell-derived 
signals; production of IFN-y and CD40 ligand (Abbas & Lichtman, 2003). In some cases 
the macrophage activation also causes tissue injury in the host. This tissue injury can be 
manifested as delayed-type hypersensitivity (DTH) reactions against bacterial protein 
antigens (Kaufmann et a l, 2002).
The role of cell-mediated immune responses has not received much attention in research 
on HS. This might be because most of the knowledge on immune responses is from 
vaccination studies using killed vaccines, where a strong cellular response would not be 
expected. The other reason for this is insufficiencies in reagents commercially available for 
analyzing bovine blood cells. Thus, the contribution of cell-mediated immunity in the 
protection against HS merits further investigation. However, the contribution of CMI was
Saeed Ataei Kachooei, 2007 61 INTRODUCTION
studied in an extensive experiment on buffaloes where cutaneous delayed-type
hypersensitivity (DTH) was used to assess the cellular response against four different kinds 
of inactivated vaccines. Vaccinated animals developed a substantial to significant 
cutaneous DTH response. Histopathological examination of selected biopsy specimens 
taken from the site of inoculation showed a predominance of infiltrating lymphocytes, thus 
indicating a probable DTH response. An apparent relationship was demonstrated between 
the DTH response and protection of buffaloes in different vaccination groups. However, it 
was suggested that, because the antigen used for intradermal inoculation was an
ultrasonicate of cells (intradermal inoculation in the caudal fold of 0.1 ml at a 
concentration of 220 jig protein per ml) which contained a wide range of possible 
protective and non-protective antigens, it was not possible to reach a definitive conclusion 
about the extent of the contribution of the cellular response in protection (Chandrasekaran 
e ta l,  1994b).
In a study on water buffaloes, the capacity to mount humoral and cell-mediated immune 
responses against a HS aluminium-precipitated vaccine was suppressed due to infection 
with Trypanosoma evansL The subcutaneous inflammatory response (SIR) to primary and 
secondary vaccination at the vaccination site, which was measured as a cellular response, 
showed significant reduction in animals experimentally infected with T. evansi. On the 
other hand, no significant differences were observed in antibody responses against P.
multocida. It was concluded that reduction of local inflammatory reactions due to HS
vaccination was due to reduced levels or reduced reactivity of certain T cell phenotypes, 
and that the reduced skin induration would suggest diminished levels of protection against 
P. multocida (Holland et a l, 2001). However, in this study the protection against 
challenge, which could have been very informative, was not determined.
The role of CMI in protection of cattle against P. multocida after vaccination was 
investigated in another study. The leukocyte migration inhibition test (LMIT) was used as 
an indicator of cellular immunity in calves vaccinated with a killed oil-adjuvanted vaccine. 
LMIT showed more than 20% migration inliibition during all pre- and post-challenge 
periods in vaccinated animals suggesting an involvement of cell-mediated immune 
mechanisms in protection (Verma & Jaiswal, 1997). It was suggested that both humoral 
and cell-mediated immune responses contribute to protection in vaccinated calves (Verma 
& Jaiswal, 1997). Overall, however, the contribution and extent of CMI in protection 
against P. mutocida serotype B:2 is not completely understood. A fatal human case of 
Pasteurella sepsis has been reported in a patient with hairy-cell leukemia (CLL, a 
lymphoproliferative disorder), which can be indicative of the importance of cellular
Saeed Ataei Kachooei, 2007 62 INTRODUCTION
immunity against the bacterium, since the disease has usually been associated with 
increased rates of infection caused by microorganisms normally controlled by CMI (Athar 
et a l, 2003).
1.13.3 In vitro lymphocytic responses
To study the modulatory effects of Pasteurella and other bacterial pathogens on immune 
response, several in vitro experiments have investigated the stimulation, proliferation, and 
cytokine responses of mononuclear cells after treatment with different components of the 
bacteria.
1.13.3.1 Lymphocyte stimulation assay
The lymphocyte stimulation assay (also called antigen-stimulated lymphocyte proliferation 
or lymphoblastogenesis) is one of the most useful assays for assessment of cellular 
immune response. In the body, stimulation of primed (activated) lymphocytes, occurs in 
lymphoid tissues in response to antigen presented to them. However the ability of isolated 
lymphocytes (such as PBMCs) to be stimulated (expressed as proliferation and/or cytokine 
secretion) when cultured in the presence of the antigen to which then are activated has 
been exploited as a tool to assess cellular response in vitro.
The proliferative response of activated peripheral blood mononuclear cells (PBMCs) to 
antigen has been extensively used to study cellular immunity, as PBMCs from infected or 
immune hosts will proliferate in response to antigen obtained from the organism they have 
been exposed to. In a study on HS- and shipping fever-related Pasteurella it was reported 
that PBMCs from HS-immunised cattle exhibited higher stimulation indices when 
incubated with antigen preparations from homologous strains than with the heterologous 
shipping fever strain. Conversely, PBMCs from cattle immunised with the shipping fever 
strain of P. multocida exhibited a higher stimulation index when incubated with an antigen 
preparation from the homologous strain than with antigen preparation from heterologous 
HS strains (Maheswaran & Thies, 1979).
To investigate the cellular response of calves in a pneumonia model caused by M. 
haemolytica, proliferative responses and IFN-y production of PBMCs and lymph node 
cells were assessed after vaccination with live and inactivated vaccines or intratracheal 
infection. Different antigen preparations, including capsular polysaccharide (CP), 
lipopolysaccharide (LPS), lipopolysacchaiide-associated protein (LAP), bacterial cell
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sonicate (SON) and outer membrane protein (OMP) were used for the lymphocyte 
stimulation assay. Of them, OMP was found to be the best component for this puipose and 
no stimulation was observed using capsular polysaccharide. Lymph node cells from calves 
in the live vaccine group and infected group showed strong proliferation and TFN-y 
production after stimulation. In the infection group, a stronger cellular respose was 
observed in cells obtained from lymph nodes nearer the site of bacterial administration. In 
the live vaccine group, a stronger response was observed in distant lymph nodes compared 
to lymph nodes near to infection site. In PBMCs obtained from animals intratracheally 
inoculated before challenge, no proliferation or IFN-y production was detected in any of 
the groups. In an attempt to explain this unresponsiveness of PBMCs, it was suggested that 
reactive lymphocytes were absent in the blood and they possibly were partitioned in the 
lymph nodes. Another suggested possible reason was that the antigen presenting cells in 
lymph nodes acted more effectively than those in peripheral blood in the in vitro assay 
(DeBey et a l, 1996). However, in this experiment the PBMC stimulation assay was not 
done in parallel with cells obtained from lymph nodes on the day of necropsy and therefore 
it is quite difficult to compare the responsiveness of these two sets of cells. In another 
study, PBMCs from M. haemolytica~miQC\.QÔ. calves gave a poor lymphoproliferative 
response to leukotoxin despite their high serum antibody levels against the leukotoxin and 
M. haemolytica (Hughes et a l,  1992).
1.13.3.2 In vitro proliferative responses
The in vitro proliferative response of PBMCs to mitogens has also been extensively used to 
study cellular immunity and investigation of T and B cell functions. Mitogens are 
lymphoid proliferative agents, which can non-specifically induce cell division. They are 
polyclonoal activators as they activate most T and/or B cells. Lectins, which are 
carbohydrate-binding proteins, are commonly used mitogens. Three of the most commonly 
used lectins are: 1) concanavalin A (ConA), a T cell mitogen derived from jack bean seeds; 
2) phytohaemagglutinin (PHA), a T cell mitogen derived from kidney beans; 3) pokeweed 
mitogen (PWM), a mitogen for both T and B cells derived from pokeweed. LPS although 
not a lectin, has mitogenic activity on B cells.
Mitogen proliferation of lymphocytes in vitro, which is done by cross-linking the BCRs (B 
cell receptors) or TCRs (T cell receptors), is believed to mimic stimulation by specific 
antigens fairly closely. The use of these agents in vitro has shown that activation of T and 
B cells leads to the production of cytokines and their receptors, which together drive the 
cells through their cell cycle (proliferation) and ultimately to maturation and to the
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production of effector cells (Roitt et a l, 1998). Concanavalin A (Con A) is a lectin with 
potent T cell mitogenic activity and has been extensively used to study in vitro lymphocyte 
responses. In cattle, blood lymphocytes acquired the ability to respond to mitogens 
between 75 and 80 days age of the foetus, but this ability is lost temporarily around the 
time of birth as a result of high serum steroid levels (Tizard, 2000).
In different studies, the inhibition of proliferative response of lymphocytes to mitogens has 
been investigated as suppression of cellular immunity due to infection caused by 
pathogens. In a study on sheep, it was shown that infection with Trypanosoma evansi 
suppressed the proliferative responses of PBMCs to ConA and LPS. This study also 
showed that the proliferative response of PBMCs obtained from M. haemolytica- 
vaccinated animals to conesponding antigen (assessed by lymphocyte stimulation assay) 
was suppressed by infection with T. evansi. Interestingly, it was shown that treatment of 
animals with a trypanocide restored the proliferative ability of the cells (Onah et a l, 1998). 
In another study on cattle, the proliferative response to lectins and S. aureus antigens in 
lymphocytes obtained from mammary glands infected with S. aureus was less than the 
response of cells from healthy animals (Park et a l, 1993).
The suppressive effects of some bacteria or their components have also been investigated 
using in vitro systems. A study on the suppressive properties of Helicobacter pylori 
showed that the lysate of the bacterium was able to inhibit mitogen-induced proliferation 
of human PBMCs (Knipp et a l, 1993). Further studies on murine spleen and mesenteric 
lymph node cells showed that the pre-exposure (incubation for 2 h) of cells to CFE of the 
bacterium had the same inhibitory effects on T cell proliferative agents (Con A, phorbol- 
myristate-acetate and ionomycin, and the anti-CD3epsilon monoclonal antibody). Heating 
of the CFE at 80°C for 30 minutes, completely abolished its inhibitory action (Chen et a l,
2000). Vacuolating cytotoxin (VacA) was identified by further studies as the suppressive 
agent (Gebert et a l, 2003) and the mechanism involved is believed to be independent of 
IL-2 (Sundrud et a l, 2004). A study on Mycoplasma bovis (a pathogen of cattle that 
causes pneumonia, arthritis, and mastitis), showed that the organism was able to induce 
apoptosis in bovine lymphocytes (Vanden Bush & Rosenbusch, 2002). Further study 
revealed immunosuppressive properties of a protein component of the organism with anti- 
lymphoproliferative effects on cattle PBMCs. This study also introduced a 26-amino acid 
recombinant peptide from Mycoplasma bovis, which showed suppressive effects and was 
able to suppress the ConA-induced proliferation of bovine lymphocytes (Vanden Bush & 
Rosenbusch, 2004). No similar studies, on the immunomodulatory effects of P. multocida,
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especially serotype B;2 or its structural components, on proliferation of lymphocytes have 
been reported.
1.13.3.3 In vitro cytokine responses
Immunoregulatory cytokines play an important role in the immune response against 
different pathogens. Several studies have used in vitro systems to investigate changes in 
cytokines after exposure of immune cells to different microbial pathogens or their 
components. In vitro systems have also been used to study the profiles of cytokines and 
their function as a model of protective response.
The effect of P. multocida porin and LPS on mouse splenocyte cultures has been studied 
by analysing the expression and release of IL-la, IL-6, TNF-a, IL-4, IFN-y, IL-10 and IL- 
12 cytokines (lovane et a l, 1998b). Treatment of splenocytes with either purified porin or 
LPS for 3 hours caused an increase in intensity of the signal from IL-la, IL-6, TNF-a, 
IFN-y and IL-12 mRNA while no effect was detected on IL-4 and IL-10 mRNA under the 
same conditions. These purified components also showed a dose-dependent regulatory 
effect on the induction and release of pro-inflammatory cytokines (EL-1 a, IL-6, and TNF- 
a) after 24 hours and immunoregulatory cytokines (IFN-y and IL-12) after 48 hours. Both 
of the LPS and porin induced release of IL-la, IL-6, TNF-a, IFN-y and IL-12 in cultures. 
Stimulation with LPS induced the release of IL-la, IL-6 and TNF-a, which began at 3 
hours and was completed after 12 hours. LPS induction of IFN-y and IL-12 began after 12 
hours and was completed at 36 hours. Stimulation with porin caused IL-la, IL-6 and TNF- 
a release after 6 hours and was completed after 24 hours. Porin induction of IFN-y and IL- 
12 reached a significant level after 24 hours and was completed after 48 hours. It was 
concluded that the stimulation with LPS is a faster process than porin and it happens at a 
greater rate (lovane et al., 1998b).
1.13.4 Naturally-acquired immunity
Naturally-acquired immunity is the immunity against HS that occurs on exposure to the 
organism but without any vaccination. This status was recorded for the first time among 
buffaloes in Thailand and it was concluded that about 10% of the buffalo herds were 
naturally immune (Bain, 1954). Further studies in Sri Lanka showed that naturally- 
acquired immunity of animals resulted from natural exposure to infection and the 
proportion of immunity varied from herd to herd and also from time to time (de Alwis & 
Sumanadasa, 1982). After outbreaks of HS, antibody levels rise in two to four weeks and
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persist in some animals for over a year. The percentage of naturally-immune animals is 
highest in endemic areas and least in non-endemic areas (De Alwis, 1982). Natural 
immunity has also been reported in some areas where HS does not exist, including 
Australia and United States (De Alwis, 1994). In a study in USA, antibodies against HS- 
related serotypes B and E were demonstrated among a high percentage of sera from 
domestic feeder calves. The antibodies were demonstrated by passive mouse protection 
(BMP), agglutination, and indirect haemagglutination (IHA) tests. In the PMP test, 
injection of mice with sera obtained from calves caused protection against challenge with 
serotypes B and E in 81% and 91 % of cases respectively. IHA and agglutination tests 
demonstrated antibody in nearly all sera. It was concluded that the source of these 
antibodies was not HS-related serotypes, as serotype E has been isolated only in Africa and 
there is only one report of serotype B isolation from cattle in the United States (Sawada et 
a l, 1985). Since, these organisms were not considered likely sources of the antigenic 
stimulation that provoked production of these antibodies, it is believed that in these 
situations immunity may have been due to exposure to other antigenitcally-related P. 
multocida (De Alwis, 1999). Thus, it can be infemed from the studies on naturally-acquired 
immunity against HS that this immunity could be attributed to two different sources: to 
protective antibodies that develop as a result of non-fatal exposure to the organism, and to 
the exposure to antigenically-related organisms, sometimes called non-specific immunity, 
particularly in areas where HS does not exist.
1.14 Objectives and experimental approach of this study
The primary objective of this study was to investigate safety and potency of an aroA 
mutant of P. multocida serotype B:2 (JRMT12, section 2.1.1) as a live vaccine candidate in 
cattle against experimental HS. To do this, three different experiments were set up to study 
the responses of 2-4 week old calves to vaccination with the aroA strain and their response 
to challenge with the parent wild type 85020 strain one week after vaccination: 1) Different 
routes of vaccination, IN and IM, using two doses of 10  ^CPU of the aroA strain with a 4- 
week interval; 2) Different doses (10^ 10  ^and 10  ^CPU) injected twice IM; 3) A single IM 
vaccination with 10  ^CPU.
Safety of JRMT12 was assessed by determination of clinical responses (rectal temperature, 
dullness, respiration, appetite, incidence of nasal/oral discharges) and changes in SAA and 
Hp, taken as indicators of the progress and severity of infection. Potency was assessed by
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measurement of serum antibodies (IgG and IgM) to P. multocida B:2 and by survival rate 
after subcutaneous challenge with the wild type strain.
Immunogenic components of P. multocida to which antibody were raised during different 
stages of vaccination and challenge were detected by SDS-PAGE and immunoblotting. For 
further identification of immunogenic components, OMPs of the bacterium were prepared 
and subjected to identification by mass spectrometry (MS). Changes in OMPs prepared 
from P. multocida B:2 grown under iron-depleted conditions and the possibility of 
presence of immunogenic components were also investigated.
A possible contributory role of cellular immunity against HS was investigated in calves 
given a single IM dose of 10  ^ CPU and in control calves after challenge. A lymphocyte 
stimulation assay was used to assess the effects of a cell-free extract (CFE) of P. multocida 
on PBMCs isolated from calves at different times after challenge. Following the 
observation of inhibitory effect of challenge with P. multocida B;2 on calf PBMCs, further 
in vitro experiments were earned out to investigate the possibility of suppressive properties 
of CPE on PBMCs obtained from noimal calves. Further investigations were focused on 
preliminary characterisation of the suppressive agent(s) and identification of the 
suppressed cell population(s) of PBMCs. FACS analysis, was used to determine the 
populations of PBMCs, which were affected by treatment with CPE. B cell and T cell 
subpopulations (CD4‘*‘, CDS'*' and yô'*') in normal calf PBMCs were identified and the 
changes in their relative proportions after different treatments were also investigated.
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Chapter 2 
MATERIALS and METHODS
2.1 General bacteriological procedures
2.1.1 Source of bacteria
Bacterial strains used in the experiments were obtained from culture collections of the 
Division of Infection and Immunity, University of Glasgow or the Moredun Research 
Institute, Edinburgh (Table 1). Pasteurella multocida serotype B:2 strain 85020 was 
originally imported from Sri Lanka under licence PO/95/22. JRMT12 was an aroA mutant 
constructed from P. multocida B:2 strain 85020 (Tabatabaei et a l, 2002).
2.1.2 Growth media and bacterial storage
Media used for growth of bacteria were Brain Heart Infusion (BHI, Oxoid) broth 
(Appendix A.l), Nutrient Broth (NB, Oxoid) (Appendix A.2), or Sheep Blood Agar (SBA, 
Oxoid) [supplemented with 5% (v/v) defibrinated sheep blood (B&E Laboratories, 
Scotland)] (Appendix A.3). All strains were stored at -70°C in 1 ml aliquots in 50% (v/v) 
autoclaved glycerol in BHI broth. All media were sterilised by autoclaving at 15 p.s.i., 
12UC for 15 min except where stated. Heat-labile ingredients such as antibiotics were 
sterilised by filtration through a sterile 0.2-pm pore size membrane (Saitorius). Glassware 
was sterilised by dry heating to 160 °C for 2 h.
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Table 1 Different bacteria used in experiments
S p e c ie s  o r  S t r a in O r ig in S u p p l ie d  b y
Pasteurella multocida Bovine haemorrhagic Division of Infection and
serotype B:2 (85020) septicaemia Immunity, University of 
Glasgow (Dr. John Coote)
JRMT12 (an aroA mutant o f Bovine haemorrhagic Division of Infection and
Pasteurella multocida  B:2 septicaemia Immunity, University of
85020) Glasgow, (Dr. John Coote)
Pasteurella multocida Bovine pneumonia M oredun Research Institute,
serotype A3 (MRJ, 671/90) (Dr. J. Christopher Hodgson)
Pasteurella multocida Swine atrophic rhinitis Division o f Infection and
serotype D Immunity, University of 
Glasgow, (Dr. Robert L. Davies)
Pasteurella multocida Ovine pneumonia Division o f Infection and
serotype A Immunity, University of 
Glasgow, (Dr. Robert L. Davies)
Pasteurella multocida Avian fowl cholera Division o f Infection and
serotype A Immunity, University of 
Glasgow, (Dr. Robert L. Davies)
M annheimia haemolytica Bovine pneumonia Division of Infection and
serotype A1 Immunity, University of 
Glasgow, (Dr. Robert L. Davies)
M annheimia haemolytica Ovine pneumonia Division o f Infection and
serotype A2 immunity, University o f 
Glasgow, (Dr. Robert L. Davies)
Escherichia colt Division o f infection and
Strain K I2 Immunity, University of 
Glasgow, (Dr. John Coote)
Staphylococcus aureus Division of Infection and 
Immunity, University of 
Glasgow, (Dr. John Coote)
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2.1.3 Growth of P. multocida
P. multocida strains, from -70°C glycerol stock, were inoculated in 1 ml aliquots into 9 ml 
of BHI broth, NB or onto SBA. Incubation was for 16-18 h at 37°C statically. For large- 
scale culture for preparation of different components of the bacteria, 16 h broths were 
inoculated into 250 ml amounts of BHI broth in 1-L flasks (5-10 percent inoculum) and 
incubated in the same conditions statically.
For growth of P. multocida strain 85020 under iron-limited conditions, 2.2’-dipyridyl was 
added to BHI broth at 150pM concentration (Appendix A7). In preliminary experiments, 
the growth rate was assessed at five different concentrations (120, 140, 150, 170, and 220 
pM) of dipyridyl. The 150pM concentration of dipyridyl was highest concentration at 
which P. multocida grew.
2.1.4 Preparation and administration of vaccination and challenge doses
To keep the vaccination and challenge doses uniform, 1 ml aliquots of a single batch of a 
stock bacterial suspension containing either the P. multocida 85020 wild type or JRMT12 
mutant strain (Table 1), from the -7 0 °C freezer, were inoculated into 9 ml of BHI broth, 
and incubated overnight (16 h statically) at 37°C, and 3 ml of the resulting culture was 
transferred to 27 ml of BHI broth in 50-ml flasks. The flasks were incubated at 37°C with 
shaking at 200 rpm for 2.5 h (strain 85020) or 3 h (strain JRMT12) to obtain cultures 
containing around 10  ^ CFU/ml as measured by previous experiments where bacterial 
counts were confirmed by spreading dilutions on SBA. Cells were collected by 
centrifugation, resuspended in PBS, and diluted in PBS to the desired vaccination or 
challenge doses, confirmed by viable counts on SBA. For administration of vaccination 
doses in IM-vaccinated groups, desired doses of P. multocida JRMT12 mutant strain were 
prepared in 5 ml of PBS as two 2.5 ml doses and injeeted into semi-tendinosus muscle of 
each hind limb. In IN-vaccinated group the 5 ml dose was inoculated into nostrils of calves 
while the head was kept up. For administration of the challenge dose, the desired dose of 
P. multocida strain 85020 was prepared in 5 ml of PBS as two 2.5 doses injected SC, one 
over each prescapular region.
Intratracheal challenge of calves with Pasteurella multocida serotype A3 was carried out 
according to the procedure of Dowling (Dowling et a l, 2002). The challenge dose was 
prepared in 300 ml of PBS containing 10  ^ CFU of P. multocida strain MRI-671/90 (Table 
1). A one ml aliquot of a stock culture of the strain was inoculated into 10 ml of nutrient
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broth (NB) (Appendix A2), and incubated at 37°C statically overnight. Aliquots of 0.5 ml 
of this overnight culture were inoculated into 10 ml of NB and incubated at 37°C with 
shaking for 3.5 h. Cultures were diluted with pre-warmed (37°C) PBS to produce challenge 
inocula containing an estimated 10  ^ CFU in 300 ml volumes. Actual challenge doses were 
estimated retrospectively by plating out serial dilutions of each dose onto SBA.
2.2 Animal procedures at Moredun Research Institute
All animal experimental protocols were approved by the Moredun Research Institute 
Animals Experiments Committee and authorized under the United Kingdom Animals 
(Scientific Procedures) Act of 1986. The work with calves was performed by Dr. J.C. 
Hodgson (Bacteriology Laboratory, Moredun Research Institute) and my involvement in 
the conduct of the experiments was done under his supervision.
During the course of animal experiments, any calf showing pyrexia was treated with 
intravenous Flunixin meglumin (Finadyne; Schering-Plough Animal Health, Welwyn 
Garden City, United Kingdom), a nonsteroidal anti-inflammatory drug (NSAID), at 2.2 
mg/kg. At the end of the experiments, the calves were killed humanely within the 
contaimnent facility by intravenous injection of 25 ml of Pentobarbitone sodium B.P. (200 
mg/ml; Animal care, York, United Kingdom), surface disinfected, and bagged before 
transport to the post-mortem suite for gross pathological examination and removal of 
tissues for bacteriology and histopathology. Any of the animals showing clinical signs of 
pain or very high stages of sickness, after challenge or at any stages of the experiments, 
were killed for humane reasons.
2.2.1 Selection of P. multocida-free calves
Infection of the upper respiratory tract of calves with Pasteurella multocida serogroup A is 
common in the United Kingdom (Dowling et a l, 2002). To reduce the possibility of an 
active humoral immune response compromising the vaccination studies, only F. multocida- 
free calves were selected for experiments. To check the calves, nasal swabs (Cultureswab 
Plus; BD Biosciences, Oxford, United Kingdom) were obtained from calves within 24 h of 
birth by Dr. Hodgson and assessed for growth of F. multocida after being plated on SBA 
containing vancomycin (1 mg/ml) (Appendix A.5) to prevent the growth of Gram-positive 
bacteria. Chosen calves that had been shown to be free of F. multocida infection were 
treated at 2 days of age with em'ofloxacin at 2.5 mg/kg of body weight (Baytril Max; Bayer 
Animal Health, Newbury, United Kingdom) by subcutaneous injection, housed in air-
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filtered isolation pens, offered milk and, at 7 weeks old, weaned onto a diet of calf creep 
feed and hay.
2.2.2 Conditions for containment of calves
Throughout the experiments the animals were maintained at a high standard of care and 
sanitation with their health and well-being assessed daily; veterinary assistance from the 
Clinical Division of the Moredun Research Institute was available at all times, and feed 
and water were provided ad libitum. The conditions for containment and handling of 
animals inoculated with either the mutant or parent strain of P. multocida B:2, which has 
not been reported from the United kingdom, were set at containment category 2 (Health 
and Safety Executive Advisory Committee on Dangerous Pathogens). The animal 
accommodation used for the experiments provided this level of containment, but as added 
safety precautions to prevent the escape of P. multocida B:2 into the environment, 
ventilation was adjusted so that the rooms were under negative pressure during the 
experiments, drains were blocked, matting and absorbent bedding were provided and 
renewed regularly, and all waste materials were bagged, surface disinfected, and 
incinerated.
2.2.3. Experimental design
Three sets of experiments were designed to assess safety and potency of different doses of 
JRMT12 by different routes of vaccination. In each experiment, the calves were allocated 
randomly to different groups of vaccinated and control animals. The number of animals in 
each group was restricted to the minimum likely to generate a statistically significant 
result.
2.2.3.1 First experiment
The object of this experiment was to investigate whether vaccination of calves twice either 
intramuscularly or intranasally with 10  ^CFU of P. multocida B:2 mutant strain JRMT12 
would provide protection against subcutaneous challenge with 10  ^ CFU of the P. 
multocida B:2 parent strain 85020.
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N u m b e r  
o f  c a lv e s
Treatment Purpose
v a c c in a t io n  
(2  w e e k s  o ld )
2 “** v a c c in a t io n  
( a t  6 w e e k s  o ld )
C h a lle n g e  
( a t  8 w e e k s  o ld )
3 - - 10" cfu Challenge controls
4 Intranasal, (10^ cfu)
Actual dose'*': 
(6x10®  cfu)
Intranasal (10^ cfu) 
Actual dose: (10^ cfu) lO" cfu
To determine if two 
intranasal
vaccinations with 10® 
cfu dose protects 
against challenge
4 Intramuscular, (10^ cfu) 
Actual dose:(6 x 10® cfu)
Intramusculai,(10^ cfu) 
Actual dose:(10^ cfu) lO" cfu
To determine if two 
intramuscular 
vaccinations with 10® 
cfu dose protects 
agciinst challenge
* Actual dose: determined by spreading dilutions on S]BA.
2.2,3.2 Second experiment
The object of this experiment was to investigate whether vaccination of calves twice 
intramuscularly with 10®, 10®, or 10  ^ CFU of P. multocida B:2 mutant strain JRMT12 
would provide protection against subcutaneous challenge with 10  ^ CFU P. multocida B:2 
parent strain 85020, in the absence of an inflammatory response.
N u m b e r  
o f  c a lv e s
Treatment Purpose
F ‘ v a c c in a t io n  
( a t  4  w e e k s  o ld )
2"** v a c c in a t io n  
( a t  8 w e e k s  o ld )
C h a lle n g e  
( a t  10 w e ek s  
o ld )
3 - - lO’cfu Challenge controls
5 Intramuscular: ( 10^ cftij 
Actual dose: (1.1 x 10®)
Intramuscular, (10® 
cfu)
Actual dose: (8x10® )
10" cfu
Confirm protection 
obtained in first Expt. 
with 10® cfu
5 Intramuscular: (10® cfu) 
Actual dose: (6.3 x lo")
Intramuscular(10® cfu ) 
Actual dose: (1 x 10®) 10"cfu
Determine if 10® cfu 
dose protects
5 Intramuscular: (lO" cfu) 
Actual dose: (8.5 x 10^)
Intramuscular, (lO" 
cfu)
Actual dose: (1.1 x lo" 
cfu)
10"cfu
Determine if  lO" cfu 
dose protects
2.2.3.3 Third experiment
The object of this experiment was to investigate whether a single vaccination of calves 
intramuscularly with 10® cfu of P. multocida B:2 mutant strain JRMT12 at 4 weeks of age 
would provide protection against subcutaneous challenge at 8 weeks of age with 10  ^cfu P. 
multocida B:2 parent strain 85020.
S a e e d  Ataei Kachooei, 2007 74 MATERIALS and METHODS
N u m b e r  
o f  c a lv e s
Treatment Purpose
V a c c in a t io n  
( a t  4 w e e k s  o ld )
C h a lle n g e  
( a t  8 w e e k s  o ld )
5 - 10" cfu Challenge controls
4 Intramuscular: (10® cfu) 
Actual dose: (5 x lo" 
cfu)
lO" cfu
Determine if single vaccination protects 
against challenge
2.2.4 Clinical responses
Following vaccination or challenge, clinical responses including: rectal temperature, 
dullness, respiration (rate and nature), appetite, incidence of nasal/oral discharges, of 
animals were monitored and recorded at 2-3 h intervals or as necessary, by experienced 
observers of the Clinical Division of Moredun Research Institute. Clinical reaction to 
vaccination and challenge was expressed as a clinical score that was assessed by general 
demeanom' (scored zero to 3; calf normal scored as 0; calf dull, slow to move, appears 
inattentive scored as 1 ; calf depressed and reluctant to stand unassisted scored as 2; calf 
severely depressed, recumbent, unable to rise scored as 3).
2.2.5 Blood analysis
Blood samples (10 ml) were collected by Dr, Hodgson from the jugular vein of animals 
into plain and heparinised Vacutainers (Becton Dickinson, Meylan, France). Blood 
samples were collected from all calves before vaccination, after each vaccination and at 
weekly intervals in between. Blood samples were also collected before challenge, and at 
different time points after challenge. Sera or plasmas were separated and stored at -40°C 
for further investigation.
2.2.6 Bacterioiogicai examination
Tissue samples of size of around 1 cm® were taken post-mortem by Dr. M. Dagleish 
(Department of Pathology, Moredun Research Institute) from lung, kidney, heart, spleen, 
liver, brain, and different lymph nodes and were homogenised in 9 ml of peptone-water 
(Appendix A.4). Aliquots of 10 pi were spread on SBA containing 1 mg/ml vancomycin 
(Appendix A.5) and incubated for 16-20 hours at 37"C prior to phenotypic and numerical 
analysis. Blood samples (10 pi) were cultured in the same way. P. multocida serotypes A 
colonies were distinguished from P. multocida B:2 by a mucoid consistency and creamy 
colour.
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2.2.7 Necropsy
All animals were subjected to post-mortem examination by Dr. Dagleish at the Clinical and 
Pathology Departments of Moredun Research Institute. Gross pathology was assessed, and 
tissue samples from different organs including lung, liver, kidney, spleen, brain, tonsil, 
thymus, and lymph nodes (prescapular, bronchial, mid- and caudal mediastinal, 
mesenteric, submandibular, axillary, retropharyngeal, and prefemoral) were preserved in 
saline containing 4% (w/v) formaldehyde: formol-saline and prepared for histopathological 
examination using standard techniques (embedded in paraffin wax, sectioned, mounted on 
microscope slides, and stained with haematoxylin and eosin [H&E]).
2.3 Laboratory procedures
2.3.1 Preparation of bacterial cell-free extract (CFE)
CFEs of different bacterial strains were prepared from 18 h broth cultures. A purity test 
was done by Gram staining a smear preparation of the culture and direct checking by light 
microscopy. Cells were collected by centrifugation at 3,000 x g for 30 min at 4°C (RC-5B, 
Sorvall) and washed three times with PBS (Appendix A.6). A thick suspension of bacteria 
in PBS was lysed by sonication using a Vibra Cell ultrasonic processor (Jencons-PLS, 
Leighton Buzzard, United Kingdom) for three 60-s bursts with intermittent cooling on ice. 
The broken-cell suspension was centrifuged at 3,000 x g for 30 min at 4°C, and the 
supernate was filtered through a 0.2-)Um-pore-size membrane (Sartorius). The protein 
concentration was determined by Bradford assay (Section 2.3.6.1) and adjusted to a desired 
concentration by adding sterile PBS.
2.3.2 Dialysis of CFE
CFE obtained from P. multocida 85020 was dialysed using dialysis tubing with a 
molecular weight cut off of 10,000 Da (Medicell International Ltd.). The tubing was boiled 
in 0.5 inM EDTA (pH 8.0) for 30 min and stored in 70% (v/v) ethanol at 4°C until ready to 
be used. The tubing was rinsed thoroughly with distilled water before use. 5 ml of the CFE 
was dialysed in 1000 ml PBS (Appendix A.6) twice overnight at 4°C with constant stirring. 
The dialysed preparation was kept at -70°C until use.
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2.3.3 Outer-membrane protein (OMP) preparation
OMPs were prepared by Sarkosyl extraction according to Davies with modifications 
(Davies et a l, 1992). Bacteria were harvested from 18 h cultures of BHI broth (Appendix
A .l) then washed three times with PBS (pH 7.2) by centrifugation at 3,000 x g for 30 min 
at 4°C. The cells were suspended in cold 20 mM-Tris/HCl (pH 7.2) buffer and sonicated on 
ice for three 60-s bursts with intermittent cooling on ice with a Vibra Cell ultrasonic 
processor (Jencons-PLS, Leighton Buzzard, United Kingdom). The suspension was 
centrifuged at 10,000xg for 30 min at 4°C to remove unbroken cells. The supernate was 
then centrifuged at 100,000xg for 1 h at 4°C (Combi, Sorvall) to pellet the cell envelopes. 
The pellet was resuspended in 0.5% (w/v) V-lauroylsarcosine (Sarkosyl, Sigma) (Appendix
B.8) and left for 20 min at room temperature to solublise the cytoplasmic membranes. 
Outer-membrane proteins (sarcosine-insoluble membrane fraction) were then pelleted by 
centrifugation at 100,000xg for 30 min at 4°C. The pellet was washed once in distilled 
water and resuspended in PBS (pH 7.2) at a protein concentration of 2 mg/ml, assessed by 
Bradford assay (Section 2.3.6.1), and stored at -70°C.
Outer-membrane proteins were also prepared from the P. multocida strain 85020 grown 
under iron-limited conditions (Section 2.1.3). The same procedure detailed above was used 
for the OMP preparation.
2.3.4 Polysaccharide capsule and culture supernate preparation
Polysaccharide capsule of P. multocida 85020 was isolated based on the procedure of 
Carter (OIL, 2004). An overnight culture in BHI was centrifuged at 3,000 x g for 30 min at 
4“C. The culture supernate was filtered through a 0.2 pm-pore-size membrane (Sartorius), 
a sample was removed for estimation of protein concentration by Bradford assay (Section 
2.3.6.1) and the remainder was kept at -70^C until used. The pellet was washed three times 
with PBS (pH 7.2) by centrifugation at 3,000 x g for 30 min at 4°C. The cells were 
suspended in PBS and heated in a water bath at 56°C for 30 min, centrifuged at 3,000 x g 
for 15 min at 4°C and the clear supernatant fluid separated and filtered through 0.2 pm- 
pore-size membrane. This preparation was used as polysaccharide capsule and kept at -  
70°C until used.
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2.3.5 LPS from E. coli
Purified LPS was extracted from E. coli, and was kindly supplied by Dr. G. Cheung 
(Division of Infection and Immunity, University of Glasgow). Briefly, a 3 h culture of E 
coli grown in LB at 37°C with shaking at 200 rpm was harvested by centrifugation at 
13,700 X g for 30 min (Sorvall, RC-5B). A thick suspension of the resulting bacteria was 
freeze-dried (Clnist technologies, alpha 1-4) and then, to each gram of dry weight, 10 ml of 
PBS containing 5mM EDTA was added and incubated for 2 h at 37°C. Lysozyme (Sigma) 
was added at 0.02 g for each gram of dry weight and incubated at 4°C for 16 h, with 
constant stirring. The solution was further incubated at 37°C for 20 min and then an equal 
volume of 20 mM magnesium chloride was added. RNAase (Sigma) and DNAase (Sigma) 
were added to the mixture, both at final concentrations of 1 pg/ml, and incubated for 10 
min at 37°C then at 60°C for a further 10 min. An equal volume of pre-heated (70°C) 
phenol solution, equilibrated with 10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 7.5-7.8) 
(Sigma), was added to the mixture and incubated for 20 min at 70°C with constant stining. 
The aqueous/phenol mixture was placed on ice for 20 min with stirring, then overnight at 
4°C with no stirring. The upper aqueous phase (containing LPS) was removed and dialysed 
(MW cut off 12-14 kDa) against water for 3 days (Section 2.3.2). The dialysed LPS 
material was centrifuged at 4,220 x g (Sorvall, RC-5B) for 15 min at 4°C. The supernate 
was collected and freeze-dried and the fine LPS powder was stored at 4°C. Once 
reconstituted with endotoxin-free water (Sigma), the LPS was stored at -20°C. The LPS 
content was assessed by the LAL-Chromogenic method (LAL reagent. Bio Whittaker, UK) 
and expressed in Endotoxin Units (EU)/ml.
2.3.6 Quantification of proteins
All of the CFEs, OMPs, and other bacterial preparations were subjected to protein 
quantification to measure the protein content and set to the desired concentrations. Two 
methods were used for this puipose. Bradford assay was used to measure the protein 
content of all preparations and, if the protein concentration was less than 200 pg/ml, the 
sample was then subjected to modified Lowry assay.
2,3.6,1. Bradford assay
The Bradford reagent (BioRad) was used to provide a quantitative measurement of protein 
concentration of samples containing soluble proteins (excluding OMP preparations). When 
Coomassie dye binds protein in an acidic environment, an immediate absorbance shift
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occui's from 465 nm to 595 nm with a simultaneous colour change of the reagent from 
green/blue to blue. The Bradford’s reagent was diluted 1 in 5 with distilled water and 
filtered through a 0.45 pm Sartorius filter before use. The method needs a standard curve 
which is established with different concentrations of bovine serum albumin (BS A) (Sigma) 
(Appendix B.7) in PBS. A solution of 2 mg/ml of BSA was prepared in PBS and 2-fold 
dilutions of this in PBS were prepared in a microtitre plate. PBS alone served as a negative 
eontrol and blank. To a new flat-bottomed 96-well microtitre plate, 25 pi of each dilutions 
of BSA and sample were mixed with 200 pi of diluted Bradford’s reagent. After incubation 
for 10 min at room temperature, the absorbance values were read at ODgio nm in a plate 
reader (Dynex technologies). Once the blank CD values had been subtracted from all OD 
values, the protein concentrations of the samples were deteimined from the BSA standard 
curve.
2.3.6.2. Modified Lowry assay
This assay, which is appropriate for quantification of soluble and non-soluble proteins, 
relies on the formation of a protein-copper eomplex (Biuret reaction) and the reduction of 
the phosphomolybdate-phosphotungstate reagent (Folin-Ciocalteu phenol reagent. Sigma) 
(Appendix B 6.3) by the tyrosine and tryptophan residues of the protein. The method also 
needs a standard curve, which is generally established with BSA (Appendix B.7). Protein 
standards containing 25 to 200 pg/ml of BSA in PBS were used. Dilutions of the sample of 
unknown protein concentrations were prepared in duplicate. 100 parts of reagent A was 
mixed with 1 pail of reagent B (Appendix B 6.2) to form reagent C (the alkaline copper 
reagent) (Appendix B 6.3). A sample volume of 1 ml containing 20 to 200 pg/ml of protein 
was added to 3 ml of reagent C and then incubated at room temperature for 10 to 60 min. 
The samples were then mixed vigorously with 0.3 ml of diluted Folin-Ciocalteu (Sigma) 
phenol reagent (Appendix B 6.3) and incubated for 45 min at room temperature. The OD 
was read at 660 nm by spectrophotometer (Gilbert 250), and the results expressed in pg/ml 
of protein.
2.3.7 Acute phase protein (APR) assay
Serum amyloid A (SAA) and haptoglobin (Hp) were measured by Prof. David Eckersall in 
calf serum samples obtained at different stages of vaccination and challenge. Serum 
samples were supplied to the Centre for Integrated Diagnostinc Systems (CIDS) of 
University of Glasgow. The assay method was based on an ELISA for SAA and a
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biochemical haemoglobin binding assay for Hp according to Horadagoda method 
(Horadagodaef a/., 1999).
2.3.8 Serum sensitivity assay
The serum sensitivity assay was done according to Boyce and Adler with modifications 
(Boyce & Adler, 2000). Guinea pig complement serum (Sigma) and sera from young 
calves (fresh normal calf serum [Bov.Ser]) were used as the complement source. Jugular 
blood from normal young calves collected (kindly peraiitted by Dr. Harold Thompson and 
helped by Mr. Richard h  vin) in sterile glass containers when the calves were put down at 
the Department of Pathology, School of Veterinary Medicine, University of Glasgow. 
Collected blood was then left at room temperature for 4 h and the serum was separated, 
aliquoted and kept at -  20°C. The assay was performed in 96-well, tissue culture-grade, 
flat-bottomed, micro-plates (Costar, USA). To prepare a bacterial suspension, a few 
separate colonies from an overnight culture of P. multocida 85020 on SBA (Appendix A.3) 
were inoculated into 9 ml of BHI broth and incubated statieally overnight at 37°C. An 
inoculum of 0.5 ml was transferred into 9 ml of pre-warmed BHI broth (Appendix A .l) 
and incubated at 37°C with shaking at 200 rpm for 4 h. The cells were collected by 
centrifugation at 3,000 X g for 30 min at 4°C and then washed onee with PBS (pH 7.2) and 
re-suspended in PBS. A bacterial suspension of 2x10^ CFU/ml in PBS was prepared from 
P. multocida 85020 or E. coli and used as the bacterial suspension. Different test sera (25 
pi) were added in duplicate in the wells of sterile micro-plates, except when evaluating the 
effect of complement alone, where the serum was replaced with PBS. Bacterial inoculum 
(50 pi) was then added to each well. The complement source (25 pi) was added, except to 
the control wells for evaluation of the effect of test sera on P. multocida in the absence of 
complement and the complement control wells in which heat-inactivated (56°C for 30 min) 
complement was added. Plates were then covered with a lid and incubated at 37°C for the 
required time. Diluted (10‘  ^ and 10'^) and undiluted samples (lOpl) from each well were 
plated on SBA in 10 xio cm square plates (Bibby Sterilin, United Kingdom) at the 
beginning (time zero) and at one h after incubation. The plates were allowed to dry and 
then incubated overnight at 37“C. The count of each countable test was calculated as the 
mean number of colonies derived from in each of the three different dilutions. The killing 
effect of each serum was calculated as a bactericidal index: CFU/ml after 1 h incubation 
divided by CFU/ml at time zero. Data presented as the average of two assays ± standard 
deviation.
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2.3.9 Sodium dodecyl sulphate-poiyacrylamide gel electrophoresis (SDS- 
PAGE)
The SDS-PAGE for analysing P. multocida CFEs and outer membrane proteins was done 
according to the method of Laemmli (Laemmli, 1970). Samples were diluted 1:6 with 5x 
loading buffer (Appendix B .l) and boiled for 5 min. A vertical gel electrophoresis tank 
using the Mini Protean 3™ slab gel electrophoresis system (Mini Protean, Bio-Rad, 
Richmond) was used with 4% polyacrylamide gel as stacking gel (Appendix B.2) and 10% 
polyaerylamide gel as resolving gel. Resolving gels (Appendix) were poured between the 
assembled glass plates with a 1.5-cm space left on top for the later addition of the stacking 
gel. Immediately, absolute ethanol was poured on top of the gel to eliminate any bubbles 
and form a horizontal interface for addition of the stacking gel. Once set, the ethanol was 
removed and then a stacking gel (Appendix B.2) was poured onto the polymerised 
resolving gel and a comb with 10 wells was placed into the gel solution which was allowed 
to set. The wells were rinsed out with distilled water and any residual polymerised gel on 
the face of the assembled glass plates was removed using tissues. The electrophoresis tank 
and gels were assembled according to the manufacturer’s instructions. Electrophoresis was 
performed in Ix electrode miming buffer (Appendix B.4) with a constant voltage of 100 V 
for 2 h or until the dye front ran off the gel. Protein bands were then visualised by staining 
with Coomassie blue (Appendix B.5) for a minimum of 30 min on a rotating platform. 
After incubation, the Coomassie blue stain was decanted and the gel was destained 
(Appendix B.5) several times, for a minimum of 30 min in between changes, on a rotating 
platform until protein bands could be visualised. At this stage, the gel was immersed in 
water and photographed using a transilluminator with camera attached.
2.3.10 Immunoblotting
Following SDS-PAGE, polypeptide bands were transferred to Hybond-C Extra membrane, 
(Amersham Biosciences) using the Mini Protean 3™ electrophoresis tank containing the 
Mini Transblot™ electroblot apparatus (BioRad) according to the method of the 
manufacturer. The stacking gel was removed and the gel was placed in an electroblotting 
apparatus. This was placed into the electrophoresis tank containing Ix transfer buffer 
(Appendix C .l) and an ice pack. After transfer for 1 h at 100 volts, the nitrocellulose 
membrane was soaked in Ponceau S solution (Sigma) for several minutes and then rinsed 
with distilled water to confinn the transfer of proteins onto the membrane. The membranes 
were incubated for 1 h in blocking buffer (PBS-SMT) (Appendix C.3) with shaking at 
room temperature. Membranes were then incubated overnight with a 1/250 dilution of
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immune calf serum in PB ST diluent (Appendix C.4) as primary antibody at 4°C on a 
shaker. After washing 3 times with PBST (Appendix C.2) for 10 min each, the membranes 
were incubated on a shaker for 1 h in 1/1000 dilution of sheep anti-bovine IgG-horseradish 
peroxidase (HRP) conjugate, as secondary antibody (Serotec Ltd., Kidlington, United 
Kingdom). They were then washed 3 times with PBS for 10 min and the substrate (3- 
diaminobenzidine tetrahydrochloride (0.05% w/v) (Sigma) in Tris buffer pH 7.4, 
containing hydrogen peroxide) (Sigma) was added for colour development (substrate 
solution) of reactive bands (Appendix C.5). After the appearance of bands the reaction was 
stopped by washing with excess water.
2.3.11 Protein identification by mass spectrometry
Designated bands were manually excised from a SDS-PAGE gel and placed in 1.5 ml 
eppendoif tubes which were sent to the Sir Henry Wellcome Functional Genomics 
Laboratory at University of Glasgow. Mass spectrometry analysis was performed by Dr. 
Richard Burchmore following standard protocols for LC-MS/Ms (Mutapi et a l, 2005). Gel 
pieces were cut into several pieces and then washed in 500 pi of 100 mM ammonium 
bicarbonate for 30 min to 1 h. Gel pieces were washed in 50% acetonitrile, 100 mM 
ammonium bicarbonate for 30 min to 1 h. To reduce samples, 150 pi of 100 mM 
ammonium bicarbonate and 10 pi of 45 mM DTT were added and incubated at 60“C for 30 
min. To alkylate samples, 10 pi of 100 mM iodoacetamide was added and incubated at 
room temperature in the dark for 30 min. Solvent was discarded and gel pieces were 
washed then in 500 pi of 50% acetonitrile, 100 mM ammonium bicarbonate with shaking 
for 1 h. The supernate was discarded and 50 pi of acetonitrile was added for 10 min to 
dehydrate the gel pieces. Solvent was removed and gel pieces were dried in a vacuum 
centrifuge. A sufficient amount of 0.2 pg/pl sequencing grade modified Porcine Trypsin 
(Promega) in 25 mM ammonium bicarbonate was added to each gel piece and left for 15 
min to rehydrate. Finally, rehydrated gel pieces were covered by 25 mM ammonium 
bicarbonate and incubated at 37 “C overnight for digestion of proteins. Peptides were 
extracted by addition of acetonitrile and dried before analysis by LC-MS/MS. All peptide 
samples were separated on an LC system (Famos / Switches / Ultimate, LC Packings) 
before being analysed by electrospray ionisation (ESI) mass spectrometry on a QSTAR® 
XL Hybrid LC/MS/MS System. Peptide mixtures, extracted from trypsinized gel bands, 
were separated on a single dimension using a Pepmap 018 reversed phase column (LC 
Packings), using a 5 - 85% v/v acetonitrile gradient (in 0.5% v/v formic acid) run over 45 
min. The flow rate was maintained at 0.2 pi / min. Mass spectrometric analysis was 
performed using a 3 sec survey MS scan followed by up to four MS/MS analyses of the
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most abundant peptides (3 sec per peak) in Information Dependent Acquisition (IDA) 
mode, choosing 2"^  to 4"^  ions above thieshold of 30 counts, with dynamic exclusion for 180 
sec. MS/.MS ions data was extracted using Analyst QS software and submitted to the 
Mascot search engine (Matrix Science) for protein identification (Appendix G),
2.3.12 ELISA for IgG and IgM antibodies to P. multocida B:2
The ELISA for detection of antibody to P. multocida B:2 CFE (Section 2.3.1) was based 
on that of Pati with modifications (Pati et a l, 1996). High-binding, 96-well ELISA plates 
(Greiner Bio-One Ltd., Stonehouse, United Kingdom) were coated with a CFE from the 
wild-type 85020 strain. For this, 1 ml of frozen stock culture was thawed, inoculated into 9 
ml of BHI broth, and incubated statically at 37°C for 18 h. Cells were collected by 
centrifugation at 3,000 x g for 30 min at 4°C and washed three times with PBS, and a 
suspension of 7 x 10  ^ CFU/ml was prepared. A CFE was prepared from the suspension. 
The extract was diluted 1 in 8 with carbonate-bicarbonate buffer, pH 9.6 (Sigma) 
(Appendix D l), to give a final concentration of 60 pg of protein/ml assessed by Modified 
Lowry (Section 2.3.6.2). Plates were filled with 50 pi per well of CFE and left overnight at 
4°C, after which the plates were washed thiee times with PBST (Appendix D.2) and then 
incubated for 2 h at room temperature with 200 pi of 0.1% (w/v) gelatin (Sigma) 
(Appendix D.3) in PBS per well as a blocking buffer. Following further washing with PBS, 
50 pi of 1-in-100 dilutions of serum samples were added to the wells, and doubling 
dilutions were prepared in duplicate in PBS. The plates were incubated at 37°C for 1 h and 
then washed three times with PBST, followed by incubation with 50 pi of a 1-in-10,000 
dilution of sheep anti-bovine immunoglobulin G (IgG) or IgM-horseradish peroxidase 
(HRP) conjugate (Serotec Ltd., Kidlington, United Kingdom) at 37°C for 1 h. After a final 
three-wash step with PBST, bound conjugate was detected using 50 pi of the peroxidase 
substrate Fast OPD (Sigma) per well in the dark for 30 min. The reaction was stopped by 
the addition of 50 pi of stop solution (Appendix D.4) per well. Optical density values were 
measured at 492 mn in an Anthos ELISA reader (Labtech, United Kingdom). Antibody 
titers were determined as the number of ELISA units of undiluted calf serum per ml by 
comparison with values obtained for sera with intermediate IgG or IgM titers (from the 
survivor of the intranasal-vaccinated group at 7 days postchallenge for IgG and from an 
intrarauscular-vaccinated calf on the day of challenge for IgM), each arbitrarily assigned 
the reference value of 1,000 ELISA units/ml. The antibody titers (in ELISA units/ml) of 
samples were calculated as the ratio of test serum titre to reference serum titre x ft000.
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2.3.13 Isolation and preparation of peripheral blood mononuclear cells 
(PBMCs)
PBMCs were isolated by the procedure of Vanden Bush with some modifications (Vanden 
Bush & Rosenbusch, 2002). Blood samples were provided by Dr. Hodgson. Samples were 
collected from the jugular vein of calves in heparinised Vacutainers (Becton Dickinson, 
Meylan, France) containing 170 I.U. heparin and kept on ice until being centrifuged at 
1730 X g for 20 min at 20°C (Fleraeus multifuge 3 S-R). The buffy coat was transferred 
into a universal tube containing Hank’s balanced salt solution (HBSS, Invitrogen, United 
Kingdom) without Ca^^ and Mg^ "^ , at room temperature. Then the mixture was layered 
carefully on top of an equal volume of NycoPrep™ 1.077 A (Fresenius Kabi Norge, 
Norway) and centrifuged at 600 x for 20 min, at 20°C. The interface opaque band was 
transfened to HBSS without Ca^’*' and Mg^ "*" and washed once with HBSS by centrifugation 
at 200 X g at 4°C for 10 min. To lyse the contaminating erythrocytes, the pellet was re­
suspended in red blood cell lysis buffer (Appendix E.3) and kept for 10 min on ice and 
then washed once with HBSS by centrifugation at 200 x g at 4°C for 10 min. The pellet 
was suspended in complete RPMI medium supplemented with 10% heat-inactivated fetal 
bovine serum (Bio West), 2 mM L-glutamine (Gibco), 100 U of penicillin per ml, 100 pg 
of streptomycin per ml, 0.5% (w/v) nystatin, 1% (w/v) gentamycin, and 30mM FÏEPES 
(Sigma).to reach a final concentration of 1.0 x 10  ^ live cells/ml, as estimated by trypan 
blue staining and haemocytometer cell count, (Life Technologies) (Appendix E.l).
2.3.14 Lymphocyte stimulation assay
The assay was based on that of Vanden Bush with some modifications (Vanden Bush & 
Rosenbusch, 2004). PBMCs (2x10^) were mixed in flat-bottom 96-well plates (Costar, 
USA) in triplicate with 50pg/ml antigen, 5pg/ml concanavalin A (Con A) (Sigma) 
(Appendix E.2) or left as control cultures in a total volume of 220 p.1. Wells containing 
Con A were prepared by adding 10 pi of RPMI containing a concentration of 100 pg/ml of 
Con A. To the wells to be stimulated with antigen, 10 pi of RPMI containing the required 
concentration of CFE was added before adding PBMCs (section 2.3.1). As control, 10 pi 
of RPMI without ConA was added to 200 pi of cell suspension. Plates were incubated at 
37°C in a humidified atmosphere of 5% (v/v) CO2 and 95% (v/v) air (Wolf laboratories. 
Galaxy R). On the third day of incubation, each well was pulsed with 37 KBq [methyl-^H] 
thymidine (Amersham) in 20 pi RPMI and incubated for another 18 hour. The cultures 
were then harvested onto printed filtermat (glass fiber filter size 90 x 120 mm) (Wallac,
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Finland) by a semi-automated 96-well plate harvester (Tomtec M i l l )  and allowed to dry 
at 37°C. Dried filtermats then were bagged (Sample bag, PerkinElmer) with 4 ml of liquid 
scintillation cocktail (Betaplate Scint, PerkinElmer) and sealed. The amount of 
incorporated [methyl-^H] thymidine was determined by a scintillation counter (Microbeta 
TriLux, PerkinElmer) and expressed as counts per minute (cpm). The stimulation index (si) 
was expressed as: cpm of treated cultures/cpm of control cultures without treatment.
2.3.15 Lymphocyte proliferation inhibition assay
To investigate inhibitory effects of P. multocida B:2 and other bacteria on proliferative 
response of PBMCs to ConA, the required concentration of a CFE was added to the wells 
and after adding the PBMCs, the cells were incubated for 1 h in the CO2 incubator. After 
incubation, 10 pi of RPMI containing a concentration of 100 pg/ml of ConA was added to 
the wells. The proliferative response of PBMCs, was then assessed in the same way as the 
lymphocyte proliferation assay (Section 2.3.14).
2.3.16 Fluorescence-activated cell sorter (FACS) analysis
A FACS Calibur cytometer (Becton Dickinson) was used for the assay and analysis was 
performed using CellQuest or ModFit LT™ software. Principally, cells are passed through 
a laser beam and the scatters of fluorescent cells are used for detection of size (forward 
scatter) and density (side scatter) of cells. Status of cells can also be detected based on 
these data for example, it could be concluded that a cell was proliferative with a smaller 
size identified based on their size. This analysis was earned out under the supervision of 
Dr. Mara Rocchi at the Moredun Research Institute. Acquisition of 10,000 events was 
earned out on control PBMCs and cells cultured after different treatments with different 
bacterial preparations. The results are expressed as percentage of each cell population in 
PBMCs under different treatments.
2.3.17 CFSE loading of cells
PBMCs were loaded with CFSE (carboxyfluorescein diacetate succinimidyl ester) 
(Appendix F .l) for analysis of different generations of each cell population, according to 
Sathiyaseelan and Baldwin with modifications (Sathiyaseelan & Baldwin, 2000). In CFSE- 
loaded cells, CFSE binds to cytoplasmic proteins and the loaded cells are detectable based 
on the level of fluorescence activity. After each division in CFSE-loaded cells, the quantity 
of CFSE and consequently the fluorescence activity is halved. Thus, different generations
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show different CFSE levels and ail the cells in each generation contain the same level of 
CFSE. Briefly, a suspensions of 2 x 10  ^ PBMCs/ml were washed 3 times in wash buffer 
(Appendix F.2) then re-suspended very gently at a 2-fold concentration in cold PBS and 
left to reach room temperature gradually. An equal volume of CFSE-PBS (Appendix F.l) 
was added to the cell suspension and mixed gently. The cells were covered by a lid and 
incubated at 37“C for 5 min in the CO2 incubator. The reaction was stopped by adding an 
equal volume of ice-cold FBS (BioWest). Cells were centriffiged at 600 x g for 10 min at 
4°C and the supernatant was discarded. The pellet was then re-suspended gently and 
washed thiee times in 10 ml of complete RPMI medium (Appendix E.l). Viable counting 
was done by a haemocytometer after trypan blue (Sigma) staining of the sample, and the 
cells re-suspended at an appropriate concentration in complete RPMI medium.
2.3.18 Immunofluorescence and flow cytometry
CFSE-loaded and un-loaded PBMCs were counter-stained by indirect immunofluorescence 
for surface antigens based on the procedure of Baldwin (Baldwin et a l, 2002). For surface 
antigen staining, the following mouse IgG monoclonal antibodies were used: IL-A12 to 
detect CD4, IL-A105 to detect CDS, IL-A29 to detect WCl molecule of yô T cells, IL-A30 
to detect the IgM molecule of B cells. Goat FITC-conjugated (fluorescein isothiocyanate) 
anti-mouse IgG was used as the secondary antibody for detecting cell-surface antigens 
bound to primary antibodies, and also as negative control (Section 3.4.5.1). PBMCs were 
washed in FACS buffer (Appendix F.3) and re-suspended at 2 x 10  ^ cell/ml in FACS 
buffer. Aliquots of 50 pi were dispensed into wells of U-bottomed 96-well plates (Costar, 
USA). Then, 50 pi of primary antibody at the appropriate dilution in FACS buffer was 
added to each well and incubated at 4°C for 30 min. 150 pi of FACS buffer was added and 
the cells centrifuged in pre-chilled tubes at 4°C for 30 s at 1000 x g. Cells were 
resuspended in 50 pi goat anti-mouse secondary antibody, at appropriate dilution, and 
incubated for 30 min at 4°C in dark. 150 pi FACS buffer were added and cells were 
washed once as before. Cells were washed again in 200 pi PBS by centrifugation at 4“C for 
30 s at 1000 X g, and resuspended in 200 pi FACS Fix buffer (Appendix F.4). Plates were 
sealed in a FACS tube and stored at 4°C in the dark until FACS analysis (Section 2.3.18).
2.4 Statistical methods
The results for rectal temperatures were obtained at intervals after each vaccination and 
post-challenge and analysed separately for each period by fitting linear mixed models with
S a eed  Ataei Kachooei, 2 007  86 MATERIALS and METHODS
calf fitted as a random effect. The effect of treatment on rectal temperatures were analysed 
as differences from the baseline temperature at time zero. For the analysis of clinical scores 
in the first experiment, both the mean and maximum score attained by each calf during 
each treatment were calculated, and the difference in the proportion of calves from 
different groups that had maximum scores of either 0 or >0 was investigated using Fisher’s 
exact test. The differences in mean scores over each 12 h surveillance period were 
analysed using either the Mann-Whitney U test (for comparision between two groups) or 
the Kruskal-Wallis test (for three groups), in these tests allowance was made for the small 
sample size. Readings for the IgM and IgG titres and SAA levels showed increased 
variability with higher values and so a log transformation was used on the data before 
fitting the repeated measure models. Serum Hp concentrations in all groups were often 
zero and because of this, small sample size and a high correlation between successive time- 
points, it was not sensible to fit a repeated measures model either to the raw data or to the 
data treated as a binary variable. Instead, the effect of treatment on Hp concentrations was 
compared using a Kruska-Wallis test base on a median for each group of the maximum Hp 
value observed for each calf. These statistical methods were applied with the help of Dr. 
Jill Sales from Biomathematics and Statistics Scotland.
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Chapter 3 
RESULTS
3.1 Responses of calves to administration of JRMT12 by 
different routes of vaccination (First experiment)
In this experiment (Section 2.2.3.1), two groups of four 2-week old calves were vaccinated 
twice intramuscularly (IM) or intranasally (IN) with a 4-week interval using c. 10  ^CPU of 
the JRMT12 aroA strain. Two weeks after the second vaccination, all of the vaccinated and 
three non-vaccinated control calves were challenged subcutaneously with c^  10  ^ CPU P. 
multocida B;2 wild strain 85020.
3.1.1 Clinical response to vaccination and challenge
3.1.1.1 Mean rectal temperature
At 3 and 7 h after the first vaccination with the JRMT12 strain (Figure 5A), the mean rectal 
temperatures (±pooled standard errors of the mean [SEM]) of IM-vaccinated animals 
showed an average rise of 0.7°C (± 0.17). By comparison, IN-vaccinated animals showed 
no significant change from a mean (± SEM) rectal temperature of 39.2°C (± 0.14) at time 
zero, and this difference between groups was statistically significant {p = 0.011).
At 4 and 6 h after the second vaccination (Figure 5B), the mean rectal temperatures (± 
pooled SEM) of IM- and IN-vaccinated animals showed an average rise of 1.6 and 0.3 °C 
(± 0.13°C), respectively, and this difference between groups was statistically significant (p 
< 0 .001).
Between 3 and 12 h after challenge with the wild-type 85020 strain (Figure 5C), the rectal 
temperatures for IN-vaccinated and control calves showed similar patterns of response, 
during which the mean values rose by 1.2 and 0.9°C (± 0.12®C), respectively. By 
comparison, IM-vaccinated animals showed no significant change from a mean rectal 
temperature of 39. EC (± 0.16) at time zero, and the difference between this group and the 
IN-vaccinated and control groups was statistically significant (p<0.001).
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Figure 5 Changes in rectal temperatures with different routes of vaccination and 
after challenge (First experiment)
Rectal temperatures of calves in intramuscularly-vaccinated (IM), intranasally-vaccinated 
(IN), and non-vaccinated (control) groups were measured at different intervals after first 
vaccination (5A), second vaccination (5B), and after challenge with the wild type strain 
(5C). Results are the mean rectal temperatures of animals in each group, with SEM as error 
bars.
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Figure 5A Rectal temperature changes after first vaccination
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3.1.3.2 Changes in clinical score
During the period G to 11 h after the first vaccination, the mean clinical score for IM 
vaccinated animals was 0.8 (range, 0 to 2), whereas that for IN-vaccinated animals was 0, 
and this difference was significant (p < 0.05). The corresponding value for IM-vaccinated 
animals after the second vaccination was 0.6 (range, 0 to 1), whereas clinical scores of all 
IN vaccinated animals were 0, apart from one calf that had a score of 2 at 11 h post­
vaccination. Because of this individual, the difference between the mean clinical scores for 
the two groups was not statistically significant. Because the IM-vaccinated group showed 
elevated temperature and change in demeanor, they were treated with NSAID (Section 
2.2). Within 4 to 5 h of treating IM-vaccinated calves with NSAID (7 h after the first 
vaccination and 6 h after the second vaccination), rectal temperatures returned to pre­
treatment (time zero) values and clinical scores returned to 0 (Section 2.2.4).
Mean clinical scores 3 to 12 h post-challenge were 0.8 (range, 0 to 2) and 1.0 (range, 0 to 
2) for IN-vaccinated and control animals, respectively, whereas that for IM-vaccinated 
animals was 0.1 due to a score of 1 on one occasion, and this difference was significant (p 
< 0.01). Animals that were dull and febrile were treated with NSAID between 9 and 12 h 
post-challenge, but in three IN-vaccinated and two control calves, temperatures and 
clinical scores continued to increase and, for humane reasons, they were killed within 14 h 
post-challenge. The temperatures of each remaining calf from these groups returned to 
normal within 2 h of NSAID administration, and the clinical scores returned to 0 within 24 
to 48 h post-challenge. None of the calves in the IM-vaccinated group required treatment 
with NSAID, and all survived challenge.
Post-mortem examination earned out by clinical department of Moredun Research Institute 
confirmed the gross pathological signs of HS in two control and three IN-vaccinated calves 
that were humanely put down within 14 h of challenge. Post-mortem examination of IM- 
vaccinated calves showed that there was no pathological signs of HS.
3.3.1.2 Changes in Serum Amyloid A (SAA)
Sera were supplied to CIDS (Centre for Integrated Diagnostic Systems) of University of 
Glasgow for determination of SAA levels. The concentrations of SAA in sera of individual 
calves varied considerably. The patterns of response in SAA concentrations after first 
vaccination (Figure 6A) were different in IM and IN-vaccinated calves; the concentrations 
increased significantly (p < 0.05) in IM vaccinated calves but showed no significant
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changes in IN-vaccinated calves. SAA levels were also measured in IN and IM groups on 
the day of the second vaccination (day 28) and 24 h later. In IM-vaccinated group SAA 
levels increased significantly 24 h after second vaccination (from 39.3 ± 12.6 to 660 ± 
32.7) but in IN-vaccinated group slightly decreased (from 21.3 ± 8 to 14.4 ± 1.7) (data not 
shown). The SAA concentrations declined in IM-vaccinated calves after 24 h (Figure 6A) 
but increased again significantly (p < 0.001) in response to the second vaccination. No 
significant changes due to the second vaccination were noted for IN-vaccinated calves.
The mean of SAA levels before challenge were highest in the control calves, followed by 
IM vaccinated and then by IN-vaccinated calves (Figure 6B). The mean SAA 
concentration in IN-vaccinated animals increased 13-fold by 10 h after challenge but by 
only 66 and 11 % in control and IM-vaccinated calves, respectively. This difference 
between IN-vaccinated calves and the others was statistically significant (p < 0.01). At 23 
h post-challenge, SAA values exceeded 158 pg/ml in the two calves, one each from the IN- 
vaccinated and control groups, that had survived, whereas the maximum increase observed 
for calves in the IM-vaccinated group was only three fold (to 37 ±15.6 pg/ml). High SAA 
concentrations took 72 to 140 h to return to pre-challenge levels in the surviving calves 
(Figure 6B).
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Figure 6 Changes in (SAA) levels after different routes of vaccinations and 
challenge (First experiment)
Calves were vaccinated twice with a 4-week interval. SAA concentrations were measured 
in sera collected on the day of first vaccination (day 0), and at intervals thereafter, and on 
the day of the second vaccination (day 28) and 24 h later (A). Two weeks after the second 
vaccination, the animals were challenged with the wild-type strain. SAA levels were 
measured in sera collected on the day of challenge (day 42) and at intervals thereafter. For 
control and IN-vaccinated groups at 14 h after challenge 3 calves were put down in IN- 
vaccinated and 2 in control group and the data onward represents results for one calf in 
each of these groups (B). Results represent the mean SAA concentrations of animals in 
each group with SEM as error bars.
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Figure 6A Changes in SAA levels after vaccination
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3.1.3 Antibody responses to vaccination and challenge
An ELISA system was used with a CFE of P. multocida serotype B:2 as coating antigen to 
measure the serum IgG and IgM levels at different stages before and after vaccination and 
after challenge.
3.1.3.1 Serum IgG levels
IgG titres to the P. multocida antigen preparation obtained from individual calves varied 
considerably. There was a significant difference in the pattern of change in the mean IgG 
titres between IM-vaccinated group and IN-vaccinated and control groups (p < 0.001).The 
mean (± SEM) ELISA data for IgG showed little response 28 days after first vaccination 
(Figure 7). At day 35 (7 days after second vaccination) the sera from IM-vaccinated calves 
had markedly increased IgG titres, which had increased further by day 42 (the day of 
challenge). There was no evidence of an increase in IgG titre in IN-vaccinated and control 
animals.
The data showed that IgG titres in IM-vaccinated calves at 7 days post-challenge (5285 ± 
878.6 ELISA units/ml) had increased compared to the values obtained on the day of 
challenge (4522 ± 900.5 ELISA units/ml). Only one calf survived the challenge in each of 
the IN-vaccinated and control groups at 7 days post-challenge, so the ELISA data 7 days 
post-challenge are not included in (Figure 7), The IgG titres in the surviving calves in the 
IN and control group were 1000 and 263 ELISA units/ml, respectively.
3.1.3.2 Serum IgM levels
IgM antibody titres to the P. multocida antigen preparation of individual calves also varied 
considerably. Data for IgM in pre-vaccinated calves showed a wide range of titres, from 67 
to 1548 ELISA units/ml in individual animals but by 14 and 28 days post-vaccination, 
these values had fallen (Figure 8). As with IgG, the IgM titres had increased markedly by 7 
days after the second vaccination in the IM-vaccinated animals but remained low in the IN- 
vaccinated and control calves. The pattern of responses was significantly different (p < 
0.001) between the IM-vaccinated group with the mean level in the IN-vaccinated and 
control groups. The mean IgM titre in the IN-vaeeinated calves remained fairly constant 
over the course of the experiment.
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IgM titres in IM-vaccinated calves had not altered at 7 days post-challenge (795 ± 172.2 
units) compared to the values obtained on the day o f challenge (783 ± 90.1 units). IgM 
titres in the surviving calves in the IN-vaccinated and control groups (data are not plotted 
in figine) were 617 and 631 ELISA units/ml, respectively.
3.1.4 Survivors after challenge
All of the four IM-vaccinated animals survived the challenge, up to one week after 
challenge (Figure 9). Three of four IN-vaccinated animals and two of three non-vaccinated 
calves did not survive the challenge. Calves that were depressed, with rectal temperatures 
of 40.5°C or above were put down humanely.
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Figure 7 P. multocida-s^Qciûc IgG titres in sera from vaccinated and control 
calves (First experiment)
Titres were assessed by ELISA using P. multocida CFE as coating antigen from sera 
collected 5 days before the first vaccination (day -5), 28 days after the first vaccination and 
the day of the second vaccination (day 28), 7 days after the second vaccination (day 35), 
the day of the challenge (day 42), and 1 week post-challenge (day 49). Results are mean 
values with eiTor bars indicating SEM.
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3.1.5 Bacteriology
3.1.5.1 Blood samples
Direct culturing of calf blood samples onto SBA at different times after challenge, 
including immediately prior to euthanasia, provided no evidence of bacteraemia in any of 
the animals.
3.1.5.2 Post-mortem bacteriology
Bacteriological examination post-mortem (Table 2) found P. multocida in the tonsilar 
tissue of all IN-, IM-vaccinated and two of the control calves (range, 3.6 x 10  ^to 2 x 10^  
CFU/g). P. multocida was isolated from prescapular lymph node of three of the IN- 
vaccinated and two of the control animals but only in one of the IM-vaccinated calves. P. 
multocida was found in kidney and lung of one and also in the pleural fluid of one other 
calf in IN-vaccinated group. P. multocida was not found in any of the tested organs of IN- 
and IM-vaccinated calves. P. multocida was also found in prescapular and/or 
retropharyngeal lymph nodes in one control and three IN-vaccinated calves (range, 1 x 10^  
to 1.4 X 10  ^ CFU/g) that developed early signs of disease and were killed for humane 
reasons.
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Figure 8 P. multocida-sp^ciüc IgM titres in sera from vaccinated and control 
calves (First experiment)
Titres were assessed by ELISA using P. multocida CFE as coating antigen from sera 
collected 5 days before the first vaccination (day -5), 14 days after the first vaccination 
(day 14), 28 days after the first vaccination and the day of second vaccination (day 28), 7 
days after the second vaccination (day 35), the day of the challenge (day 42), and 7 days 
post-challenge (day 49). Results are mean values with error bars indicating SEM.
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Figure 9 Number of survivors after challenge (First experiment)
Number of calves in intramuscularly (IM), intranasally (IN) vaccinated and non-vaccinated 
(Control) groups at different times after challenge.
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3.2 Response of calves to different doses of JRMT12 after 
IM vaccination (Second experiment)
In this experiment (Section 2.2.3.2), 4-week-old calves were vaccinated twice 
intramuscularly with doses of 10 ,^ 10 ,^ 10  ^CFU of the JRMT12 aroA strain, at a 4 week 
interval. Two weeks after the second vaccination all of the vaccinated and non-vaccinated 
control calves were challenged subcutaneously with c. 10  ^ CFU of P. multocida B:2 wild 
strain 85020 (Section 2.2.3.2).
3.2.1 Clinical responses to vaccination and challenge
3.2.1.1 Mean rectal temperature
At 2 and 5.5 h after the first vaccination, the mean rectal temperatures (± pooled standard 
eiTors of the mean [SEM]) of all three vaccinated groups had risen (Figure 10A) and mean 
temperatures reached the highest level at time 5.5 h in all vaccinated groups. Average 
temperatures at 5,5 h, for calves vaccinated with 10 ,^ 10  ^and 10  ^CFU increased from time 
zero values of 38.76 ± 0.32, 38.72 ± 0.26 and 38.9 ± 0.31 respectively, to highest levels of 
40.28±0.18, 40.16±0.34 and 39.72±0.18, respectively. These differences in rectal 
temperatures for calves vaccinated with 10 ,^ 10  ^and 10  ^CFU were 1.52, 1.44 and 0.82 °C 
respectively at 5.5 h after first vaccination, which was significant (p = 0.002). The patterns 
of increase in rectal temperature over time were very similar in calves vaccinated with 10® 
and 10  ^CFU, with a peak at 5.5 h and returning to baseline by 18 h after vaccination. This 
was despite a single treatment invention with NSAID (Section 2.2.4) for each calf in the 
10® CFU vaccinated group at either 2 h (n = 1) or 5.5 h (n = 4) after vaccination. However, 
the mean rectal temperature in calves vaccinated with 10  ^ CFU plateaued after 2 h and 
remained above the baseline up to 24 h after vaccination.
By 7.5 h after the second vaccination, the mean rectal temperatures (± pooled SEM) of all 
three groups of vaccinated animals had again shown an average rise (Figure lOB). At 7.5 h 
after the second vaccination dose using 10®, 10  ^ and 10  ^ CFU, the mean temperatures 
reached the highest levels of 40.64 ± 0.13, 40.44 ± 0 .19  and 39.76 ± 0.26 respectively, 
compared to the baseline values of 38.74 ± 0.09, 38.58 ± 0.13 and 39.08 ± 0.2 respectively. 
Average temperatures at 7.5 h for calves vaccinated with 10®, 10  ^ and 10  ^ CFU had 
therefore increased by 1.9, 1.86 and 0.68 °C respectively. The increase in mean rectal 
temperature values of 10  ^ CFU group had a lower peak and was significantly different
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from other groups (p = 0.001). By 24 h after the second vaccination, the mean rectal 
temperatures of all vaccinated calves had returned to baseline values.
The mean temperatures in all vaccinated and control groups increased between 4.5 and 
11.5 h after challenge and reached the highest level at 11.5 h but had returned to baseline 
values by 28 h (Figure IOC), with the 10® CFU vaccinated group returning significantly 
more quickly. Average temperatures at 11.5 h, for calves vaccinated with 10®, 10  ^ and 10^  
CFU increased 0.66, 0.92 and 1.22 ®C, respectively and for the control group it was 1.23 
”C. The pattern of responses between the three vaccinated groups were significantly 
different (p < 0.001), with the 10® CFU vaccinated group showing only a slight increase in 
mean temperature after challenge. In the control group, two of the three calves required 
treatment with NSAID (one at 11.5 h and the other at 23 h after challenge) due to severe 
dullness and pyrexia. As this treatment resulted in variable results, the data of this group 
was not statistically analysed.
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Figure 10 Changes in rectal temperatures after different vaccine doses given 
intramuscularly and after challenge (Second experiment)
Rectal temperatures of three groups of calves vaccinated intramuscularly with three 
different doses of vaccine (10®, 10 ,^ and 10  ^ CFU), were measured at different intervals 
after the first vaccination (12A), second vaccination (12B), and challenge with the wild 
type (12C). Results are the mean rectal temperatures of animals in each group plus a non- 
vaccinated control group (12C) with SEM as error bars.
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3.2.2. Changes in Serum Amyloid A (SAA)
The SAA concentrations after the first vaccination were measured in serum from calves 
vaccinated with 10  ^ CFU as a representative of all vaccinated animals to study the SAA 
response to vaccination. Concentrations of SAA varied widely between individual calves. 
The mean SAA level had increased from 29.97 (11.8 ~ 85.5) pg/ml to 88.3 (61.5 -  122.75) 
pg/ml by 24 h after vaccination and remained at this level in four calves but the level rose 
exceptionally high in one of the calves where it increased to a 262.5 pg/ml. The mean SAA 
concentration at 36 h was high because of this calf. The increase in the mean SAA level 
after vaccination with 10* CFU was remarkably lower than the SAA response to 
vaccination with 10  ^CFU that was obtained in first experiment which had reached a mean 
value of 392.5 ± 110.09 jug/ml by 24 h. Vaccination with 10  ^CFU dose caused an 8-fold 
increase in mean SAA levels with the highest measined level of 715 pg/ml while 
vaccination with 10* CFU dose caused only a 3-fold increase with the highest measured 
level of 122.75 pg/ml.
The concentrations of SAA varied in individual calves. The mean values before challenge 
were low in all of the vaccinated and control animals (Figure 11 A). After challenge on day 
42, all vaccinated groups showed increasing mean concentrations of SAA until 23 h post­
challenge. The mean SAA levels appeared to be dropping in all vaccinated groups by 72 li 
post-challenge In the control group, the mean SAA concentration increased over the whole 
time period. There was marked variability in SAA levels in different animals The SAA 
concentrations increased slightly by 11.5 h after challenge in the control group but had 
increased 26-fold overall by 48 h after challenge, (Figure 11 A), whereas only a 3-fold 
increase was seen in all of the vaccinated groups at this time. Over the period until 72 h 
post-challenge, mean concentrations of SAA were significantly (p < 0.001) higher in the 
control group than in the vaccinated groups. There was only one calf alive in control 
group, 72 h after challenge with SAA of 716 pg/ml (data are not plotted in Figure 1 lA).
3.2.3. Changes in haptoglobin (Hp) concentrations
The serum concentration of haptoglobin (Hp) was also measured. Hp changes after 
challenge in vaccinated and control animals showed a similar pattern to those observed for 
SAA (Figure IIB). The mean values before challenge were undetectable in all of the 
vaccinated and control animals until 7.5 h post-challenge, after which the Hp 
concentrations increased and, in all but one calf in lO’ CFU group, reached a maximum 
value at 48 h post-challenge. At 48 h post-challenge the mean concentration of Hp was
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highest in control animals (607±474 pg/ml), followed by the group vaccinated with lO’ 
CFU (210±149 pg/ml). Once an animal showed a positive reading it generally had positive 
readings for the rest of the experiment period. Vaccinated groups (10^, 10*, and lO^CFU) 
had low median maximum Hp concentrations over the whole period of 10, 10 and 220 
p,g/ml, respectively, whereas the control group had a median maximum of 860 pg/ml.
There was only one calf alive in control group, 72 h after challenge with Hp of 1510
jug/ml (data are not plotted in Figure IIB).. These observed differences were not
statistically significant using a Kruska-Wallis test. Larger samples would be needed to 
determine if the observed lower levels in vaccinated groups are a consequence of 
vaccination.
S a eed  Ataei Kachooei, 2007  109 RESULTS
Figure 11 Changes in SAA and haptoglobin after challenge (Second experiment)
Calves were vaccinated twice intramuscularly using three different doses of vaccine (10^,
10*, and 10  ^ CFU). Two weeks after the second vaccination, the vaccinated and control 
animals were challenged with the wild-type strain. SAA (A) and haptoglobin (B) levels 
were measured in sera collected on the day of challenge (0 h) and at intervals thereafter.
Results represent the mean value of concentrations in each group with SEM as error bars.
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Figure 11A Changes in SAA levels after challenge in vaccinated and control calves
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3.2.4 Antibody responses to vaccination and challenge
IgG and IgM levels were measured by ELISA, with CFE as antigen, in sera taken at 
different stages before and after vaccination and challenge.
3.2.4.1 Serum IgG levels
ELISA data for IgG showed a similar pattern to the IgG titres from first experiment 
(Section 3.1.3.1). IgG titres showed little change at 28 days after the first vaccination 
(Figure 12), but increased rapidly 7 days after the second vaccination in calves given 10  ^
and 10  ^ CFU. For calves given 10  ^CFU, only a slight increase in IgG titres was detected 
up to the day of challenge and mean IgG titres continued to increase slowly from second 
vaccination (Day 28) to 3 days after challenge. There was a clear relationship between 
dose of vaccine and IgG levels, the higher the dose of vaccination, the higher the IgG titre. 
In the control group, the IgG titres remained fairly static during the experiment and 7 days 
after second vaccination this was significantly different from 10  ^ (p = 0.018), 10  ^ {p = 
0.001), and 10  ^{p = 0.03) CFU vaccinated groups.
3.2.4.2 Serum IgM levels
ELISA data for IgM showed a similar pattern to the IgM titres from first experiment 
(Section 3.1.3.2). In pre-vaccinated calves, IgM titres were again high but, by 14 and 28 
days after the first vaccination, the IgM titres had decreased and continued at a low level 
until the second vaccination (Day 28) (Figure 13). In all three vaccination groups, the IgM 
titres had increased by 7 days after the second vaccination (Day 35) but remained low in 
control calves and at this point the antibody levels in 10  ^CFU group was significantly (p = 
0.002) higher than the control group. The graded response seen for IgG titres (Figure 12) 
was not apparent for the IgM titres and all vaccinated groups achieved similar levels of 
IgM by the day of challenge. The mean IgM titre in the control group remained fairly 
constant over the course of the experiment.
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Figure 12 IgG titres lu sera from vaccinated and control calves (Second 
experiment)
Titres were assessed by ELISA using P. multocida CFE as coating antigen from sera 
collected before the first vaccination (Day 0), 14 days after the first vaccination (Day 14),
28 days after the first vaccination (Day 28), 7 days after the second vaccination (Day 35), 
the day of the challenge (Day 42), 2 days post-challenge (Day 44) and 3 days post­
challenge (day 45). Results aie mean values with error bars indicating SEM.
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Figure 13 IgM titres in sera from vaccinated and control calves (Second 
experiment)
Titres were assessed by ELISA using P. multocida CFE as coating antigen from sera 
collected before the first vaccination (Day 0), 14 days after the first vaccination (Day 14),
28 days after the first vaccination (Day 28), 7 days after the second vaccination (Day 35), 
the day of the challenge (day 42), 2 days post-challenge (Day 44) and 3 days post­
challenge (Day 45). Results are mean values with error bars indicating SEM.
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3.2.5 Survivors after challenge
All of the vaccinated calves survived the challenge. All of the non-vaccinated animals in 
control group became clinically ill (as shown by dullness and high temperature) between 
7.5-11 h after challenge. Two of them were in critical condition and unresponsive to 
treatment with NSAID and were eventually put down at 48 and 55 h after challenge. Tliree 
calves in 10  ^ CFU vaccinated group, and one in the 10^  CFU vaccinated group, were dull 
but none of them required administration of NSAID and all recovered prior to scheduled 
euthanasia on the day after challenge.
3.2.6 Serum sensitivity assay
This assay was performed as described in section 2.3.8. Sera with high IgG and IgM titres 
obtained after the second vaccination on day 42 from IM-vaccinated calves were selected 
for use in this assay. P. multocida wild type was incubated in these sera in the presence of 
fresh normal calf serum, as a source of complement, to study their bactericidal effects on 
the organism. A control included the assay with the same conditions in which PBS was 
used instead of serum. A typical result obtained with one such serum is shown in Figure 
14. None of the immune sera obtained from vaccinated calves or fresh calf semm obtained 
from naïve calves, showed any adverse effects on P. multocida, which grew in these sera 
as shown by a bacteriocidal index > 1, rather than indices < 1 which would represented a 
killing effect (Figure 14). This is in contrast to results obtained with E. coli strain K12 
which was not killed in fetal calf serum but was rapidly killed in fresh calf serum and 
guinea pig serum as complement sources (Figure 15). Heating (56°C for 30 min, for 
inactivation of complement) fresh calf serum or guinea pig serum had no adverse effects 
on E. coli.
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Figure 14 Bactericidal activity of bovine serum on P. multocida
Each well of a 96-well microtitre plate (Section 2.3.8) contained 25pi of immune serum 
from a calf vaccinated twice intramuscularly with high level of IgG and IgM antibody 
(Imniune.Ser), with or without 25pl of fresh normal calf serum (NC.Ser) or 25pl heated 
Iimnune Ser. with or without 25pi heated NC.Ser. or 25pi fresh normal calf serum 
(NC.Ser.) or 50pl heated NC.Ser. or 50pl PBS. A 50pl suspension of P. multocida B:2 was 
added to each well and then incubated for 1 h at 37°C. Sample of 10 pi from undiluted, and 
dilutions of 10'' and 10'  ^ were taken before and after incubation and were plated out on 
SB A (Appendix A3) and then incubated overnight.
The bactericidal index is defined as CFU/ml after incubation for 1 h divided by CFU/ml at 
time zero. Data are the average of two assays ± standard deviation. An index of < 1 would 
indicate a bactericidal effect.
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Figure 15 Bactericidal activity of calf serum and guinea pig complement on E. coli
Each well of a 96-well microplate (Section 2.3.8) contained 50pl of fetal calf serum (Fetal 
Calf Ser. Sigma®) heated fetal calf serum (Heat.Fetal Calf Ser.) fresh normal calf serum 
(N.C.Ser.) or heated calf serum or guinea pig complement (Sigma®) (Guinea Pig 
Complement) or PBS. A 50pl of a suspension of E. coli was added to each well and then 
incubated for 1 h at 37®C. Sample of 10 pi from undiluted, and dilutions of 10'' and 10'^ 
were taken before (time zero) and after incubation and were plated out on SB A (Appendix 
A3) and then incubated overnight.
The bactericidal index is defined as CFU/ml after incubation for 1 h divided by CFU/ml at 
time zero. Data ai'e the average of two assays ± standard deviation. An index of < 1 would 
indicate a bactericidal effect.
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3.2.7 Investigation of immunogenic components
In this part of the experiment different preparations of P. multocida 85020 were prepared 
and run on SDS-PAGE. Cell components that were separated by SDS-PAGE were then 
subjected to immunoblotting (Section 2.3.10) with sera obtained from immunised calves. 
Different components separated by SDS-PAGE and detected by immunoblots were 
identified by estimation of their molecular weights by comparing with standard MW 
markers run in parallel with the samples. Some of the immunogenic components were then 
subjected to mass spectrometry (MS) for identification.
3.2.7.1 SDS-PAGE of P, multocida proteins
The SDS-PAGE profiles of a crude CFE (Section 2.3.1) and the sarkosyl-extracted OMP 
preparation (Section 2.3.3) of P, multocida strain 85020 were analysed (Figure 16 and 
Figure 17). In SDS-PAGE of the CFE, up to 32 bands were observed. On the basis 
of stain intensity, two bands at 30 and 37 kDa were identified as prominent bands (Figure 
16). SDS-PAGE of the OMP preparation revealed up to ten major and 4 minor bands 
Figure 17) and again the 30 and 37 kDa bands were the predominant bands.
The OMP was also extracted from P. multocida strain 85020 grown under iron-depleted 
conditions by adding 2,2’-dipyridyl 150 pM/ml to BHI (Appendix A.7). Based on intensity 
of bands on SDS-PAGE gels, 4 bands with molecular weights of 97, 95, 82 and 24 kDa 
were upregulated and a protein of 26 kDa was downregulated (Figure 18).
3.2.7.2 Immunoblots
To investigate the immunogenic components of P. multocida, to which IgG antibody was 
raised, a CFE of P. multocida was blotted against calf sera collected at different stages of 
vaccination and challenge. The Western blots revealed five major immunogenic bands (51, 
37, 30, 26 and 16 kDa) which only appeared using serum one week after the second 
intramuscular vaccination and which were still present in serum from this calf after 
challenge that has been shown as a representative of calves. Sera obtained from different 
individual calves showed essentially the same pattern of blots (Figure 19). A 44 kDa band 
appeared after first vaccination and remained in all other sera. This band was not taken for 
identification because however, further studies using a single IM vaccination regime 
(Section 2.2.3.3) showed the appearance of this band after primary vaccination was not
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associated with protection (Section 3.3.1). Sera obtained from different individual calves 
showed essentially the same pattern of blots.
For clearer separation and subsequent identification of immunogenic bands, 
immunobloting was also caiiied out on an OMP preparation. The immunoblot of the OMP 
preparation against calf immune serum (serum obtained one week after second 
intramuscular vaccination) revealed two strong bands of 50 and 37 kDa (Figure 20A). The 
37 kDa band was the second dominant band in the Coomassie blue stained (Figure 20B) 
OMP preparation, but appeared as the strongest band in coiTesponding immunoblot. The 
50 kDa band was a faint band by Coomassie blue staining, but showed also a fairly strong 
band in the immunoblot. The most dominant band in Coomassie blue stained OMP 
preparation of 30 kDa showed little or no reaction in the corresponding blot. However, the 
30 kDa band was visible in Figure 19, the immunoblot of the CFE. This band appeared as a 
result of vaccination, along with a 16, 26 and 44 kDa bands, but none of these tliree bands 
that showed a strong reaction in immunoblot against sera obtained after second vaccination 
was prominent in the OMP preparation. It is possible that the 50 kDa band identified in 
OMP immunoblot (Figure 20) may be the same as 51 kDa band identified in CFE 
immunoblot (Figure 19).
No additional band was observed in immunoblotts of OMP prepared from P. multocida 
grown under iron-depleted conditions (data not shown).
3.2.7.4 Protein identification using mass spectrometry
Two of the strong immunogenic bands (37 and 50 kDa) and the most dominant band (30 
kDa) from SDS-PAGE of the OMP preparation were chosen for protein identification. 
Bands were excised from a SDS-PAGE gel and sent for mass spectrometry (Section 
2.3.11). Appendices G l, G2, and G3 show the MASCOT output for the studied bands. The 
30 kDa band from SDS-PAGE gel was identified as major outer membrane protein 
precursor; OmpH of Pasteurella multocida (Appendix G. 1.2.1). This protein identification 
has a score of 569, a score of > 63 is significant. The 37 kDa band was identified as an 
unknown Omp or OmpA of Pasteurella multocida with a scores of 759 and 750 
respectively (Appendix G.2.2. and G.2.2.2). The 50 kDa band was identified most likely as 
OmpH Pasteurella multocida with a score of 218 (Appendix G.3.2.1).
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Coom assie Blue stained SDS-PAG E (10% slab gel) profiles o f  CFE (Fig. 16) and OMP 
preparation (Fig. 17) from P. multocida 85020 (right lanes). Left lanes on both gels show  
the molecular weight standard markers. Samples o f  20 pg protein content were used for 
loading lanes. Figure 18 show s OMP prepared from cells obtained in BHI (lane 1) and 
BHI+ Dipyridyl (lane 2). Samples o f  40pg protein content were used for OMP prepared 
under iron-limited conditions.
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Immunoblot of CFE of P. multocida 85020 against calf sera collected at 
different stages of vaccination and challenge.
M
98 kDa
64 kDa
50 kDa
36 kDa
16 kDa
#  53 kDa
51 kDa
4  44 kDa
#  37 kDa
4- 30 kDa
4  26 kDa
4 16 kDa
Immunoblots using sera from one o f the vaccinated calves taken at intervals after 
vaccination and challenge (Section 2.2 .3 .1), as a representative o f  the IM -vaccinated and 
challenged animals.
M; Marker, 1; Before vaccination, 2; Four weeks after first vaccination, 3; One week after 
second vaccination, 4; One w eek after challenge.
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Immunoblot of OMP preparation of P. multocida 85020 against serum 
from a calf one week after second intramuscular vaccination.
SDS-PAGE of OMP preparation (B) and corresponding immunoblot (A) using serum from 
the calf obtained one week after second IM vaccination (serum number 3 used in Figure 
19).
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A; Immunoblot of OMP preparation against calf immune serum. B; SDS-PAGE of OMP 
preparation. M; Molecular weight standards, 1 ; OMP preparation
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3.3 Responses of calves to a single dose of JRMT12 after 
IM vaccination (Third experiment)
In this experiment, 4-week-old calves were vaccinated once IM using 10* CFU JRMT12 
Strain. Four weeks after vaccination, all of the vaccinated and non-vaccinated control 
calves were challenged subcutaneously with 10  ^ CFU P. multocida B:2 wild strain 85020 
(Section 2.2.3.3).
3.3.1 Survivors after challenge
In the vaccinated group, only two of the four vaccinated calves survived the challenge. The 
calves in vaccinated group were five but one calf died and four calves were used in this 
group. In the non-vaccinated control group, only two of the five calves survived the 
challenge. These data indicated that a single vaccination of calves does not confer 
protection against subcutaneous challenge. Therefore, serum antibody responses and APP 
responses were not investigated.
3.3.2 Cellular responses after vaccination and challenge
Although no protection was afforded by a single vaccination, advantage was taken of the 
vaccinated and control calves to examine the possible cellular response and to develop 
assays for this study. Peripheral blood mononuclear cells (PBMCs) were obtained from 
vaccinated or control calves at different stages before and after challenge (Section 2.3.13), 
to study their response to CFEs of P. multocida B:2 or P. multocida A3 or concanavalin-A 
(ConA) as a known stimulator of the lymphocyte proliferative response.
3.3.2.1 Stimulation of lymphocytes from calves challenged with P. multocida B:2 
85020 by CFE of P. multocida B:2 85020
CFE of P. multocida 85020 did not show any stimulatory effects on proliferation of 
PBMCs isolated from calves at different stages of vaccination (data are not shown). Little 
stimulatory effect of CFE was observed on PBMCs obtained from calves before and after 
challenge (Figure 21 A). PBMCs from the vaccinated and non-vaccinated control groups 
showed similar responses to CFE.
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3.3.2.2 Stimulation of lymphocytes by concanavalin A (ConA) from calves challenged 
by P. multocida B:2 85020
PBMCs from vaccinated and non-vaccinated control calves, sampled prior to challenge, 
proliferated in response to ConA. The mean of stimulation index [SI] was 7.8 ± 3.1 in the 
control and 10.45 ± 4.52 in the vaccinated group (Figure 21B). In both vaccinated and 
control groups, the mean SI decreased markedly at 12 h after challenge and reached an 
even lower level 3 days after challenge. In control animals, 7 days after challenge the mean 
SI had increased to around the pre-challenge value (mean SI=8.1 ± 3.25) but, in vaccinated 
animals, it had increased only slightly (mean SI=2.05 ±0.92).
3.3.3 Stimulation of lymphocytes from calves challenged with P. multocida 
A3
A comparison was made between the lymphocyte response to P. multocida A3 challenge 
(pulmonary pasteurellosis) and P. multocida B:2 challenge (septicaemic pasteurellosis). 
The lymphocyte stimulation assay was used to assess the response of PBMCs obtained 
from calves at different times after intratracheal challenge with P. multocida A3 (Section 
2.1.4). On the second day after intratracheal challenge with P. multocida A3 (experiment 
performed by Dr. Hodgson at Moredun Research Institute), PBMCs responded to 
stimulation with the CFE of P. multocida A3 (mean SI= 10.45 ± 2.79) while PBMCs 
obtained from control calves that were injected intratracheally with PBS showed no 
response to stimulation (mean SI=0.18 ± 0.02) (Figure 22A). As indicated by this 
experiment, PBMCs of challenged calves were able to proliferate by stimulation with CFE, 
in contrast to the unresponsiveness of PBMCs to CFE of P. multocida B:2 after challenge 
with P. multocida serotype B:2 (Section 3.3.2.1).
To investigate any cross reaction, the stimulatory effects of the CFE of P. multocida B:2 
was also assessed on PBMCs obtained from P. multocida A3 challenged calves. The same 
pattern of response was observed, on the second day of challenge. PBMCs responded to 
stimulation with sonicated extract of P. multocida B:2 (Figure 22B). The similarity in 
pattern of response, in both of the stimulation assays using different CFEs of A3 and B:2 
serotypes of P. multocida, indicated a cross reaction between the extracts these serotypes 
in stimulating the PBMCs. However, the fact that PBMCs from calves challenged with P. 
multocida B:2 did not respond to extract of P. multocida B:2 suggested that challenge with 
this strain was exerting a suppressive effect on the capacity of the lymphocytes to 
proliferate.
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Figure 21 PBMCs response to CFE and ConA before and after challenge with P. 
multocida 85020 (Third experiment)
PBMCs were prepared from vaccinated and non-vaccinated groups of calves on the day of 
challenge and at different times after challenge with P. multocida 85020. In vaccinated 
group, calves were vaccinated once (third experiment) and all of the animals were 
challenged after 28 days. For the stimulation assay (21 A), 10 pg/well of CFE was added to 
the cells. For the proliferation assay (2IB), 1 pg/well of concanavalin A (ConA) was added 
to the cells. All of the treated cells along with untreated cells as controls were incubated at 
37 °C (Section 2.3.15). On the 3^^^ day, cells were pulsed with [methyl-^H] thymidine and 
incubated for 18 h and the amount of incorporated thymidine was measured by 
scintillation. Proliferation of cells was detected by the level of thymidine incorporation and 
is shown as bars, which represent the stimulation index (SI). SI is the ratio of treated (CFE 
or ConA added) compared to untreated cells. Results are the mean of the stimulation 
indeces for different calves in each vaccinated and non-vaccinated group, error bars 
showing SEM or SDM (for 3 and 7 days post-challenge data as only 2 calves in each group 
survived).
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Figure 21A Stimulation of lymphocytes from calves challenged with P. multocida 
B:2 85020 by CFE of the same strain
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Figure 21B Proliferative response of lymphocytes to ConA after challenge with P. 
multocida B:2
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Figure 22 PBMCs response to CFE before and after challenge with P. multocida 
A3
PBMCs were prepared from calves before and at different times after challenge. In the 
challenged group, P. multocida serotype A3 was inoculated intratracheally and the control 
group received PBS by the same route. For stimulation assay, a CFE of P. multocida 
serotype A3 (Figure 22A) was added to the cells and the proliferation was assessed by 
thymidine incorporation (see legend to Figure 21). Stimulation assay was also carried out 
with CFE of P. multocida 85020 (Figure 22B).
Bars indicate the proliferative response of PBMCs after stimulation with CFE, measured 
by thymidine incorporation and shown as stimulation index (SI), which shows the ratio of 
radiolabel incoiporation in treated (CFE was added) compared to untreated cells. Results 
aie the mean values for two calves in each group and eiTor bars indicate the standard 
deviation.
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Figure 22A Stimulation of lymphocytes from calves challenged with P. multocida 
A3 by P. multocida A3 CFE
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Figure 22B Stimulation of lymphocytes from calves challenged with P. multocida 
A3 by P. multocida B:2 85020 CFE
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3.4 In vitro responses of PBMC
As calves challenged with P. multocida B:2 were not readily available, it was decided to 
investigate the possible suppressive effects of this pathogen on lymphocyte proliferation by 
using cultured PBMCs obtained from noi*mal calves and treated in vitro with CFE of P. 
multocida B:2.
3.4.1 In vitro suppression of PBMC proliferation
An in vitro system was set up in which the PBMCs obtained from normal calves were 
treated with CFE, before adding ConA (Section 2.3.15).
Preliminary experiments showed that lOpg protein/well was the optimal concentration of 
CFE in which PBMCs grew in a similar manner to untreated control cells (Figure 23A). 
Lower concentrations of CFE promoted increased proliferation presumably due to the extra 
nutrient components that it contained. CFE at higher concentrations showed adverse effects 
on growth of PBMC.
Different concentrations of ConA showed that concentrations between 0.5 and 2 pg/well 
were optimal for strong proliferation of PBMCs (Figure 23B). Figure 23 also shows that 
addition of CFE at all concentrations (5, 10, and 20|ag/well) for 1 h before addition of 
ConA suppressed the proliferative effect of ConA at the concentration of (Ipg/well).
A further in vitro experiment (Figure 24) again showed that the proliferative response of 
calf PBMCs to ConA (SI=101.9 ± 3.6) was markedly suppressed (SI=29.3 ± 3.1) when the 
cells were incubated with the optimal concentration (10 pg/well) of P. multocida B:2 CFE 
for one hour before adding the ConA (a 3-5 fold decrease in response). Incubation of 
PBMCs with CFE alone (10 p,g/well) produced a SI=1.5 which indicated that the extract 
alone had no suppressive effect on growth of PBMCs. The lOpg/well concentration of 
CFE and the 1 pg/well concentration of ConA together with the 1 h incubation of cells 
with extract before addition of ConA, as performed in this in vitro assay, were designated 
as optimal conditions and were followed in all other in vitro assays.
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Figure 23 Effect of different concentrations of P. multocida CFE and ConA on 
proliferation of calf PBMCs
PBMCs obtained from normal calves (Section 2.3.13) were cultured in the presence of 
different concentrations of CFE of P. multocida B:2 (Figure 23 A). The proliferative effect 
of different concentrations of ConA was also measured after addition of three different 
concentrations of CFE (Figure 23B). Cells were incubated for 1 h with extract before 
adding the ConA. PBMC proliferation was assessed by measurement of thymidine 
incoiporation and is expressed as scintillation counts per minute (cpm). Bars show the 
mean values of triple wells, and enor bars indicate the SD.
Saeed Ataei Kachooei, 2007 134 RESULTS
Figure 23A Effect of different concentrations of P. multocida CFE on calf PBMCs
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Figure 23B Suppressive effect of different concentrations of P. multocida CFE on 
proliferative effect of different concentrations of ConA on calf PBMCs
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Figure 24 The effect of CFE of P. multocida B:2 on proliferative response of 
PBMCs to ConA
Bars represent the proliferative response o f  normal ca lf PBM Cs after incubation for 1 h 
with lO pg/well CFE before addition o f  Ipg/w ell ConA. Proliferation was detected by 
measurement o f thymidine incorporation and expressed as stimulation index, which shows 
the ratio o f incorporation in treated (CFE was added) compared to untreated cells. PBM Cs 
were cultured in triplicate and results are mean values, and error bars indicate the standard 
deviation.
ConA
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3.4.2 Specificity of the suppressive effects of P. multocida B:2 CFE on PBMC 
proliferation
To study if the suppressive effects of P. multocida B:2 CFE were specific for this 
serotype, CFE of a number of other bacteria were prepared and used in the optimised in 
vitro assay (Figure 25). All of the extracts were prepared in the same way as that of P. 
multocida B:2 (Section 2.3.1) and the protein concentrations, measured by modified Lowry 
assay (Section 2.3.6.2), were adjusted to lOpg/well. CFE prepared from Staphylococcus 
aureus (Figure 25A) or Mannheimia haemolytica serotypes A1 or A2 (Figure 25B) did not 
affect the proliferative response of PBMCs to ConA. CFE prepared from Escherichia coli 
(Figure 25A) slightly increased the proliferative response to ConA. CFE of P. multocida 
serotype D (pig isolate) (Figure 25 A) strongly suppressed the proliferative response of calf 
PBMCs to ConA. P. multocida serotype A3 (bovine pulmonary) (Figure 25A) and P. 
multocida serotype A (ovine pulmonary) (Figure 25B) extracts had a slightly less effect on 
the proliferative response than P. multocida B:2 but appeared to have some suppressive 
effect. An avian serotype A strain of P. multocida (Figure 25B) had no effect. Overall, 
various degrees of suppression were observed but only with some of the P. multocida 
extracts. None of the other species tested showed suppressive properties.
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Figure 25 Effect of CFE of different bacteria on PBMCs and on the proliferative 
response to ConA.
CFE prepared from different bacteria (lOpg protein /well) was added to PBMCs 
prepared from normal calves and incubated for 1 h before addition of ConA (1 pg/well).
Bars represent the proliferative response in the presence (treated cells) and absence 
(untreated cells) of CFE of different bacterial species. Proliferation measured by 
thymidine incorporation and shown as stimulation index, which shows the ratio of 
incoi*poration in treated to untreated cells (control). The column named as ConA shows 
the stimulation index of untreated cells to ConA. Cells were cultured in triplicate and 
results are the mean values of them, error bars indicate the standard deviation. Results 
shown in the graph A and B were obtained in the same experiment.
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3.4.3 Characterisation of the suppressive component(s) of P. multocida B:2
To begin to characterise the suppressive agent(s) of P. multocida B:2 CFE, different 
treatments were performed on the CFE and fractions were prepared and studied for their 
suppressive activity (Figure 26). Heating at 80°C for 5 min completely destroyed the 
suppressive effects of CFE. An OMP prepaiation of P. multocida B:2 (Section 2.3.2) 
markedly suppressed the proliferative response of PBMCs to ConA (Figure 26A). The 
suppressive activity of the OMP preparation was also partially destroyed by heating 
(Figure 26A). CFE dialysed overnight against PBS with a cut off 10,000 Da was still 
suppressive for calf PBMCs (Figure 26A). A polysaccharide capsule preparation (Section 
2.3.4) of P. multocida showed no effect on the PBMCs proliferative response to ConA 
(Figure 26A). The supernate of an 18 h P. multocida broth culture increased the PBMC 
proliferative response to ConA (Figure 26A).
3.4.4 Effect of LPS on PBMC proliferative response to ConA
It was very likely that the CFE prepared from P. multocida B:2 contained some traces of 
LPS. LPS is known as a B cell proliferative agent. As endotoxin, it also could have some 
adverse effects on different cells. To study the effect of LPS, calf PBMCs were treated 
with LPS purified from E. coli (Section 2.3.5). LPS showed a synergism with ConA in 
proliferative effects on PBMCs at certain concentrations (Figure 26B). LPS at 2 x 10  ^
EU/well did not cause any changes in proliferative response of PBMCs to ConA. At the 
higher concentrations, LPS increased the proliferative response of PBMCs to ConA with 
the highest effect at 2 x 10  ^EU/well in which the stimulation index increased to 267.07 ± 
15.39 (a 2.8-fold increase). At this concentration, LPS alone also caused a 2,8-fold 
proliferation on PBMCs, but lower concentrations of LPS showed no significant effect on 
PBMCs. It was concluded that LPS, at least that from E. coli, was not having a detrimental 
effect on the proliferation of PBMCs in response to ConA.
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Figure 26 Effect of different preparations of P. multocida B;2 and LPS on the 
proliferative response of PBMCs to ConA
PBMCs were prepared from normal calves and incubated for 1 h with lOpg protein/well of 
different preparations (Figure 26A) before addition of 1 pg/well ConA. CFE of P. 
multocida B:2 after heating at 80° C for 5 min, overnight dialysis with 10,000 Da cut off 
against PBS. An OMP preparation of P. multocida B:2 (Section 2.3.3), and used at 10 
jitg/well before and after heat-treatment. A capsular polysaccharide preparation and also a 
culture filtrate (0.20 pm) of an overnight broth culture of P. multocida B:2 (Section 2.3.4) 
were also assessed. Different concentrations of LPS (purified from E. coli, section 2.3.5) 
were used in another experiment (Figure 26B). Bars show the proliferative response of calf 
PBMCs to ConA in the presence of these different fractions of P. multocida B:2 and E. coli 
LPS. Proliferation was detected by measurement of thymidine incorporation and shown as 
stimulation index, which shows the ratio of incorporation in treated to untreated cells 
(control). Bars are the mean values of triplicate cells cultures and error bars indicate the 
standard deviation.
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3.4.5 Identification of the population of lymphocytes affected by CFE of P.
multocida
To determine which population of lymphocytic cells was affected by the presence of P. 
multocida components, FACS (fluorescence-activated cell sorter) analysis was conducted 
on PBMCs at different stages of proliferation and suppression (Section 2.3.18), for 
identification of B cell and T cell subpopulations (CD4^, CD8'*' and yô’^ T cells). At the 
same time, FACS analysis on CFSE-loaded (carboxyfluorescein diacetate succinimidyl 
ester) cells was also earned out on the cells of the same experiment, to differentiate the 
different generations of each cell population that had been affected by the bacterial extract 
(Section 2.3.16). The FACS analysis assay on CFSE unloaded and loaded cells was done 
in parallel to the lymphocyte proliferation assay and samples for FACS analysis assays 
were taken at different stages of the in vitro proliferation assay.
3.4.5.1 FACS analysis of PBMCs
The ratio of different cell populations was identified in PBMCs before and after different 
treatments (Table 3A). Four different cell populations (B cell and CD4'*', CD8^, y8+,T cells) 
were identified by indirect immunofluorescence staining of coiTesponding cell markers 
using mouse monoclonal antibodies against them as primary antibody, and FITC- 
conjugated goat antibodies specific for the mouse Ig isotype as the secondary antibody 
(Section 2.3.17). FACS analysis (using CellQuest®) was earned out on the samples taken 
at the beginning of the experiment (time zero) and after 72 h (Section 2.3.18). In each 
population the proliferative and non-proliferative cells were also identified based on their 
size and the total cells in each population was expressed as sum. A sample of each 
population was also stained by Ig isotype to assess the negative control (expressed as 
Isotype) in which the cells were stained only with secondary antibody.
In the Table 3 A it can be seen that the percentage of B cells in the control culture increased 
over the course of the experiment from 11.9 to 28.34 and although the percentage of B 
cells in the ConA-treated culture (27.81) was similar to the control (28.34), an increase was 
seen in cultures treated with CFE+ConA (54.31) or CFE (53.25) in which the percentage 
roughly doubled. Although the percentage of B cells in total showed an increase, the 
percentage of proliferating B cells, which was differentiated from non-proliferating cells 
by their smaller size, was at approximately the same level in all samples at the time of 
harvest at 72 h (between 3.54 and 5.28). The percentage of B cells in ConA and control is 
about the same level (27.81 and 28.34 respectively). The overall percentage of B cells
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increased by 1.92 times in the cells treated with CFE+ConA which was similar to CFE- 
treated cells which had an increase of 1.88 times compared to control cells. This indicated 
that the increase in overall percentage of B cells was due to the presence of CFE. It seems 
that the proliferative response of the B cells to CFE happened in the early stages of culture 
because, although the overall percentage of B cells increased, the proliferating fraction of 
B cells was estimated to be low at the time of harvest. It can be concluded that B cells do 
not play a direct role in lymphocyte proliferation caused by ConA and consequently would 
not be the target of any suppressive effect by the P. multocida extract.
The percentage of CD4^ T cells decreased during the course of the experiment with all 
treatments including control cells. Comparison between control cells and ConA-treated 
cells revealed that the proliferating fraction of CD4^ cells increased due to the presence of 
ConA by a factor of 10-fold. In the presence of CFE, however, ConA stimulated only a 3- 
fold increase. ConA appeared to stimulate CD4^ cells in a delayed manner because, on the 
day of harvest (72 h), the proliferating fraction had apparently increased although the 
overall percentage had not yet increased. Comparison between the percentage of control 
(15.37) and CFE-treated (15.78) cells revealed that CD4'^ T cells were not affected 
markedly by CFE, and there was no toxic effect of CFE on these cells, so the suppression 
of the proliferative response was unlikely to be due to toxicity. It can be concluded that, 
CD4^ T cells are at least one of the populations that responded to ConA in terms of 
proliferation, as measured by thymidine incorporation, and that this response was 
suppressed due to the presence of CFE.
Total overall percentage of CDS^T cells showed only slight changes during the course of 
the experiment with the exception of decrease in cells treated with CFE. The CD8^ 
proliferating T cell percentage increased markedly in response to ConA (5.78 -fold 
compared to control cells) but remained the same in CFE+ConA-treated cells. Comparison 
between control cells and CFE-treated cells revealed that both the overall percentage of 
CD8^ T cells (from 11.85 to 8.14) and also the proliferating fraction of these cells was 
decreased in the presence of CFE (fi'om 1.35 to 0.33). It can be concluded that CFE had 
some adverse effects on this cell population and that the suppression in the proliferative 
response of CDS^T cells to ConA by CFE might be partly accounted for this effect.
The overall percentage of T cells increased slightly during the experiment. The 
proliferating fraction increased in response to ConA by 10.48-fold compared to control 
cells and this fraction was only slightly lowered to a 8.42-fold increase in CFE+ConA- 
treated cells. Comparison between control cells and CFE-treated cells showed that the
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percentage of the proliferative fraction of yô'^T cells was not affected by CFE (from 1.75 to 
1.49) although the overall percentage of this population slightly decreased compared to 
control cells (from 21.48 to 16.09), indicating that the slight suppression in proliferative 
response of y5^ T cells to ConA in the presence of CFE may have been due to a slight 
adverse effect of CFE on these cells.
3.4.5.2 FACS analysis of CFSE-loaded PBMCs
CFSE loading of PBMCs was used to more accurately detennine the number of cell 
divisions that the different cell populations had undergone during the 72 h culture period 
with the different treatments. CFSE-loaded PBMCs were counter-stained in parallel to 
CFSE-unloaded cells, by indirect immunofluorescence, to detect CD4^, CD8^, yô'^T cells, 
and B cells (Table 3B).
The ratio of different populations of CFSE-loaded cells and proliferative and non­
proliferative cells were similar to those shown in Table 3 A exept that the percentage of the 
B cell population was decreased maikedly under all treatments. The percentage of B cells 
at time zero was less (3.01) compared to the value (11.9) for the CFSE-unloaded cells and, 
in the control, the CFSE-loaded B cells did not increase in 72 h (9.56) cultures as much as 
it increased in CFSE-unloaded cells (28.34). In fact, the total B cell population did not 
increase in the presence of CFE, as was seen in (Table 3A).
The percentage of CFSE-loaded CD4^, CD8^ T cells was apparently decreased at the time 
zero compared to CFSE-unloaded cells (from 43.53 to 28.15 and from 12.56 to 8.59 
respectively). However, at the time of harvest under all treatments, the ratio of CFSE- 
loaded CD4^, CD8^ T cells was the same as CFSE-unloaded cells. The noticeable 
difference was the increase in the percentage of the proliferating CFSE-loaded CD4^, 
CD8+ T cells under CFE+ConA treatment (from 5.11 to 9.56 and from 1.29 to 5.69 
respectively). It was again clear, however, that CFE affected the proliferative response of 
CD4‘^ and CDS’*" T cells with a slight effect on yb^T cells.
The pattern of changes of CFSE-loaded yô^ T cells was the same as CFSE-unloaded y6‘^ T 
cells. The only notable difference was the increase in proliferating fraction of control 
CFSE-loaded yô'^T cells (from 1.75 to 5.46).
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3.4.S.3 Proliferative responses evaluated by CFSE staining
Different generations of each cell population were evaluated with CFSE after counter- 
staining of PBMCs. The results which has been shown in Table 3B for percentages of 
different populations of T cells (CD4‘^ , CD8"^ , and this was elaborated by software 
ModFit® (Section 2.3.18), to generate the frequency of different generations in each 
population, after treatment with ConA or CFE+ConA (Figure 27).
The CD4^ T cells proliferated (Proliferation lndex===2.54) in response to ConA (Figure 
27A1), but the proliferative response reduced (Proliferation lndex=1.92) in CFE+ConA- 
treated cells (Figure 27A2). The nonproliferative fraction of CD4^ T cells increased by 
1.55-fold (from 0.2 to 0.31) in response to CFE treatment (Figure 27A). The decrease in 
proliferative response of CFE-treated CD4"^  T cells to ConA started from generation 2 and 
was quite marked in later generations (Figure 27A2).
CD8^ T cells proliferated (Proliferation lndex=3.26) strongly in response to ConA (Figure 
27B1). However, the proliferative response (Proliferation lndex=1.77) of the CD8^ cells to 
ConA was suppressed by CFE (Figure 27B2). The nonproliferative fraction showed a 3.35- 
fold increase (from 0.17 to 0.57) in CFE+ConA-treated CD8"^  T cells, which indicated a 
more than 3-fold increase in the fraction of cells that, had not proliferated in response to 
ConA. The parent generation increased by two fold in CFE-treated CDS’*" cells although all 
of the daughter generations decreased were noticeably less proliferative compared to CFE- 
untreated cells (Figure 27B2).
The yô'  ^T cells showed proliferation (Proliferation Index=2.56) in response to ConA in a 
manner similar to CD4^ T cells in which the Proliferation Index was 2.54. The proliferative 
response of CFE-treated yô'*' T cells to ConA was only slightly reduced from 2.56 to 2.22 
(Figure 27C). The nonproliferative fraction of yô"*" T cells only increased by 1.46-fold 
(from 0.13 to 0.19) in CFE+ConA-treated cells, but progress through the generations was 
not as adversely affeeted as with CD4^ and CD8^T cells.
B cells were not included in Figure 27 because they did not show a similar response as that 
observed in CFSE-unloaded assay (Table 3) due to apparent adverse effects of CFSE on 
them.
S a eed  Ataei Kachooei, 2007  148 RESULTS
Figure 27 The CFSE fluorescence histograms of different T cell suhpopulations 
(CD4+, CD8+ and, yô )^
PBMCs were prepared from a normal calf and were loaded with CFSE and treated as 
indicated in Table 3. Data for CFSE-loaded PBMCs in Table 3B was elaborated through 
software ModFit® to visualise different generations of T cells sub-populations including:
CD4+T cells (Figure 27A), CD8^T cells (Figure 27B), and yô^T cells (Figure 27C). Each 
time the parental cell population divides, the fluorescence of the next generation halves.
Proliferation Index is the sum of the cells in all generations divided by the computed 
number of original parent cells and represents the increase in cell number over the course 
of the experiment. The Nonproliferative Fraction is the number of cells in the parent 
generation at the time of data collection divided by the computed number of cells present 
in the original culture and represents the fraction in the original culture of cells that have 
not proliferated during the course of the experiment.
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Figure 27A The CFSE fluorescence histogram of CD4 T cells after treatment with
ConA (Figure A l) and CFE+ConA (Figure A2)
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The CFSE fluorescence histogram of CDS T cells after treatment with
ConA (Figure B l) and CFE+ConA (Figure B2)
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Figure 27C The CFSE fluorescence histogram of yô  ^T ceils after treatment with
ConA (Figure C l) and CFE+ConA (Figure C2)
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Chapter 4 
DISCUSSION
4.1 Prevention of HS
HaemoiThagic septicaemia (HS) bas been ranked as a primary fatal disease affecting cattle 
and buffaloes. HS is economically very important in tropical areas of South and Southeast 
Asia, Near and Middle East where a noticeably large proportion of the world’s population 
of buffalo (95%) and cattle (30%) exists (FAO, 2003). In these areas, climate conditions 
are ideal for development and high incidence of the disease.
Treatment is of little value after the appearance of visible clinical signs. Early detection of 
HS is a crucial element in the success of treatment (Radostits et a l, 2000). In primitive 
husbandry conditions, which are the dominant system in endemic areas, the conditions for 
early detection of the disease are lacking. Consequently, in all countries where HS occurs, 
vaccination has been adopted as the practical method of control. Vaccination has been 
accepted as an effective means of HS control, because the rapid onset and short course of 
the disease leaves little opportunity for treatment (De Alwis, 1999).
For prevention and control of HS, there are three categories of measures. Measures to be 
followed in endemic countries on a prophylactic basis, measures to be adopted in an 
outbreak and measures needed for prevention of spread across regional or national borders. 
Vaccination is the most important element in all of these measures (Benkirane, 2002).
Currently there are four different types of vaccine commercially available for HS; plain 
bacterins, alum-precipitated, aluminium hydroxide gel and oil adjuvant vaccines. These 
vaccines, all of which are inactivated whole-cell vaccines, are being used in different 
countries and under different regimens (OIE, 2004; Verma & Jaiswal, 1998).
Although the achievements in controlling HS by vaccination have proved the importance 
of this strategy, there are some deficiencies in current vaccines. Plain bacterins confer only 
an immunity of very short duration. The alum-precipitated and aluminium hydroxide gel 
vaccines are believed to confer immunity for 6 months (Bain et a l, 1982) and even shorter 
durations for only about 3-4 months are also reported (De Alwis, 1999). Thus, in some
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endemic areas the recommended administration of these vaccines is twice a year. Oil 
adjuvant vaccine, which is able to confer longer immunity, suffers from difficulty of 
injection because of the high viscosity of the vaccine. This has made the vaccine unpopular 
among field users (Shah & de Graaf, 1997). Reactogenicity is another important obstacle 
for the use of cunent vaccines. There are different reports of the rate of postvaccination 
shock which vary from 0.1% (Bain et a l, 1982) to 10% (De Alwis, 1999). The high LPS 
content of these vaccines is identified as the cause of adverse reactions, due to the 
requirement for high numbers of cells to be present for adequate potency (De Alwis, 1999).
Vaccine development has become an important field of investigation to overcome the 
deficiencies of current vaccines. The importance of vaccine development was highlighted 
at the International Workshop on HS (Proceedings of the FAO/APHCA Workshop on 
Haemorrhagic Septicaemia, February 1991, Colombo, Sri Lanka). It is generally believed 
that exposure to live organisms is able to confer more solid immunity than immunisation 
through inactivated vaccines. This has been shown in HS where naturally-acquired 
immunity, resulting from aixested infection of animals, was superior to immunity caused 
by vaccination (de Alwis & Sumanadasa, 1982). Thus, a live attenuated vaccine, which has 
the ability to infect the animal, might also be able to cause stronger and long-term 
protective immunity against disease.
The efforts towards the introduction of new HS vaccines have focused mainly on the 
development of live vaccines (involving the production of suitable avirulent, protective 
mutants by genetic manipulation). Such studies, have resulted in the introduction of three 
different live vaccine candidates namely; streptomycin-dependent (Str°) mutant (Wei & 
Carter, 1978), deer strain (Myint et a l, 1987) and acapsular mutants (Boyce & Adler, 
2001). Only the deer strain, which is P. multocida serotype B;3,4 isolated from a fallow 
deer in England after an outbreak of septicaemic disease (Jones & Hussaini, 1982), has 
been subjected to pilot field study (Myint & Carter, 1989). However, the field studies 
revealed that, by subcutaneous administration, the deer strain was pathogenic in buffalo 
calves (Myint & Carter, 1989; Myint, 1990). Although aerosol vaccination with this strain 
is used in Myanmar (Myint et a l, 2005), it has not been accepted in other countries 
(Benkirane, 2002). One reason for this is that the vaccine strain has occasionally been 
associated with sporadic outbreaks of disease due to unknown reasons (Aalbaek et a l, 
1999; OIE, 2000; Rimler & Wilson, 1994). Furthemiore, because the vaccine contains a 
potential pathogen, vaccination could be done only under controlled conditions, to prevent 
the spread of the organism (De Alwis, 1999).
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A marker-free aroA deletion derivative (strain JRMT12) was constructed in our laboratory 
from a HS-associated P. multocida serotype B:2 (strain 85020) obtained from Sri Lanka. 
Preliminary experiments confirmed that JRMT12 was highly attenuated for virulence in a 
mouse model of HS. In the mouse model it was also shown that JRMT12 conferred a high 
degree of protection against challenge with the wild-type parent strain, when it was 
injected intraperitoneally or intranasally as a live vaccine (Tabatabaei et a l, 2002). These 
promising results suggested that further studies, on attenuation and the ability of JRMT12 
to promote protection, should be done in the natural host.
In the present study, three sets of experiments were carried out to determine the 
pathogenicity and immunogenicity of the JRMT12 strain in calves as natural hosts of P. 
multocida B:2. Investigation of immune mechanisms involved in possible protection was 
also a major part of our study.
4.2 Calf responses to JRMT12
4.2.1 Safety of JRMT12
Our results showed that the virulence of the JRMT12 mutant decreased for calves. 
Intranasal (IN) injection of calves with ç. 10  ^ CPU of the mutant did not cause the clinical 
signs of HS. The rectal temperature and SAA levels of animals, taken as an indication of 
the progress and severity of infection, in the IN vaccinated group remained at normal 
levels up to 24 h after administration. This indicated that the mutant did not mount an 
infection in this group via the intranasal route. One possible reason could be the low 
virulence of the strain. To cause systemic disease like HS, the bacteria at first step would 
need to cross the respiratory epithelium in sufficient numbers to cause infection and then in 
next step, the disease. JRMT12 may be too attenuated to cause the infection by this route. 
There is also the problem of animals swallowing a large part of the vaccine dose given 
intranasally. In future studies, it would be of interest to challenge the animals intranasally 
with larger doses of JRMT12, or to deliver the vaccine as a spray or aerosol, and to 
monitor signs of infection, such as temperature rise and SAA levels. It would also be of 
interest to swab those animals at regular intervals after vaccination, to try to determine the 
length of presence of the vaccine strain by this route.
Intramuscular (IM) injection of c, 10  ^ CPU of the mutant caused some typical clinical 
signs of the disease such as dullness and there was a clinical response manifested by a rise 
in rectal temperature and SAA levels. SAA levels increased significantly after each dose of
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IM vaccine and, in each case, reached the highest level in 24 h. The transient febrile 
response of these animals that, for humane reasons, was controlled by injection of NSAID, 
was possibly caused by associated bacterial endotoxin. This was considered in setting up 
the second experiment to study lower doses of vaccine to overcome this reactogenicity. IM 
injection of calves with three different doses (c l^O  ^ CPU, c l^O  ^ CPU, c.10^ CPU) of 
JRMT12 showed some typical clinical signs of HS. Rectal temperatures of all vaccinated 
groups were raised after each dose of vaccine. The patterns of temperature increase over 
time were very similar for the 10  ^ and 10  ^ CPU groups despite the intervention with 
NSAID treatment in the 10  ^ CPU group. In calves that received -10^ CPU the febrile 
response was less than in the other two groups (p=0.002) as it plateaued after 2 h and 
remained higher than the baseline up to 24 h after vaccination. In this experiment only 
SAA level of the 10  ^ CPU group was measured after the first vaccination, as a 
representative response. The SAA levels after vaccination in this group were lower than 
the SAA responses in the 10  ^ CPU group deteiTnined in the first experiment. Because of 
this lower response, and a generally lower reactogenicity, 10  ^ CPU was considered a safe 
dose for IM vaccination. The SAA response to the EM vaccination paralleled the increased 
rectal temperature, indicating that the attenuated bacteria persisted for some time in the 
animals, perhaps for long enough to promote an immunogenic response.
In the first experiment, clinical signs of HS after challenge with the wild type strain were 
prevented by IM vaccination of calves with two doses of JRMT12 at 10  ^CPU. Vaccination 
by the IN route was not able to prevent clinical signs of the disease after challenge. There 
was a clear difference between the temperature responses of calves to challenge: IM- 
vaccinated animals did not show any changes but, in control and EN-vaccinated animals, 
rectal temperature increased after challenge. SAA levels showed the same pattern of 
changes in this experiment. EM vaccination with two doses of the mutant prevented 
dramatic changes in SAA response upon challenge, but IN vaccination of calves did not 
prevent this rise. In the control and IN-vaccinated groups, SAA levels increased 
dramatically after challenge. A lack of clinical reaction in IM-vaccinated calves was an 
indication of the protection confeiTed in these animals by vaccination.
In this experiment one calf from each of the IN-vaccinated and control groups did not 
develop the clinical signs of HS after challenge with wild type. Generally, the exact 
reasons why not all calves develop the disease after challenge has not been understood. As 
possible reasons, it has been suggested by a study on buffalo calves that the reduced 
endotoxaemia and a gradual but sustained rise in AFP may contribute in helping to control 
disease (Horadagoda et a l, 2001). In this way, the high levels of SAA observed in these
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particular calves due to challenge may have played a role in their survival. On the other 
hand the increase in SAA levels have been used as an indication of severity of infection 
(Horadagoda et a l, 1999). Thus, the lai'ge increase in SAA levels recorded in IN- 
vaccinated calves after challenge, compared with the moderate response of the IM- 
vaccinated group, was considered the result of a less well-developed immune protection in 
the IN-vaccinated group. However, there was no clear relation between prechallenge 
concentrations of SAA and survival after challenge, as the IN-vaccinated calf that survived 
the challenge had a low SAA level (4.3 pg/ml) while the only survivor calf in control 
group had a relatively high level of SAA (128 |ug/ml).
In the second experiment (IM vaccination using different doses), rectal temperature of 
calves in the 10  ^ and 10  ^ CPU groups increased in response to challenge but returned to 
normal levels by 28 h. At 12 h after challenge the recorded rises in temperatures were 
dose-dependent: the higher the dose of vaccine the lower the temperature rise after 
challenge. The temperature response of the 10  ^ CPU vaccinated group was about the same 
as that in the control group after challenge. Because of this observation the 10  ^CPU dose 
of vaccination could be considered as inadequate for prevention of clinical signs. However, 
all the calves given 10  ^ CPU survived challenge and did not need NSAID asministration, 
whereas 2 of 3 control calves were given NSAID treatment, but were unresponsive and had 
to be put down early. In this experiment, haptoglobin (Hp) levels were measured along 
with SAA levels. In all vaccinated groups SAA and Hp responses to challenge were 
prevented. Hp showed similar pattern of changes to SAA. The pattern of Hp response that 
was observed in our experiments supports the studies that identified SAA and Hp as a 
reliable index to show the level of inflammation (Horadagoda et a l, 1993; Horadagoda et 
a l, 1994; Horadagoda et a l, 1999). A study on calves challenged intratracheally with P. 
multocida A3 also showed that plasma concentrations of SAA and Hp increased rapidly 
between 5 and 23 hours in response to challenge and decreased dramatically between 72 
and 96 hours after challenge (Dowling et a l, 2002). All together, our data and the results 
of these studies indicate the role of SAA and Hp in inflammatory response of calves to 
infection which can be used as markers of the severity and progress of the disease.
4.2.2 Potency of JRMT12
Our results indicated that JRMT12 at doses of 10 ,^ 10^  and 10  ^ CPU injected IM could 
protect calves against challenge with the wild type 85020 strain. A dose of 10  ^ CPU was 
considered optimal as this produced little reactogenicity either on vaccination or 
subsequently as a result of challenge. Our results indicated that JRMT12 was able to
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induce a strong antibody response only after second IM vaccination. Concentrations of 
serum IgG rose 50-fold within 7 days after the second IM vaccination using the 10  ^ CPU 
dose and had risen further by the day of challenge. There was no increase in IgG levels of 
these animals 28 days after the first IM vaccination. On the other hand, IN-vaccinated 
calves showed no detectable IgG response to vaccination. The lack of an IgG response to 
IN vaccination dose not preclude the induction of mucosal IgA antibody which was not 
assessed in our study, although even if this occured, it did not contribute to protection as 
IN-vaccinated animals were not resistant to challenge. In the second experiment, using 
three different doses delivered IM, IgG again increased only after the second vaccination 
and in a dose dependent manner: the higher the dose of vaccine the higher the titre of 
serum IgG. The reason for the lack of IgG response after primary vaccination is not clear 
but could be due to a rapid clearance of the JRMT12 vaccine strain. A persistent or 
repeated exposure to antigen is a key requirement for a strong IgG response. Our data are 
in agreement with other studies that reported only a gradual increase in serum IgG titres 
during 6-10 weeks after vaccination with an oil-adjuvant vaccine, which provides a slow 
release of antigen and prolonged exposure to it (Chandrasekaran et a l, 1994a; 
Chandrasekaran et a l, 1994b; Horadagoda et a l, 1994; Shah & de Graaf, 1997). The rapid 
IgG response after a second IM vaccination was also noted in another study which showed 
a rapid and significant rise in IgG levels 14 days after a booster injection (Horadagoda et 
a l, 1994). However, it appeared that the first dose of IM-vaccination in our experiments 
acted as priming dose, although it did not persist long enough to raise antibody and the 
second dose of IM-vaccination acted as a booster that raised high levels of IgG.
A single IM vaccination of calves with 10  ^ CPU of JRMT12 did not confer protection 
against subcutaneous challenge. As discussed before, IM vaccination twice with 10  ^ CPU 
was considered an optimum dose that fully protected calves but showed no obvious 
reactogenicity. It was of interest, therefore to check if a single vaccination was protective. 
In the third experiment the efficacy of single IM vaccination regime was studied. Two of 
the four vaccinated calves and two of the five non-vaccinated calves survived the 
challenge. The antibody and APP responses of the animals were not investigated, because 
our results showed that the single vaccination regime was not able to cause protection, as 
there was no difference between the survival rate of vaccinated and non-vaccinated 
animals. These data were consistent with the pattern of antibody response observed in 
previous experiments using two IM vaccinations, which indicated a lack of antibody 
response after the first vaccination. The results are suggestive of a strong correlation 
between the induction of humoral responses and active protection.
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One possible explanation for the rapid clearance of the vaccine strain could be this aroA 
mutant strain is too attenuated and might have lost the ability to persist long enough for 
stimulation of a clear primary humoral response in the host. Given that a second 
vaccination was able to induce a strong IgG response, a possible explanation for rapid 
clearance of the mutant by the host might be the presence of non-specific cross-reacting 
antibodies which are able to inactivate the mutant. This theory was supported by our 
experiments, which indicated the presence of maternal IgM antibodies in the 2 week old 
calves before vaccination which progressively declined. Maternal IgM may have cross­
reacted with and neutralised the live vaccine and minimised any humoral response. This 
phenomenon has been noted previously in young animals (Black et a l, 1985). It was 
shown by a study that calves vaccinated too young may succumb to HS up to the age of 5 
to 6 months due to the presence of maternal immunity (Sheikh et a l, 1995), which 
presumably interferes with the development of an active immune response to the vaccine. 
It was also found by another study that when calves in the age range of 2 to 5 months were 
vaccinated, the number of calves under 3.5 months that developed detectable antibody 
titres was low in comparison with 72% of calves over 3.5 months that responded (De 
Alwis, 1992). It was recommended commencing the HS vaccination of calves at the age 
between 4 to 6 month of age to avoid antibodies interfering with vaccination (el-Eragi et 
a l, 2001).
Concentrations of serum IgM rose markedly by 7 days following the second IM 
vaccination, in a similar manner to IgG, and the concentration achieved at that time was 
maintained until termination of the experiment. In IN-vaccinated calves there was no 
increase in serum IgM levels during the experiment. IgM levels were high before 
vaccination in some groups of animals, including the IM-vaccinated calves. The IgM levels 
declined following first vaccination and rose again after second dose of vaccine. As 
indicated earlier, the earlier IgM antibodies were possibly maternally-derived due to 
infection of the original herd with organisms showing antigenic similaiities with P. 
multocida B:2. Because HS has not been reported from UK, these maternal antibodies 
could not have been due to infection with P. multocida B:2. Infection of the upper 
respiratory system of cattle with P. multocida serogroup A is common in the United 
Kingdom (Dowling et a l, 2004). My work has shown cross-reaction of the P. multocida 
B:2 CFE, which was used for coating ELISA plates, with antiserum raised to P. multocida 
A3 strain after using anti-bovine IgM HRP conjugate as secondary antibody, a high titre 
(3981 U/ml) was obtained, whereas cross-reaction when anti-bovine IgG HRP conjugate 
was used was minimal (87 U/ml). Therefore, it seems likely, that the presence of IgM 
antibodies in some of the calves used in our study before vaccination was due to cross-
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reacting maternai antibodies determined from infection with P. multocida A serogroup in 
the mother.
The calves used in our study were checked for the presence of P. multocida infection by 
nasal swabbing and any calf showed infection was not used in the experiments. To avoid 
the problem of cross-reacting antibodies in future studies, the animals should also be 
monitored for the presence of the cross-reacting antibodies by serological tests such as 
ELISA. Antigens obtained from P. multocida serotype B:2 can be used for coating ELISA 
microplates. Antigens obtained from other serotypes of P. multocida including serotype A3 
can also be used for detection of maternal antibodies in animals to be used in experiments 
to check the presence of infection with other serotypes. Another possible solution to avoid 
the cross-reacting antibodies would be the selection of animals of higher ages (4-5 months 
old) or animals that have not consumed colostrum.
In a study on the transfer of colostrum-derived antibodies in newborn calves from HS- 
vaccinated dams, it was shown that maternal anti-HS IgG antibodies increased rapidly after 
suckling and then declined over a period between 2 and 4 weeks (el-Eragi et ah, 2001). 
This is different from our results which showed that the IgM declined 2 weeks after first 
vaccination and reached the lowest level 2 weeks later in both the first and second 
experiments. In ruminants the intestine is unselectively permeable and all 
immunoglobulins are absorbed. The passively acquired antibodies decline through normal 
catabolic processes. The rate of decline differs among immunoglobulin classes and the 
time taken for them to decline depends on their initial concentration (Tizard, 2000). The 
initial concentration of colostrum-derived antibodies depends on the amount of colostrum 
consumed by the newborn calves and the maternal antibody titre (el-Eragi et a l,  2001). 
Exposure of colostrum-derived antibodies to reacting antigens can also accelerate the 
clearance of maternal antibodies and this would be a possible factor in their decline (el- 
Eragi et a l, 2001). In our experiment this could also have had an impact on clearance of 
antibodies and would explain the similarity of clearance patterns, despite the difference in 
age of calves used in first and second experiments. This could also be a possible reason for 
the differences between our results and the study on kinetics of decline of maternal 
antibodies in calves.
4.2.3 Serum sensitivity
Our experiments on assessment of the bactericidal activity of the serum showed that, P. 
multocida B:2 strain 85020 is highly resistant to positive serum (containing high levels of
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IgG and IgM obtained from calves one week after second IM vaccination) and complement 
activity in normal fresh calf serum. The wild type strain was incubated in sera obtained 
from IM-vaccinated calves with high titres of IgG and IgM, in the presence or absence of 
normal fresh calf serum as a source of complement, to study its sensitivity to complement- 
mediated killing. P. multocida B:2 strain 85020 was resistant and grew in the positive and 
heated positive serum. The strain also grew in the normal fresh calf serum and the mixture 
of positive serum and noiTnal fresh calf serum. Heated normal fresh calf serum and the 
mixture of heated positive serum and heated normal calf serum had no effect on the strain. 
Each of the fresh and positive sera had stimulatory effects on growth of the strain allowing 
the number of organisms to double during incubation. On the other hand, after heating of 
these sera, growth was not apparent, maybe because of the destruction of the growth 
stimulatory agent(s) due to heating. In order to check the complement activity, the 
bactericidal effect of these sera was also assessed on an E. coli K12 strain. Fresh normal 
calf serum completely killed all the organisms within one hour but the heated calf serum 
had no effect. Guinea pig complement was also able to kill the E. coli K12 strain.
Fetal calf serum (used as an additive for mammalian cell cultures) had no effect on the 
organism. The rapid progress of HS disease in naïve animals is indicative of resistance of 
the bacterium to innate immunity elements such as the complement system. These results 
support another study which showed that P. multocida B:2 was highly resistant to 
complement activity of normal bovine and murine serum and grew rapidly in either fresh 
or heat-treated calf serum (Boyce & Adler, 2000). Our results would also support studies 
which showed that different monoclonal antibodies reacting with the EPS of the bacterium 
were not bactericidal in the presence of complement, although these antibodies were able 
to opsonise the bacterium for phagocytosis by mouse macrophages (Adler et a l, 1996; 
Ramdani & Adler, 1991). It would be predicted that, anti-EPS antibodies would be raised 
in calves after vaccination with the aroA strain. Although it is generally believed that 
immunity to P. multocida B:2 is antibody-mediated, the exact mechanisms involved in 
protection confened by antibodies is not clear yet. Our results showed that in vitro 
exposure of the organism to sera with high levels of antibody in the presence and absence 
of complement does not have an adverse effect on the organism. As also shown by our 
experiments, challenge of vaccinated animals, which had high levels of antibody, 
prevented the progress of disease. Thus, it can be assumed either that these antibodies 
promoted clearance by opsonophagocytosis or neutralised the activity of important 
virulence factor(s), but the nature of these remains elusive. It would be of interest to test 
the opsonising effect of these antibodies in vitro using isolated macrophages or a cell line. 
It should be noted that protection did not prevent the localisation of the P. multocida 85020
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in tonsilar lymph nodes (Table 2). This indicated that antibodies against the organism may 
contribute to protection by inhibiting the rapid spread of the organism through the body, a 
possible role of protective antibodies suggested for infection with P. multocida serotype 
A3 (Ryu & Kim, 2000). In addition, for HS-causing P. multocida B:2, latent carrier 
animals have high levels of antibody, it has also been suggested that these antibodies 
protect the carrier animals by inhibiting the rapid spread of the organism through the body 
(De Alwis et a l, 1990).
4.3 Immunogenic components
Immunogenic components of P. multocida to which antibody were raised during different 
stages of vaccination and challenge were detected by SDS-PAGE and immunoblotting. 
About 32 visible protein bands, with approximate molecular weights ranging from 16 to 90 
kDa, were detected by SDS-PAGE in CFE of P. multocida B:2 strain 85020, The 
molecular weight of protein bands was estimated by comparison with standard MW 
markers run in parallel with the samples on the same gel. The SDS-PAGE of the CFE also 
revealed that two protein bands of approximate sizes of 30 and 37 kDa were predominant, 
on the basis of the stain intensity and thickness of the bands. Immunoblotting of the CFE, 
against sera collected from individual calves one week after the second IM vaccination 
with 10  ^ CFU and after challenge, showed the same pattern. In individual sera, seven 
antigenic components of MW 16, 26, 30, 37, 44, 51 and 53 kDa were detectable. The 53 
kDa band, which was visible as a weak band in blots using sera before the first vaccination 
and was visible for all other sera was not considered as a protective component. The 44 
kDa band that appeared 4 weeks after first vaccination, and was also detectable in later 
sera, was also not considered as a protective antigen because a further experiment using a 
single vaccination regime showed no protection against challenge implying that this 
protein was not associated with protection. A protein of 44 kDa along with 37 and 30 kDa 
proteins were suggested as major immunogens in another study using rabbit hyperimmune 
serum raised to whole P. multocida cells (Pati et al., 1996). Our results are indicative of the 
presence of antibodies to this 44 kDa protein in unprotected calves. The bands with 
approximate MW of 51, 37, 30, 26 and 16 kDa, which only appeared one week after the 
second vaccination and remained after challenge were identified as immunogenic 
components with possible roles in protection against challenge. As with other Gram- 
negative bacteria, OMPs of P. multocida B:2 have been suggested as possible immunogens 
(Dawkins et ah, 1991a; Pati et a l, 1996; Srivastava, 1998). Thus it was considered 
important to show the ability of JRMT12 to induce antibodies against OMPs. For further
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identification of immunogenic components, OMPs of the bacterium were isolated and 
blotted against calf sera collected one week after second vaccination with 10  ^ CFU. Sera 
obtained from different individual calves showed reasonably similar patterns of blots. 
SDS-PAGE of the OMP preparation revealed up to ten major and four minor bands. Two 
strong bands with MW of 37 and 50 kDa, were detected in immunoblots of the OMP 
preparation. One drawback of the immunogen investigation by immune sera is that 
antibodies that react only with conformational epitopes, that would be denatured in SDS- 
PAGE, will not be detected.
For protein identification by mass spectrometry (MS), the 37 and 50 kDa (Figure 20B) 
bands, as immunogenic components, were excised form the coiTesponding SDS-PAGE gel. 
The 30 kDa band, which was the most predominant band of the OMP preparation, on the 
basis of the stain intensity and thickness of the band, was also chosen for identification by 
MS. The 30 kDa was identified as OmpH of P. multocida with a significant score of 521 (a 
score of > 63 considered as significant) by MASCOT analysis of the data. The molecular 
weight of OmpH that the MASCOT search identified was 35 kDa, from P. multocida 
serotype A (strain PM 70, an avian isolate). One reason for this difference in molecular 
weight of proteins could the unpredictability of the behaviour of membrane proteins in 
SDS-PAGE. Differences between different serotypes might also be a cause of this 
difference. The 30 kDa band showed no detectable antigenic reaction on the Western blot 
although it was the most predominant band in SDS-PAGE of the OMP preparation. 
Different studies have suggested different degrees of antigenicity for a 30 kDa OMP of P. 
multocida serotype B:2. In a study of an OMP of 31 kDa in P. multocida serotype B:2, 
which was the major band of the OMP preparation, only a faint reaction was found using 
rabbit hyperimmune serum and this protein was totally unreactive using buffalo immune 
sera, from animals vaccinated with alum-precipitated vaccine. It was concluded that this 
protein was only weakly antigenic in nature (Tomer et a l, 2002). On the other hand, in 
another study using rabbit hyperimmune serum, the 30 kDa was designated as one of the 
three major immunogens of the OMP of P. multocida serotype B:2 (Pati et a l, 1996). This 
controversy was also prominent in our study where a 30 kDa band in the CFE showed a 
strong antigenic reaction (Figure 19) but in an OMP preparation a protein of this size was 
not able to cause the reaction (Figure 20A). This implies that the 30 kDa protein detected 
by sera in the CFE was not an OMP and a different protein to that present in the OMP 
preparation. Surprisingly, the 50 kDa band of the OMP preparation which showed a strong 
reaction on immunoblot, was also identified as OmpH (see below).
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The 37 kDa band was identified as OmpA of P. multocida with a significant score of 750. 
This band on SDS-PAGE was the second major band after 30 kDa and, on the Western 
blot, revealed the strongest immunogenic reaction, based on the intensity of colour 
development and thickness of the band (Figure 20A). A 37 kDa band detected as a strong 
immunogenic antigen in CFE (Figure 19) could have been the same protein present in the 
OMP preparation. Our results support other studies that have identified a protein of similar 
size as a main antigenic protein (Johnson et al., 1989; Pati et a l, 1996; Tomer et a l, 2002). 
One study showed that an OMP of 37 kDa was one of the chief immunogens that reacted 
with immune sera from buffalos vaccinated against HS (Tomer et a l, 2002). In another 
study, using rabbit hyperimmune serum, an OMP of 37 kDa was found to be the main 
antigenic protein in different isolates of HS-related Pasteurella (Pati et a l, 1996). It can be 
postulated that the 37 kDa protein identified in our study is the corresponding protein 
detected in those studies. In those studies, the 37 kDa protein was not subjected to 
molecular identification, but our results from mass spectrometry showed that this protein 
was OmpA.
The OmpA protein, which is also called heat-modifiable protein, is an integral component 
of the OMPs of Gram-negative bacteria. Different functions related to pathogenicity have 
been attributed to OmpA in different bacteria. In E. coli, the OmpA contributes to serum 
resistance and pathogenicity (Weiser & Gotschlich, 1991), In P. multocida serotype A:3 it 
has recently been shown that the protein is involved in adherence to host cells (Dabo et a l, 
2003). It has also been suggested that the OmpA may play a role in adaptation of M. 
haemolytica strains to different hosts (Davies et a l, 2004).
Our results are supported by recent study on P. multocida serotype A (FC-associated) that 
identified OMPs as immunogenic elements. Studies using genomic and proteomics 
approaches. In a study using bioinformatic analysis of whole genome of P. multocida 
serotype A, 129 proteins were predicted as outer-membrane proteins, secreted proteins or 
lipoproteins (Al-Hasani et a l, 2007). 105 of the corresponding genes were cloned and 
recombinant proteins expressed in E. coli. To evaluate the range of proteins recognized by 
the antibody response these recombinant proteins were blotted against pooled serum 
samples obtained from chickens that had been repeatedly infected and then treated with 
antibiotics. By database similarity, this study identified 12 immunogenic determinants and 
8 of them were recognized as OMPs (including 2 lipoproteins PlpB and Lpp), 3 as 
hypothetical proteins, and 1 as SurA protein from Mannheimia. OmpH was identified as 
one of the OMPs that reacted with chicken immune serum. OmpA was identified as an 
OMP reacted with covalescent serum but it also reacted with serum obtained from control
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(uninfected) chickens. The use of the same approach, which has been termed reverse 
vaccinology or reverse immunology, on P. multocida serotype B:2 could be informative 
for identification of immunogenic components, but this method of immunogen discovery 
requires the whole genome data of this serotype which has not been sequenced yet. 
However, one drawback of this assay is that it is limited only to the recombinant proteins 
that can be expressed in vector. Furthermore, a lack of antibody response to the 
recombinant proteins may be the result of conformational differences after synthesis in E. 
coli compared with native proteins.
Different environmental conditions may cause changes in OMPs composition, as these 
proteins are critical for interaction with the environment. A study on changes in expression 
of OMPs of FC-associated P. multocida serotype A in response to environmental 
conditions showed that only 4 proteins exhibited different expression in bacteria isolated 
from the blood stream of infected chicken (the natural host) compared to bacteria grow in 
vitro (Boyce & Adler, 2006). Three proteins (TufA, TufB and Pm0803) were upregulated 
and one (OmpW, an OMP in many Gram-negative bacteria with undefined function) 
downregulated. In this study, analysis of the OMPs obtained from P. multocida grown in 
vitro (in BHI) under iron-depleted conditions showed that only Pm0803 (97 kDa) was 
upregulated in response to low iron while one protein was downregulated (OmpW with 
theoretical mass of 22 kDa) (Boyce et a l, 2006). It was concluded by this study that 
differential expression of these two proteins (Pm0803 and OmpW) is similar to that seen in 
vitro. The presence of TufA and TufB (components of elongation factor Tu) in the outer 
membrane is intriguing as under normal conditions they are cytoplasmic proteins. This 
study might suggest that TufA and TufB are preferentially targeted to the outer membrane 
under in vivo conditions (Boyce & Adler, 2006). Our experiments using iron-depleted 
conditions (by adding 2,2’-dipyridyl 150 pmol/ml to BHI) showed that 4 proteins with 
molecular weight of 97, 95, 82 and 24 kDa were upregulated (presented at higher 
concentrations based on intensity and thickness of bands on SDA-PAGE gels) and a 
protein of 26 kDa was downregulated. The 97 or 95 kDa protein could be the same as that 
identified by Boyce et a l (2006). The 82 kDa protein showed the highest increase in 
response to iron depletion. In a study on HS-associated P. multocida an 82-kDa OMP was 
found that specifically binds bovine transferrin (Veken et a l, 1996). However, the OMP 
extracts prepared from iron-depleted cultures were not included in our experiments, since 
none of these upregulated proteins showed reaction in Western blotting assays.
Although the research on P. multocida has focused on identification of virulence factors 
and immunogenic components, only a few potentially protective antigens including OmpH
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(Luc et a l, 1999), PlpB (Tabatabai & Zehr, 2004) and iron-reponsive OMPs (Ruffolo et 
a l, 1998) has clearly been characterized. Although a number of OMPs have been 
identified in other P. multocida serotypes, no comparable data are available for P. 
multocida serotype B;2. Our experiments showed that the vaccination of calves using 
JRMT12 was able to raise high levels of antibody against different components of the wild 
type organism. We also identified the 37 kDa component as OmpA to which there was a 
strong IgG response. It can be suggested that this protein may play a role in protection and 
would be a potential vaccine candidate for further studies, although immunological 
reactivity to an antigen does not necessarily indicate a role in protective immunity against 
HS. Because of the relationship of the OmpA with protection of calves against challenge, 
this protein could be a candidate for the assessment of the immune status of animals by 
using it as a coating antigen for ELISA, Recombinant OmpA could be expressed, for 
example for inclusion in an acellular vaccine containing purified antigens. It can also be 
suggested that the OmpA may play a role in pathogenesis of HS and can be a candidate for 
further studies on pathogenesis of the disease.
The identification of the 50 kDa immunogenic protein was unsatisfactory. It was 
recognised by the MASCOT search as the 35 kDa OmpH of P. multocida with a significant 
score of 218. The reason for identification of the 50 kDa band as OmpH is not clear. The 
occuiTence of OMPs on different locations of SDS-PAGE has also been reported by a 
recent study on FC-associated P. multocida serotype A. The study showed that many 
proteins were identified from more than one gel slice. In that study the whole length of 
SDS-PAGE gel was sliced into 8 pieces and OmpH and OmpA were identified from 5 and 
8 slices of gels respectively (Boyce et a l, 2006). No explanation was given for this 
observation in that study. As an explanation for the appearance of this band at a location 
not expected from its molecular weight on SDS-PAGE, the isolated band might be 
contamination due to smearing of the 35 kDa OmpH protein which was present in high 
concentrations in the OMP preparation. This may have obscured any faint band on SDS- 
PAGE, which showed a strong immunogenic reaction, and this protein, present in low 
concentration, was not then identified by MS. Another possible reason, for the appearance 
of OmpH as a 50 kDa band on SDS-PAGE of the OMP preparation, is the suggestion that 
this band was a complex of the OmpH with another, possibly periplasmic, protein which 
functions in transportation of OMPs. This was shown in E. coli where a 17 kDa 
periplasmic protein bound with high selectivity to the OMPs during SDS-PAGE. This 
protein is believed to function as a periplasmic molecular chaperone which assists OMPs 
on their way from cytoplasm to the outer membrane (Chen & Henning, 1996). However, 
further experiments are needed to identify these OMP chaperones and to prove this
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hypothesis, especially as it might be expected that this protein would be present in 
equimolai' amounts to OmpH and therefore detectable by MS. The strong immunogenicity 
of the band of 37 kDa, deserves further investigation
4.4 Cellular responses
4.4.1 In vivo experiments
The relative contributory roles of cellular and humoral immunity to long-teiTn protection 
against HS have not yet been established. Although it is generally believed that humoral 
immunity is the main component of immunity, the contribution of cell-mediated immunity 
cannot be excluded. In the third experiment (single IM vaccination regime) the cellular 
responses of vaccinated and control groups of calves after challenge were studied. A 
lymphocyte stimulation assay was used to assess the effects of a CFE of P. multocida on 
peripheral blood mononuclear cells (PBMCs) isolated from calves at different times after 
challenge.
CFE of P. multocida did not show any stimulatory effects on PBMCs isolated from 
vaccinated or control calves at different stages after challenge. The lack of stimulation of 
PBMCs by CFE could have been due to the lack of a cellular response. In other words, if in 
animals infected with P. multocida there was a cellular response (cell priming) during the 
week after challenge, the isolated PBMCs should have proliferated in the presence of CFE 
(as antigen). It might also have been expected that PBMCs from calves vaccinated with 
JRMT12 would repond to the presence of CFE but this was not observed. In further 
experiments on P, multocida serotype A:3, our results showed that the PBMCs obtained 
from calves challenged with serotype A:3, proliferated in the presence of CFE, a response 
that was not observed in similar experiment using PBMCs from calves challenged with 
serotype B:2. The lymphocyte proliferation assay was also carried out on PBMCs from 
calves challenged with P. multocida serotype A:3 to compare the cellular responses after 
P. multocida A3 challenge (pulmonary pasteurellosis) with P. multocida B:2 challenge 
(septicaemic pasteurellosis). PBMCs obtained from calves challenged intratracheally with 
P. multocida A3 responded to stimulation with the CFE of P. multocida A3, but PBMCs of 
control animals that were injected intratracheally with PBS, showed no response to 
stimulation. Time course experiments showed that the cellular response to P. multocida A3 
extract began on the second day after challenge. The cellular response of the PBMCs is 
indicative of a role for the induction of cellular response in P. multocida A3 infected
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calves. The rapid response (second day) in this experiment can be an indicative of 
sensitisation of the innate immune cells and in vitro re-exposure to CFE caused production 
of proinflamatory cytokines, which subsequently caused activation of these cells. The 
activation of macrophages obtained from experimentally infected animals by in vitro 
treatment using different bacterial components has recently been reported by other studies 
but the exact mechanism are not clear yet (Mueller et a l, 2006; Pestka & Zhou, 2006; 
Powers et a l, 2006). A study on P. multocida A3 vaccinated mice suggested that the 
immunity is not cellular (Collins, 1973; Collins & Woolcock, 1976). However, our results 
are in accordance with a recent study that showed the stimulatory effect of antigen on 
splenocytes of mice of 8 weeks age vaccinated subcutaneously with EPS-protein complex 
extracted from P. multocida A3. The authors also showed the DTH (delayed type 
hypersensitivity) reaction in footpads of vaccinated mice two weeks after vaccination as 
further evidence of cell-mediated immunity. The authors suggested further investigations 
to determine the cellular response of cattle (Ryu & Kim, 2000). Our results clearly 
indicated a difference between the two different serotypes of P. multocida, which are 
causative agents of two different diseases, in ternis of cellular responses. Interestingly, 
further experiments showed that the PBMCs obtained from P. multocida A3 challenged 
calves, were also able to respond to CFE of P. multocida B:2. This is clearly suggesting 
antigenic cross-reaction between these two serotypes, a phenomenon that had previously 
been shown in our ELISA experiments using sera positive for the A3 serotype which also 
showed that.
Our results are indicative of an immunosuppressive effect of P. multocida B:2. 
Unresponsiveness of lymphocytes after challenge may have a role in the pathogenesis of 
HS. The lack of response could be a result of a direct effect of the bacterium on the cells of 
the immune system. The injected bacteria in the challenge dose are likely to be taken to the 
regional lymph nodes by macrophages. It was observed a short time after subcutaneous 
injection of the challenge dose in the right shoulder area, that the right prescapular lymph 
node became swollen. Bacteriological investigations post-mortem also showed that tonsils 
and retropharyngeal lymph nodes were the main areas where of the organism lodged after 
challenge. In these lymphatic organs, the organism would be in close contact with 
lymphatic cells. The natural route of infection is obviously different, which is by inhalation 
and/or ingestion, and the initial site of multiplication is the tonsilar region. Artificial 
intranasal and oral infections result in a longer course of the disease and more profound 
lesions while subcutaneous injection results in a rapid onset, shorter course and fewer 
pathological lesions (De Alwis, 1999). The differences in route of infection are likely to 
have an impact on the immunosuppressive effect we observed.
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In parallel to the assessment of the stimulatory effects of CFE of P. multocida B:2, the 
proliferative response of isolated PBMCs to Con A was also assessed (lymphocyte 
proliferation assay), as a control to measure the proliferative potency of PBMCs. 
Proliferation of lymphocyte populations after stimulation with non-specific mitogens is 
used for assessment of cell-mediated immunity (Karol, 1998), and inhibition of the 
proliferative response caused by different parasites (Onah et a l, 1998; Scott et a l, 1999), 
bacteria (Majury & Shewen, 1991a; Majury & Shewen, 1991b; Park et a l, 1993), bacterial 
components (Chen et a l, 2000; Vanden Bush & Rosenbusch, 2004) or chemical agents 
(Franklin et a l, 1991; Gummert et a l, 1999; Mehrotra et a l, 2002; Peltier et a l, 2000) has 
also been studied. Our experiments showed that PBMCs of animals challenged with P. 
multocida B:2, in both vaccinated and non-vaccinated groups, transiently lost their ability 
to proliferate in response to ConA. In both vaccinated and control groups, the mean SI 
(stimulation index) as a response to ConA had decreased significantly at 12 h after 
challenge and reached the lowest level at 3 days after challenge. In control animals, 7 days 
after challenge the mean SI increased to ai'ound the pre-challenge value. The results were 
indicative of a possible suppressive effect of challenge with P. multocida B:2 on calf 
PBMCs. This observation, which does not appear to have been reported previously, is in 
keeping with the lack of response of PBMCs from challenged animals to repond to CFE, 
More experiments were undertaken to investigate the suppressive agent(s) and the 
identification of the suppressed cells.
It has been shown that high levels of acetate, which happens in a metabolic disorder of 
cattle called ketosis, were able to suppress the in vitro proliferative response of PBMCs to 
ConA, and it was suggested this may alter the immune response in vivo (Franklin et a l, 
1991). High levels of steroids in the serum of diseased calves could also be a possible 
cause of suppression in PBMCs as it has been suggested as the reason for temporarily 
unresponsivness of calf lymphocytes to mitogens around the time of birth (Tizard, 2000). 
Unfortunately little data are available for pathophysiological changes caused by HS. In one 
study, EPS was administrated to buffalo calves to produce an HS clinical syndrome. The 
study showed that endotoxic shock, similar to that seen in other septicaemic clinical 
conditions, constituted the main clinical changes, which were similar to HS (Horadagoda et 
a l, 2001). It was shown that EPS promoted an acute phase response, including production 
of tumor necrosis factor-a (TNF-a) and leucopenia (Horadagoda et a l, 2002). Eeucopenia 
as a consequence of the disease could result in the absence of a proliferative response in 
PBMCs obtained from diseased calves. Eeucopenia may result in the absence or reduction 
of the fraction(s) of cells proliferating in response to ConA or play critical role in the
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proliferative response. Further experiments using FACS analysis on identification of 
changes in population of different cells fractions after onset of HS could be informative.
4.4.2 In vitro experiments
As it was not possible to do further in vivo experiments, but as it appeared that P. 
multocida B:2 was having a suppressive effect on PBMC response, it was decided to test 
the CFE of P. multocida 85020 in vitro to see if this contained components that might 
cause the in vivo effect. To do this, an in vitro system was set up in which calf PBMCs 
obtained from a normal calf were treated with CFE before adding ConA. Preliminary 
experiments, using different concentrations of CFE, showed that 1 Opg/well was the 
optimal concentration of CFE in which PBMCs (2 x lOVwell) grew normally but where 
the proliferative response to ConA was suppressed. To find out the optimum concentration 
of ConA for in vitro assay, further experiments using different concentrations of ConA 
showed that the 1 pg/well was the optimum concentration with which PBMCs were able to 
proliferate strongly and the suppressive effect of CFE was also observed. In the in vitro 
experiments, it was shown that the proliferative response of normal PBMCs to ConA was 
60-100 times that of non-stimulated control cells and that, was markedly suppressed when 
PBMCs were incubated with the optimal concentration of CFE of P. multocida B:2 for one 
hour before adding the ConA. Different experiments showed that the addition of CFE 
caused a 3-5 fold decrease in the proliferative response to ConA. The conditions developed 
for the in vitro assay were taken as the standard method and the same protocol was 
followed in all other in vitro experiments.
To avoid difficulties of obtaining calf blood and also difficulties with PBMCs primary cell 
culture, it would have been convenient to substitute the PBMCs primary culture with a cell 
line. To be used as a substitute of PBMCs, the cell line should be able to proliferate in 
réponse to ConA and also this prolferative response should be suppressed after treatment 
with P. multocida B:2 CFE. A number of cell lines were available and were tested for their 
ability to proliferate in response to ConA. Three different cell lines including J774 (a 
mouse macrophage), BL-3 (a bovine B cell), and Jurkat (a human T cell) were tested. It 
was unfortunate that none of these three cell lines proliferated in response to ConA. 
Further experiments, testing different cell lines, could be helpful. Another possible 
substitute for calf PBMCs could be the PBMCs obtained from other small laboratory 
animals, as these are more accessible than calf PBMCs. Our preliminary experiments using 
rabbit PBMCs showed that they proliferate strongly in response to ConA. Our further 
experiments also showed that the proliferative response of rabbit PBMCs was suppressed
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after adding P. multocida B:2 to them. Although rabbit PBMCs showed promising results 
as a potential substitute for calf PBMCs, it was decided to continue the experiments on calf 
PBMCs as it was not clear to us that the same mechanisms are involved in the suppression 
of these two different PBMCs. Further experiments are needed to show that the same 
mechanism are involved in suppression of these two different PBMCs.
To study if the suppressive effect of P. multocida B:2 CFE was specific for this strain, 
CFEs of a number of other bacteria were prepared and used in the in vitro assay on calf 
PBMCs. CFEs obtained from Staphylococcus aureus or Manheimia haemolytica serotypes 
A l (bovine isolate) or A2 (ovine isolate) did not affect the proliferative response of 
PBMCs to ConA. CFE of Escherichia coli slightly increased the proliferative response. P. 
multocida serotype A3 CFE had a slightly less effect on the proliferative response than P. 
multocida B:2 CFE. A serotype A (chicken isolate) strain of P. multocida had no effect. 
CFE of P. multocida serotype D (pig isolate) strongly suppressed the proliferative response 
of calf PBMCs to ConA. Overall, the results indicated that the suppressive effect was only 
observed in two other P. multocida strains, one P. multocida serotype D (the causative 
agent of atrophic rhinitis in pigs) and the other, with less suppressive properties, P. 
multocida serotype A3 (the causative agent of pneumonia in cattle). P. multocida D 
produces a dermonecrotic toxin which is the main cause of atrophy in the nasal turbinate 
bones, the most important consequence of the disease (Jordan et a l,  2003). A contributory 
role of the toxin in the suppression of proliferation of PBMCs could be investigated. P. 
multocida serotype A3 is associated with pneumonic pasteurellosis of cattle. The 
pathogenesis of the disease caused by this organism, like that of HS caused by P. 
multocida B:2 strains, is not well understood.
4.4.2.1 Characterisation of suppressive agent(s)
After the observation of in vitro suppressive activity of CFE of P. multocida B:2, further 
investigations were focused on two main subjects; preliminary characterisation of the 
suppressive agent(s) and identification of the suppressed cells. For characterisation of the 
suppressive component(s), P. multocida B:2 CFE was investigated for its suppressive 
activity after different treatments. Heating at 80°C for 5 min completely destroyed the 
suppressive effects. In vitro experiments also showed that an OMP preparation of P. 
multocida B:2 markedly suppressed the proliferative response of PBMCs to ConA. The 
suppressive activity of OMP was again partially destroyed by heating. Dialysis of CFE 
with a cut off 10,000 Da was still suppressive for calf PBMCs. Capsule of Pasteurella, 
which is known to be polysaccharide, was possibly one of the constituents of CFE, but a
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polysaccharide capsule fraction, or the supernatant of an 18-hour broth culture of P. 
multocida B:2, was not suppressive and increased the proliferative response of PBMCs to 
ConA. The lack of suppressive activity in broth culture medium indicated that the 
suppressive agent(s) had not been secreted and/or released during growth of the bacterium. 
All together, these data suggested that the suppressive agent(s) of CFE, or at least an active 
part of the agent, which was heat-sensitive, was made of protein. The suppressive 
properties of the OMP preparation indicated the presence of the agent in this cell fraction. 
The suppressive effect of OMP was only partially destroyed by heating; one possible 
reason for this could be the contamination of the OMP with some traces of sarkosyl used 
during the process of extraction. Sarkosyl is a strong detergent and resistant to heat, and 
has detrimental effects on cells. Although the OMP was washed several times after 
sarkosyl treatment, it is quite possible that there were still some traces left in the OMP 
preparation. The suppressive activity of dialysed CFE showed that the suppressive agent(s) 
had a molecular weight higher than 10,000 Da, which was the dialysis membrane cut-off.
The effect of EPS on calf PBMCs was also investigated because it was quite likely that the 
CFE prepared from P. multocida B:2 would contain EPS. To do this, PBMCs were treated 
with EPS purified from E, coli before adding ConA. EPS at the concentration of 200 
EU/well was not suppressive and did not cause any changes in proliferative response of 
PBMCs but, at higher concentrations, EPS showed a synergism with ConA in promoting 
proliferative effects of PBMCs. EPS is known as a B cell proliferative agent and, as 
endotoxin, it also could have some adverse effects on different cells. It was unlikely that 
the EPS content of CFE had adverse effects on PBMCs because the CFE alone did not 
cause any decrease in grovrth rate of PBMCs at the concentration of 1 Opg/well used. At 
lower concentrations a slightly increased proliferative response of PBMCs (2-3 times) to 
CFE was observed which may have been the result of proliferation of the B cell fraction of 
PBMCs in response to the EPS content of cel-free exract, a phenomenon that was also 
supported by the FACS analysis results (see below). To exclude the possibility of 
proliferation of B cells at the expense of other types of cell in PBMCs, further experiments 
using FACS analysis showed that the CFE did not cause any changes to other cell 
populations (see below). Although using EPS purified from P. multocida could have been 
more relevant to the possible EPS effects of CFE, the data obtained using EPS of different 
origin excluded the possibility of adverse effects of EPS on PBMCs. In another study it 
was shown that E. coli EPS alone at 10-0.1 ug/ml induced proliferation of cattle PBMCs 
(Stevens et a l, 1997). It has also been shown that EPS purified from P. multocida A3 was 
proliferative for mouse B cells (Ryu & Kim, 2000).
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4.4.2.2 Identification of proliferated and suppressed cells
FACS analysis was used to determine which population of lymphocytic cells was affected 
over the course of the in vitro experiments. B cell and T cell subpopulations (CD4^, CD8  ^
and yô'*') in normal calf PBMCs were identified and the changes in their relative 
proportions after different treatments was investigated. The ratio of proliferating and non­
proliferating fractions was also determined, to assess the proliferative status of each 
population. The proportion of cells in different generations of each population was also 
determined using FACS analysis on CFSE loaded cells. FACS experiments on CFSE- 
loaded and unloaded cells was conducted in parallel to the lymphocyte proliferation assay 
(standard in vitro procedure) and at different stages of the in vitro proliferation assay.
FACS analysis of PBMCs showed that the overall percentage of B cells increased over the 
course of in vitro experiment on suppressive effects of P. multocida B:2 CFE and the 
increase was at highest levels in cultures treated with CFE+ConA or CFE alone in which 
the percentage was double that of the control cells. Comparing the B cell response in 
control cells with ConA-treated cells revealed that ConA did not cause any B cell 
responses. The overall percentage of B cells increased by 1.92 times in CFE+ConA -  
treated cells and by 1.88 times in CFE-treated cells compared to control cells. This 
indicated that the increase in overall percentage of B cells was due to the presence of CFE. 
It seemed that the proliferative response of B cells to CFE happened in the eaily stages of 
culture because the overall percentage of B cells increased but the proliferating fraction of 
B cells was low at the time of harvest. This idea is supported by a study indicating the 
early proliferative response of B cells to synthetic oligodeoxynucleotides (ODN, a B cell 
proliferative agent). The study also showed that the B cells of bovine PBMCs did not 
proliferate in response to ConA (Pontarollo et a l, 2002). It can be concluded that B cells 
do not respond to ConA and consequently are not involved in the suppression of ConA- 
induced proliferation of PBMCs by CFE.
FACS analysis results of CD4"^  T cells indicated that the overall percentage of CD4^ cells 
decreased during the experiment under all treatments. Comparison between ConA-treated 
and CFE+ConA-treated cells revealed that the proliferating fraction of CD4^ cells was 
markedly decreased due to the presence of CFE. ConA increased the percentage of 
proliferating CD4^ compared to the control cells by 10-fold, but by only 3-fold with 
CFE+ConA. ConA apparently stimulated CD4^ cells in a delayed manner because on the 
day of harvest (3'^ day) the proliferating fraction had increased, although the overall 
percentage had increased only slightly. The delay in response may be the consequence of
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the indirect response of T cells to ConA as it has been shown that the mitogenic response 
of T cells is through the production of IL-2 by monocytes (see section 10.3.2) and the 
expression of the mature IL-2 receptor (CD25) by T cells (Yamanaka et ah, 2003). 
Comparison between control and CEE-treated cells revealed that the percentage of CD4^ 
cells was not affected by CFE indicating that there was no toxic effect of CFE on these 
cells, which meant that the suppression of the proliferative response to ConA could not be 
accounted for by toxicity. It can be concluded that CD4^ cells responded to ConA in terms 
of proliferation and that this response was suppressed in the presence of CFE.
The overall percentage of CD8  ^T cells showed only slight changes during the experiment 
under all treatments. However, the proliferating fraction of CDS’*" cells increased markedly 
in response to ConA (6 fold compared to control cells) but this was not so apparent in 
CFE+ConA-treated cells. Comparison between control and CFE-treated cells revealed that 
the overall percentage of CD8  ^cells and also the proliferating fraction of these cells was 
decreased by CFE. It can be concluded that CFE had some adverse effects on this cell 
population and the suppression in the proliferative response to ConA could have been 
partly due to this effect on CD8  ^cells.
FACS results for T cells indicated that, in contrast to other T cell subpopulations, the 
overall percentage of this population increased slightly during the experiment except in 
CFE-treated cells. The proliferating yô"^  fraction increased in response to ConA by up to 10 
fold compared to control cells and this fraction was slightly lowered (to an 8.42 fold 
increase) in CFE+ConA-treated cells. Comparison between control and CFE-treated cells 
showed that the proliferative fraction of yÔ’^ cells was not affected by CFE although the 
overall percentage of this population was slightly decreased indicating that the decrease 
happened in the early stages of culture. These data are indicative of a slight suppression by 
CFE of the proliferative response of yô"^  T cells to ConA, perhaps due to a slight toxicity of 
CFE on these cells.
CFSE-loaded PBMCs were also analysed by FACS experiments to follow the changes in 
the different generations of each population during in vitro assay. The changes in the 
percentages of different cell populations showed the same pattern as observed for CFSE- 
unloaded cells with the exception of the B cells that were low at time zero compared to the 
previous experiment. It was believed that this dramatic decrease in the percentage of B 
cells may be due to the high sensitivity of these cells to the toxic effects of CFSE, at the 
concentration used in our experiment. The data obtained for B cells were not analysed, but 
data obtained for other cell populations were considered acceptable because the results of
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the previous experiments showed that B cells did not play a direct role in ConA 
proliferation and suppression by CFE. Comparison of the data for the other populations 
showed that the results of CFSE-loaded T cell subpopulations are almost at the same ratios, 
with the exception of ratios for the control CD4^ cells at time zero. The exact reason for 
this difference was not clear but the effects of CFSE could be the cause of this difference. 
Because the data for CD4^ cells were similar to the previous experiment, these data were 
taken as acceptable for further analysis. Data obtained for CFSE-loaded PBMCs were 
elaborated by software ModFit® to study the frequency of different generations in each 
population.
Analysed results showed that, CD8  ^ T cells proliferated strongly in response to ConA 
(Proliferation Index== 3.26). The proliferative response of the CD8  ^T cells to ConA cells 
was suppressed by CFE (Proliferation Indexai.77). The nonproliferative fi'action showed a 
3.35-fold increase in CFE-treated CD8  ^T cells, which indicated more than a three-fold 
increase in the fraction of cells that have not proliferated in response to ConA. The parent 
generation increased by two times in CFE treated CD8  ^T cells although all of the daughter 
generations decreased rationally compare to CFE untreated cells (Figure 27B). Analysis of 
data for CD4^ T cells indicated that this subpopulation of T cells proliferated in response to 
ConA (Proliferation Index=2.54), and the nonproliferative fraction of CD4^ T cells 
increased by 1.55 in response to CFE+ConA treatment. The decrease in proliferation of 
CFE+ConA-treated CD4’^ cells started from generation 2 but was most marked in 
generation 3 which constituted 17.28 % of the whole CD4^ population, yô^ T cells showed 
proliferation in response to ConA similar to CD4^ T cells (Proliferation Index=2.56) and, 
although the nonproliferative fraction of yô^ T cells increased by 1.46 fold in CFE+ConA- 
treated cells, progress through the generations was not as adversely affected as with CD4  ^
and CDS'" T cells.
4.4.3 Conclusions from cellular responses
The in vitro experiments showed that CFE of P. multocida had suppressive effects on the 
proliferative response of normal calf PBMCs to Con-A. It was also shown by FACS 
analysis experiments that CD4'" and CDS'" T cells were the principal cells which 
proliferated in response to Con-A, and were those suppressed by a CFE of P. fnultocida. 
The mechanism of the immunosuppression described here remains unclear and demands 
further study. The exact mechanism involved in in vitro T cell proliferation by ConA is 
poorly understood. Concanavalin A (ConA) belongs to the family of lectins (carbohydrate- 
binding proteins derived from plants and bacteria). It has potent T-cell mitogenic activity
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and has been extensively used to study the in vitro lymphocyte response (Mukherjee et a l , 
2005). Mitogen stimulation of lymphocytes in vitro is believed to mimic stimulation by 
specific antigens fairly closely. Stimulation of T cell receptor with ConA induces a signal 
transduction pathway which stimulates IL-2 secretion and upregulation of the a subunit of 
the IL-2 receptor, CD25 (the p and y subunits are constitutively expressed). Secreted IL-2 
functions in an autocrine and paracrine manner by binding to the full receptor (a, p, and y 
subunits) to initiate proliferation of stimulated lymphocytes (Peltier et a l, 2000). IL-2 is a 
crucial element in cell-mediated immune responses both in vivo and in vitro and, in cattle, 
IL-2 levels can be used to measure specific cellular immune responses (Miller-Edge & 
Splitter, 1986). Stimulation of bovine lymph node cells with ConA causes a biphasic IL-2 
secretion. The first phase of IL-2 production occurs after 3 hours and the second phase 
between 10 and 16 hours. This study also showed the accumulation of IL-2 mRNA before 
each phase of IL-2 secretion (Weinberg et a l, 1988). In the 2-signal model of mitogen 
activation of T cells, the first signal occurs with mitogen and monocytes (another 
population of cells in PBMCs) which cause the production of second signal that is IL-2 
(Gelfand et a l, 1985). IL-1 which is secreted by monocytes acts as the first signal and 
induces the expression of IL-2 receptors in a subpopulation of T cells which, after 
activation by IL-2, culminates in DNA synthesis and proliferation by these cells (Conti et 
a l, 1991a; Conti et a l,  1991b). In vitro experiments on bovine PBMCs have indicated that 
monocytes are necessary for optimum stimulation of T cells (Pontarollo et a l, 2002). 
According to the 2-signal model of T cell activation, suppression could be at the point of 
IL-2 secretion and/or induction of CD25. The mechanism of suppression by ovine uterin 
sei-pin (OvUs; an immunosuppressive protein secreted by the ewe uterus during pregnancy) 
on proliferative response of PBMCs has been investigated. This study showed that OvUs 
inhibited ConA-induced expression of CD25 in yÔ" T cells but not yô^ T cells. The study 
also revealed that OvUs was also inhibitory to lymphocyte proliferation induced by human 
IL-2. It was concluded that OvUs suppressed lymphocyte proliferation by blocking CD25 
expression. It was also suggested that the lack of suppressive effect of OvUs on ConA- 
stimulated CD25 expression in yô'" T cells may indicate a different mechanism of 
activation of these cells or insensitivity to inhibition by OvUs (Peltier et a l, 2000). This 
study supports a role for CD25 in the suppression observed here, since the in vitro 
experiments showed that P. multocida CFE inhibited the proliferative response in y5' T 
cells (including CD4'" and CDS'" T cells) but not yô'" T cells. More experiments are needed 
to find out the exact mechanism of suppression. Experiments to study the changes in IL-2 
concentrations during suppression and investigation of CD25 expression in different T cell 
subpopulations would be helpful in this regard.
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The relevance of the in vitro suppressive effects of P. multocida CFE and in vivo 
immunosuppression, observed in challenged calves, is not clear as these observations may 
be due to two different phenomena. In vitro suppressive properties of CFE are more likely 
to be clinically reflected as a chronic manifestation but the progress of disease in HS is 
usually acute. Although P. multocida B:2 is known as the causative agent of HS, the 
organism exists in the tonsils and nasopharynx of some apparently healthy earner cattle 
and buffaloes (De Alwis, 1999). Carrier status is actually a chronic infection with the 
bacterium but how the organism survives in canier host tonsils, which are in close contact 
with lymphatic organs, is not yet understood. Our in vitro experiments showed that P. 
multocida contains a component(s) with the potency to inhibit the activity of T cells. The 
suppressive properties of the organism would be a possible explanation of its survival in 
earner animals (see below). Other possible consequences of immunosuppression can be in 
converting a latent canier to an active earner. In the active carriers, the bacterium presents 
in nasopharynx and, from this site, is shed in nasal secretions. Latent caniers harbour the 
organism in tonsils in which the bacterium is believed to multiply and intermittently spill 
over into nasopharynx (De Alwis et a l, 1990). The mechanisms involved in converting a 
latent carrier to an active carrier have not been revealed yet. It was shown that stressful 
conditions and even administration of immunosuppressive preparations (dexamethazone 
and methylprednisolone acetate) were not able to cause latent carriers to shed the organism 
in their nasal secretions (De Alwis, 1999).
Bacterial pathogens have acquired the ability to overcome host defence mechanisms 
(Brunham et a l, 1993). Different bacterial pathogens have adopted different strategies to 
interfere with host innate and adaptive immune mechanisms (Homef et a l, 2002). 
Different bacterial components and products play different roles in modulating host 
immune reactions, most of them stimulatory but a minority are inhibitory. It has been 
suggested that every component of bacteria with adjuvant activity can also impose 
suppressive effects on the immune system by appropriate manipulation of timing, dose, 
and selection of antigen (Schwab, 1975). Virulent Gram-negative bacteria (e.g. 
Salmonella, Shigella, Pseudomonas aeruginosa), which are able to cause septicaemia and 
endotoxaemia, affect the immune system by the suppression of phagocytosis and cell- 
mediated immunity (Vorob'ev et a l, 2001), The in vitro immunomodulatory effects of P. 
multocida serotype D (the causative agent of atrophic rhinitis) was investigated in a study 
on mouse splenocytes. This study showed treatment of splenocytes with each of purified 
porin or LPS stimulated IL-1 a, lL-6, TNF-a, IFN-y and IL-12 mRNA while no effect was 
detected on IL-4 and IL-10. It was concluded that P. multocida porin was able to modulate 
immunological responses by affecting the release of different cytokines (lovane et a l.
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1998b). The immunosuppressive properties of P, multocida D was also shown in another 
study where intranasal challenge of pigs and mice with a toxigenic strain or its CFE 
reduced the IgG response of these animals (Jordan et a l, 2003).
The immunomodulatory effects of P. multocida B:2 have not been well studied. It has been 
shown that OMP of P. multocida B:2 is antiphagocytic as OMP was able to interfere with 
phagocytosis of opsonised Candida albicans by murine peritoneal cells in vivo. It was 
suggested that the antiphagocytic mechanisms induced by OMP enhanced the virulence of 
the organism (Srivastava, 1998). The immunosuppressive effects of Yersinia, which is 
close taxonomically to Pasteurella, have been extensively studied and the mechanisms 
involved in T cell suppression have been recently revealed. Yersinia pseudotuberclosis (the 
causative agent of gastroenteritis and lymphadenitis in humans) is likely to be in contact 
with lymphocytes in the intestinal Peyer’s patches, lymph nodes, spleen and liver in which 
the organism colonises and multiplies. Preliminary studies reported that T cells transiently 
exposed to Yersinia were suppressed for TCR (T cell receptor) stimulation (Yao et a l, 
1999). Further in vitro studies showed that YopH {Yersinia outer protein H), which was 
known as being antiphagocytic and had protein tyrosine kinase activity (Sing et a l, 2002), 
specifically suppressed T cells by targeting the adaptor molecules LAT (linker for 
activation of T cells) and SLP-76 (SH2-domain-containing leukocyte protein of 76 kDa) 
(Gerke et a l, 2005). As mentioned earlier, P. multocida B:2 exists in the tonsils of carrier 
animals without being affected by the destructive effects of the immune system. Our in 
vitro experiments indicated suppressive effects of a protein component(s) of CFE which 
also existed in an OMP prepaiation of P. multocida B:2. Our results indicate suppressive 
effect on T cells which, if they are similar to the immunosuppressive effects of Yersinia 
OMP on T cells, could account for the resistance of the bacterium against immunity 
elements in the tonsils. This observation may be applicable to understanding the 
pathogenicity of P. multocida B:2 and the development of the immune response during 
infection. Interactions between host cells and pathogens ai*e extremely complex and the 
involvement of multiple inter-dependent pathways in signalling and regulatory systems has 
made it very difficult to study these interactions. Therefore, it is difficult to predict the 
combined behaviour by just investigating the interactions between bacteria and individual 
components of the immune system. However, these investigations can be informative and 
helpful in understanding the process of disease development. They can also provide 
information on mechanisms that the pathogen uses to overcome or escape the host immune 
system.
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APPENDICES
Appendix A: Medium and solution composition for bacterial 
growth
A.1 Brain heart infusion (BHI broth)
Brain heart infusion, dehydrated (Oxoid) 37 g
Distilled water 1000 ml
The medium was dissolved, dispensed and autoclaved at 12 EC for 15 min and, after 
overnight incubation at 37“C, kept at 4°C.
A.2 Nutrient broth (NB)
Nutrient broth, dehydrated (Oxoid) 13 g
Distilled water 1000 ml
The medium was dissolved, dispensed and autoclaved at 121°C for 15 min and, after 
overnight incubation at 37°C, kept at 4°C.
A.3 Sheep blood agar (SBA)
Blood agar base, dehydrated (Oxoid) 40 g
Distilled water 1000 ml
The medium was suspended in water and brought to the boil to dissolve completely, then 
sterilised by autoclaving at 121°C for 15 min. It was cooled to 45-50°C and 5% sterile 
defibrinated sheep blood (B&E laboratories) added. The medium was mixed and poured 
into sterile plates.
A.4 Peptone water
Peptone water dehydrated (Oxoid) 15 g
Distilled water 1000 ml
The medium was dissolved and autoclaved at 121 °C for 15 min and, after overnight 
incubation at 37°C, kept at 4°C.
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A.5 Vancomycin stock solution
Vancomycin 1 g
Distilled water 10 ml
The stock solution was filtered tlirough a 0.2 pm-pore-size membrane (Sartorius) and 
stored at -20°C. It was added to medium to a final concentration of 1 mg/ml.
A.6 10 X Phosphate-buffered saline (PBS)
NaCl 1.7 M
KCl 100 mM
Na2HP04.12H20 40 mM
KH2PO4 10 mM
Distilled water to 1000 ml. The solution was autoclaved at 121°C for 15 min and kept at 
4°C. It was diluted 1/10 and adjusted to pH to 7.2 before use.
A.7 Dipyridyl stock solution
2,2’-Dipyridyl (Sigma) 20 mM
The stock solution was filtered thi'ough a 0.2 pm-pore-size membrane (Sartorius) and 
stored at 4°C. It was added to BHI broth to a final concentration of 150 pM. The medium 
was kept overnight at 4°C before use.
Appendix B: Protein analysis solutions
B.1 5 X loading buffer
Glycerol 5ml
20% SDS 2.5 ml
2-mercapto-ethanol 0.5 ml
1 M Tris-HCl (pH 6.8) 2.5 ml
Bromophenol blue 0.25% (w/v)
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B:2 Stacking solution
30% Acrylamide/Bis (37.5:1) (BioRad) 9 ml
1 M Tris-HCl (pH 6.8) 7.5 ml
distilled water 42 ml
10% (w/v) SDS 50 pl
B:3 Resolving gel (10%)
30% Acrylamide/Bis (37.5:1) (BioRad) 3.3 ml
1 M Tris-HCl (pH 8.8) 3.75 ml
distilled water 3 ml
10% (w/v) SDS 100 pl
10% (w/v) Ammonium persulphate 100 pl
TEMED (add last) 10 pl
Enough for casting 4 small gels.
B:4 10 X Running buffer
Tris-Base 0.25 M
Glycine 1.92 M
SDS 0.035 M
Distilled water to 2000 ml. Diluted 1 in 10 before use.
B;5 Coomassie Blue stain/Destain solution
Coomassie Blue 0.05% (w/v)
Methanol 500 ml
Glacial acetic acid 100 ml
Distilled water 400 ml
For making destain solution, Coomassie Blue was omitted.
B.6 Solutions for Modified Lowry’s protein assay
B.6.1 Reagent A
Na2C03 2 g
NaOH 0.4 g
Sodium tartrate 0.16 g
SDS 1 g
Distilled water 100 ml
B.6.2 Reagent B
CUSO4.5H2O 4 g
Distilled water 100 ml
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B.6.3 Reagent C
Reagent A 100 ml
Reagent B 1 ml
Soultions A and B are stable indefinitely at room temperature. On day of use reagent C is 
prepared and, Folin-Ciocalteu phenol reagent is dilute 1 to 1 with distilled water.
B.7 Standard protein solution (BSA in PBS)
Bovine serum albumin (BSA, Sigma) 20 mg
PBS (Appendix A.6) 10 ml
Aliquots of solution were kept in -70°C. Different concentrations were prepared with PBS. 
B:8 Sarkosyi solution
N-lauroylsarcosine sodium salt (Sigma) 500 mg
Distilled water 100 ml
Appendix C: Solutions for immunoblotting
C. 1 10 X Transfer buffer
Tris-Base 0.25 M
Glycine 1.92 M
Distilled water to 2000 ml. Diluted 1 in 10 before use and made up with 20% (v/v) 
methanol.
C.2 PBST
1 X PBS Appendix A.6
Tween 20 0.2% (v/v)
pH 7.4
S a e e d  Ataei Kachooei, 2007
C.3 Blocking buffer
182 APPENDICES
PBST
Skimmed milk (Marvel)
Appendix C.2 
10% (w/v)
C.4 PBST diluent
PBST
Skimmed milk (Marvel)
Appendix C.2 
5% (w/v)
C.5 Substrate solution
3’3-Diaminobenzidine (DAB) (Sigma) 
PBS
1% (w/v) C0CI2 
30% (v/v) H2O2
0.05 g 
98 ml 
2 ml 
100 pl
Appendix D: ELIS A solutions
D.1 Carbonate-bicarbonate coating buffer (pH 9.6)
Carbonate-bicarbonate (Sigma) 
Distilled water
Freshly prepared before use (pH 9.6).
1 capsule 
100 ml
D.2 Washing buffer (PBS-Tween)
1 xPBS 
Tween 20
Appendis A.6 
0.05% (v/v)
D.3 ELISA Blocking buffer
Gelatin (Sigma) 100 pg
PBS 100 ml
Made up to 100 ml and warmed in water bath with stirring 60°C for 1 h.
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D.4 Stop solution
Sulphuric acid 0.25 M
Appendix E: Cell culture solutions
E.1 RPMI complete
Heat-inactivated FBS* (BioWest) 10% (v/v)
L-Glutamine (Gibco) 2 mM
Penicillin (Moredun Research Institute) 50,000 U
Streptomycin (Moredun Research Institute) 50 mg
Nystatin (Moredun Research Institute) 0.5% (v/v)
Gentamicin (Sigma) 1% (w/v)
HEPES (Sigma) 30 mM
* Foetal Bovine Serum
Added to 410 ml RPMI 1640 medium (Life Teclmologies).
E.2 Concanavalin A (ConA)
ConA (Sigma) 5 mg
RPMI 1640 10 ml
Aliquot of 200 pi kept in -20“C. For use, mixed with 800 pml RPMI 1640, remainder on 
each occasion was discarded.
E.3 10 X RBC lysis buffer
NH4CI 1.5 M
NaHCO] 0.1 M
diNaEDTA 1 mM
distilled water 900 ml
Adjusted to pH 7.4 with IN HCl or IN NaOH. Made up to 1000 ml and stored up to 6 
month at 4°C. Diluted 1 to 10 for use, kept on ice, unused diluted buffer discarded.
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Appendix F: FACS solutions
F.1 CFSE (carboxyfluorescein diacetate succinimidyi ester) stock solution
CFSE in PBS 20mM
Aliquots of 20 pi kept in -20°C. For use, each vial was mixed with 40 pi of prewarmed 
(37°C) PBS to reach to working concentration of 10 pM.
F.2 Wash buffer
FBS 2 ml
Penicillin 10,000 U
Streptomycin 10 mg
BBSS* 98 ml
*Hanks Balance Solution (Sigma)
F.3 FACS buffer
FBS 5 ml
10% (w/v) NaNs 2 ml
PBS 93 ml
F.4 FACS Fix
40% (v/v) Paraformaldehyde 2.5 ml
PBS 97.5 ml
Aliquots of paraformaldehyde kept at -20“C. PBS warmed to 60°C before addition and 
thorough mixing.
Appendix G; Mascot and BLAST search results
G.1 Mass Spectrometry results used to determine the peak list for the 30 kDa 
OMP band.
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Probability Based Mowse Score
Ions score is “10*Log(P), where P is the probability that the observed match is a random event. 
Individual ions scores > 52 indicate identity or extensive homology (p<0.05).
Protein scores are derived from ions scores as a non-probabilistic.basis for ranking protein hits.
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G.1.1 Peptide Summary Report for 30 kDa OMP
1. gil323632l6 Mass: 37084 Score: 569 Queries matched; 23
Major outer membrane protein precursor (MOMP) (Outer membrane protein H)
2  gi|2853242 Mass: 34935 Score: 521 Queries matched: 20
Outer membrane protein; OmpH [Pasteurella mutfocida]
G.1,2 Amino acid sequence coverage for 30 kDa OMP 
G.1.2.1 Match to: gi|32363216 Score: 569
1. gil323632l6 Mass: 37084 Score: 569 Queries matched: 23
Major outer membrane protein precursor (MOMP) (Outer membrane protein H)
Sequence Coverage: 38%
1 MKKTIVALAV AAVAATSANA ATVYNQDGTK VDVNGSVRLI LKKEKNERGD 
51 LVDNGSRVSF KASHDLGEGL SALAYAELRF SKNEKVEVKD AQNQQVVRKY 
101 EVERIGNDVH VKRLYAGFAY EGLGTLTFGN QLTIGDDVGV SDYTYFLGGI 
151 NNLLSSGEKA INFKSAEFNG FTFGGAYVFS ADADKQAPRD GRGFVVAGLY 
201 NRKMGDVGFA LEAGYSQKYV TAAAKQEKEK AFMVGTELSY AGLALGVDYA 
251 QSKVTNVEGK KRALEVGLNY DINDKAKVYT DLIWAKEGPK GATTRDRSII 
301 LGAGYKLHKQ VETFVEGGWG REKDANGVTT KDNKVGVGLR VHF 
NCBI BLAST search of gi[32363216 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|2853238 from P a s te u r e l la  m u lto c id a  
qi|92918682 from P a s te u r e l la  m u lto c id a
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gi|92918684 from P a s te u r e l la  m u lto c id a  
gi|92918686 from P a s te u r e l la  m u lto c id a  
gi|92918688 from P a s te u r e l la  m u lto c id a  
gi| 124262427 from P a s te u r e l la  m u lto c id a
G.1.2.2 Match to: gi|2853242 Score: 521
2  gi|2853242 Mass: 34935 Score: 521 Queries matched: 20
Outer membrane protein; OmpH {Pasteurella multocida]
outer membrane protein; OmpH [ P a s te u r e l la  m u lto c ld a \
Nominal mass (Mr): 34935; Calculated pi value; 9.17 
NCBI BLAST search of gi|2853242 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage; 38%
1 ATVYNQDGTK VDVNGSVRLI LKKEKDKRGD LVDNGSRVSF KASHDLGEGL 
51 SALAYAELRF STKEEVEVTQ NQQVVRKYKV ERIGNDVHVK RLYAGFAYEG 
101 LGTLTFGNQL TIGDDVGVSD YTYFLGGINN LLSSGEKAIN FKSAEFNGFT 
151 FGGAYVFSAD ADKQAARDGR GFVVAGLYNR KMGDVGFALE AGYSQKYVTE 
201 TAKQEKEKAF MVGTELSYAG LALGVDYAQS KVTNVDGKKR ALEVGLNYDL 
251 NDKAKVYTDL IWAKKGPKGA TTRDRAIILG AGYKLHKQVE TFVEGGWGRT 
301 KNAAGVTTKD NKVGVGLRVH F
G.2 Mass spectrometry results used to determine the peak list for the 37kDa 
OMP band.
Significant hits: gi|12721089 unknown [Pasteurella multocida muitocida str. Pm70] 
gi|49182350 OmpA [Pasteurella multocidë] 
gi|49182354 OmpA [Pasteurella multoalds^  
gi|49182352 OmpA [Pasteurella muttocidd] 
gi|17861366 OmpA [Pasteurella multocld^ 
gill 9881365 hemagglutinin antigen [Haemophilus paragaiiinarum] 
gl|32363216 Major outer membrane protein precursor (MOMP) (Outer membrane protein H) 
gi|75431565 outer membrane protein and related peptidogiycan-associated (iipo)proteins [Actinobaciiius
succinog
gi|23124869 COG2199: FOG: GGDEF domain [Nostoc punctiforme PCC 73102]
gi132030015 COG2885: Outer membrane protein and related peptidogiycan-associated (Iipo) proteins
[Haemophilus somnus 2336]
gl 11332435 outer membrane protein [Aeromonas saimonicida]
Probability Based Mowse Score
Ions score is -10*Log(P), where P is the probability that the observed match is a random event.
Individual ions scores > 52 indicate identity or extensive homology (p<0.05).
Protein scores are derived from ions scores as a non-probabilistic basis for ranking protein hits.
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G.2.1 Peptide Summary Report for 37 kDa OMP
1. Mass: 38122 Score: 759 Queries matched: 13 
unknown [Pasteurella multocida subsp. multocida str. Pm70]
2. gl!49182350 Mass: 37785 Score: 750 Queries matched: 12
OmpA [Pasteurella multocida]
3. gi|49182354 Mass: 38126 Score; 727 Queries matched: 12
OmpA [Pasteureiia muitocida]
4. gil49l82352 Mass: 37620 Score: 542 Queries matched: 9
OmpA [Pasteureiia muitocida]
5. gl|I7861366 Mass: 37708 Score: 475 Queries matched: 8
OmpA [Pasteureiia muitocida]
6. gi| 19881365 Mass: 36785 Score: 171 Queries matched: 3
hemagglutinin antigen [Haemophilus paragaiiinarum]
7. gil323632l6 Mass: 37084 Score: 168 Queries matched: 5
Major outer membrane protein precursor (MOMP) (Outer membrane protein H)
8. gi[7543l565 Mass: 33452 Score: 77 Queries matched: 1
outer membrane protein and related peptidogiycan-associated (llpo)proteins [Actinobaciiius succinog
9. gil23124869 Mass: 66430 Score: 72 Queries matched: 1
COG2199: FOG: GGDEF domain [Nostoc punctiforme PCC 73102]
10. gi|32030015 Score: 55 Queries matched: 1
COG2885: Outer membrane protein and related peptidogiycan-associated (llpo)proteins [Haemophilus somnus 2336]
11. ail 1332435 Mass: 35003 Score: 54 Queries matched: 1 
outer membrane protein [Aeromonas saimonicida]
G.2.2 Amin acid sequence coverage for 37 kDa OMP
G.2.2.1 Match to: gijl2721089 Score: 759
1. gi|I2721Q89 Mass: 38122 Score: 759 Queries matched: 13
unknown [Pasteureiia muitocida subsp. multocida str. Pm70]
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unknown { P a s te u r e l la  m u lto c id a  subsp. multocida str. Pm70]
Nominal mass (Mr): 38122; Calculated pi value: 9.09
NCBI BLAST search of gi 112721089 against nr
Unformatted sequence string for pasting Into other applications
Taxonomy; P a s te u r e l la  m u lto c id a  subsp. multocida str. Pm70
Links to retrieve other entries containing this sequence from NCBI Entrez:
gi|12721089 from P a s te u r e l la  m u lto c id a  sw'os'Ç). multocida str. Pm70
Sequence Coverage: 52%
1 MKKTAIALTI AALAAASVAQ AAPQPNTFYV GAKAGWASFH DGLNQAKYLE 
51 APEATFGFKR NSVTYGVFGG YQITDNFAVE LGYDDFGRAK LRMAEKDQKA 
101 KDAAKHTNHG AHLSLKASYP VLDGLDIYAR VGAALIRSDY KVYDHSDPAK 
151 LPQFKRTHST QVSPVFAGGL EYAFMPELAL RVEYQWVNNV GKVKDVLGER 
201 VDYRPDIGSV TAGLSYRFGQ SVYVPEVVSK TFTLN8DVTF GFDKADLKPA 
251 AQNVLDGIYG EIAQLKSASV AVAGYTDRLG SDAYNLKLSQ RRADTVANYL 
301 VAKGVAQNAI SATGHGEANP VTGNKCDSVK GRKALIACLA DDRRVEIAVK 
351 GNK
G.2.2.2 Match to; gij49182350 Score: 750
2. gjl49l82.350 Mass: 37785 Score: 750 Queries matched: 12
OmpA [Pasteurella muitocida]
OmpA { P a s te u r e l la  m u lto c ld d [
Nominal mass (Mr): 37785; Calculated pi value; 8.89
NCBI BLAST search of gij49182350 against nr
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 48%
1 MKKTAIALTI AALAAASVAQ AAPQPNTFYV GAKAGWASFH DSLNQFNDIT 
51 EPATGFKRNS VTYGVFGGYQ ITDNFAVELG YDDFGRAKAR ATDPKTKETV 
101 DAAKHTNHGA HLSLKASYPV LDGLDVYARV GAALVRSDYK VYDKEPADLS 
151 FLKRTHSTQV SPVFAGGLEY AFMPELALRV EYQWLNNVGK LKDAKGERVD 
201 YRPDIGSVTA GLSYRFGQSV YVPEVVSKTF TLNSDVTFGF DKADLKPAAQ 
251 NVLDGIYGEI AQLKSASVAV AGYTDRLGSD AYNLKLSQRR ADTVANYLVA 
301 KGVAQNAISA TGHGEANPVT GNKCDSVKGR KALIACLADD RRVEIAVKGN 
351 K
G.2.2.3 Match to: gi|49182354 Score: 727
3. gi|49182354 Mass: 38126 Score: 727 Queries matched: 12
OmpA [Pasteureiia muitocida]
OmpA { P a s te u r e l la  m u lto c ld d [
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Nominal mass (Mr): 38126; Calculated pl value: 8.76 
NCBI BLAST search of gl|49182354 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 49%
1 MKKTAIALTI VALAVASVAQ AAPQPNTFYV GAKAGWASFH DGLNQAKYLE 
51 APEATFGFKR NSVTYGVFGG YQITDDFAVE LGYDDFGRAK LRIAETDQKA 
101 RDVAKHTNHG AHLSLKASYP VLDGLDVYAR VGAALIRSDY KVYDHSDPAK 
151 LPQLKRTHST QVSPVFAGGL EYAFMPELAL RVEYQWVNNV GKLKDVDGNR 
201 VDYRPDIGSV TAGLSYRFGQ SVYVPEVVSK TFTLNSDVTF GFDKADLKPA 
251 AQNVLDGIYG EIAQLKSASV AVAGYTDRLG SDAYNLKLSQ RRADTVANYL 
301 VAKGVAQNAI SATGHGEANP VTGNKCDSVK GRKALIACLA DDRRVEIAVX 
351 GNK
G.2.2.4 Match to: gi[49182352 Score: 542
4. gj|49182352 Mass: 37620 Score: 542 Queries matched: 9
OmpA {Pasteurella multocida]
OmpA { P a s te u r e l la  m u lto c ld ^
Nominal mass (Mr): 37620; Calculated pl value: 9.26 
NCBI BLAST search of gi|49182352 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 34%
1 MKKTAIALTI VALAVASVAQ AAPQPNTFYV GAKAGWASFH DGLNQIEYVS 
51 KTSFGSKRNS VTYGVFGGYQ ITDNFAVELG YDDFGRAKVR ANSKTTAFDA 
101 AKHTNHGTHL SLKASYPLLD GLDVYARVGA ALIRSDYKLY APLINKRLSP 
151 HFKITQVSPV FAGGLEYAFl PELTLRVEYQ WVNNVGKFEY ADGQYADFRP 
201 DIGSVTAGLS YRFGQSVYVP EVVSKTFTLN TDVTFGFDKA DLKPAAQNVL 
251 DGIYGEIAQL KSASVAVAGY TDRLGSDAYN LKLSQRRADT VANYLVAKGV 
301 AQNAISATGR GEANPVTGNK CDSVKGRKAL lACLADDRRV EIAVKGNK
G.2.2.5 Match to: gi|17861366 Score: 475
5, gi|17861366 Mass: 37708 Score: 475 Queries matched: 8
OmpA [Pasteureiia muitocida]
OmpA { P a s te u r e l la  m u lto c ld d i  
Nominal mass (Mr): 37708; Calculated pl value: 9.01 
NCBI BLAST search of gij 17861366 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 34%
1 MKKTAIALTI VALAVASVAQ AAPQPNTFYV GAKAGWASFH DGLNQIEYVS 
51 KTSFGSKRNS VTYGVFGGYQ ITDNFAVELG YDDFGRAKVR ANSKTTAFDA 
101 AKHTNHGTHL SLKASYPLLD GLDVYARVGA ALIRSDYKLY APLINKRLSP 
151 HFKITQVSPV FAGGLEYAFl PELTLRVEYQ WVNNVCKFEY ADGQYADFRP
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201 DIGSVTAGLS YRFGQSVYVP EVVSKTFTLN TDVTFGFDKA DLKPAAQNVL 
251 DGIYGEIAQL KSASVAVAGY TDCLGSDAYN LKLSQRRADT VANYLVAKGV
301 AQNAISATGH GEANPVTGNK CDSVKGRKAL lACLADDRRV EIAVKGNK
G.2.2.6 Match to: gi|19881365 Score: 171
6. gj|19881365 Mass: 36785 Score: 171 Queries matched: 3
hemagglutinin antigen [Haemophilus paragaiiinarum]
hemagglutinin antigen [Haemophilus paragaiiinarum]
Nominal mass (Mr): 36785; Calculated pl value: 8.62 
NCBI BLAST search of gi|19881365 against nr 
Taxonomy: Avibacterlum paragaiiinarum
Sequence Coverage: 15%
1 MKKTAIALAI AGLTAASVAQ AAPQANTFYA GAKAGWASFH DGLNQFENSQ 
51 NADGTLRNSV TYGVFGGYQI TDNFAVELGY DDFGRAKSRQ GGETVIKHTN 
101 HGAHLSLKAS YPVLEGLDVY ARVGAALIRS DYKPTKRAAP NQTHEHSLKV 
151 SPVFAGGLEY NLPSLPELAL RVEYQWVNKV GRVEKDGSRV DYTPSIGSVT 
201 AGLSYRFGQS APVVEPKVVA KTFALNSDVT FAFGKANLRP EAQNVLDGIY 
251 GEIAQLKSVQ VDVAGYTDRI GSEAANLKLS QRRADTVANY LVSKGVAQEV 
301 ISSTGYGEAN PVTGAKCDTV KGRKALIACL ADDRRVEISV KGEE
G.2.2.7 Match to: gi|32363216 Score: 168
7. gil323632l6 Mass: 37084 Score: 168 Queries matched: 5
Major outer membrane protein precursor (MOMP) (Outer membrane protein H)
Major outer membrane protein precursor (MOMP) (Outer membrane protein H)
Nominal mass (Mr): 37084; Calculated pl value: 8.96 
NCBI BLAST search of gi|32363216 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Links to retrieve other entries containing this sequence from NCBI Entrez:
gi|2853238 from P a s te u r e l la  m u lto c id a
gi|92918682 from P a s te u r e l la  m u lto c id a
gi|92918684 from P a s te u r e l la  m u lto c id a
gi|92918686 from P a s te u r e l la  m u lto c id a
gi|92918688 from P a s te u r e l la  m u lto c id a
gi| 124262427 from P a s te u r e l la  m u lto c id a
Sequence Coverage: 23%
1 MKKTIVALAV AAVAATSANA ATVYNQDGTK VDVNGSVRLI LKKEKNERGD 
51 LVDNGSRVSF KASHDLGEGL SALAYAELRF SKNEKVEVKD AQNQQVVRKY 
101 EVERIGNDVH VKRLYAGFAY EGLGTLTFGN QLTIGDDVGV SDYTYFLGGI 
151 NNLLSSGEKA INFKSAEFNG FTFGGAYVFS ADADKQAPRD GRGFVVAGLY 
201 NRKMGDVGFA LEAGYSQKYV TAAAKQEKEK AFMVGTELSY AGLALGVDYA 
251 QSKVTNVEGK KRALEVGLNY DINDKAKVYT DLIWAKEGPK GATTRDRSII
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301 LGAGYKLHKQ VETFVEGGWG REKDANGVTT KDNKVGVGLR VHF
G.2.2.8 Match to: gi|75431565 Score: 77
8. gj|7543l565 Mass: 33452 Score: 77 Queries matched: 1
outer membrane protein and related peptidogiycan-associated (iipo)proteins [Actinobaciiius succinog
outer membrane protein and related peptidogiycan-associated (llpo)proteins [Actinobaciiius 
succinog
Nominal mass (Mr): 33452; Calculated pl value: 6.53 
NCBI BLAST search of gi|75431565 against nr 
Taxonomy: Actinobaciiius succinogenes 130Z
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|74276276 from Actinobaciiius succinogenes 130Z
Sequence Coverage: 4%
1 MKKTAIALAI AGLAAASVAQ AAPQENTFYA GARVGWSAMH HGVDRIADQF 
51 VTDGGLNRNS VTYGVFGGYQ ILNQNNFGLA AELGYDFFGK TKADAAGYHA 
101 AHGASLALKP SYEIYPDLDV YGKVGVALVR NMYKAETLSA SGDAEKFNKT 
151 KASLILGAGV EYAILPELAA RLEYQWLSKA GNLDSALEDA GYNGTNARYS 
201 PDIHSVTAGL SYRFGQGAAP VAAPEVVNKT FTLNSDVTFG FNKSTLKPEA 
251 ASTLDGIYSE lAQVSSPAVA VNGYADRIGK DAANLKLSQR RAETVANYLV 
301 SKGVDSNAIT ADRLRFS
G.2.2.9 Match to: gi|23124869 Score: 72
9. gj|23 124869 Mass: 66430 Score: 72 Queries matched: 1
COG2199: FOG: GGDEF domain [Nostoc punctiforme PCC 73102]
COG2199: FOG: GGDEF domain [Nostoc punctiforme PCC 73102]
Nominal mass (Mr): 66430; Calculated pl value: 7.59 
NCBI BLAST search of gi|23124869 against nr 
Taxonomy: Nostoc punctiforme PCC 73102
Sequence Coverage: 2%
1 MQQSFLGSIR TRLIASFLIV ALIPLLLLAS INKQTTEKAL TDNARQALSA 
51 AAKETTNRID AFIDGNLNAV RVEAILPGLA RYLSLTPKQR DDSPEIQLAT 
101 ETLIRLSRKD MLNILSYALL DLNGKNILDT HTSNIGEDES VQDYFKNPLK 
151 TGFSFVSSMK RSPIISDLVT LFFSSPVRNA KGDIVGVLRV SYNATVVQQL 
201 VTRETERAGA KSFAILLDEN NIYLAHSTAS ELLFKSIVPL PADVVTQLQQ 
251 ERRLPNYPVK ELATNESKLK QALDNKQSDL ITSLSATGNQ VNLIAIARLK 
301 YKPWSVLFAQ PLTVALAPVE KQISDAMFLF AIIASVVTII AFAIGQVLTK 
351 PIIYLTNIVF QFTAGHLDIR AKISSKDEIG QLAKSFNNMA LQLQTSLETL 
401 EQRVQERTAE LVIAKEKAED ANHKLEQLVN LDGLTQVANR RCFDGRLQEE 
451 WKCLAREQRP LSLILLDVDK FKLYNDYYGH LGGDDCLITI AQTMQQVVHR 
501 PADLVARYGG EEFSVLLPNT DLLGAIKVAQ SIQQAICDRA IPHTQSDIKD 
551IVTLSLGITS VIPTCDIKPD TIIASADKAL YSAKKKGRDR YCTHLDI
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G.2.2.10 Match to: gi|32030015 Score: 55
10. gi|32030Q15 Score: 55 Queries matched: 1
COG2885: Outer membrane protein and reiated peptidogiycan-associated (iipo)proteins [Haemophilus somnus 2336] 
COG2885: Outer membrane protein and related peptidogiycan-associated (lipo)proteins 
[Haemophilus somnus 2336]
Nominal mass (Mr): 27412; Calculated pl value: 9.48 
NCBI BLAST search of gi|32030015 against nr 
Taxonomy: Haemophilus somnus 2336
Sequence Coverage: 5%
1 MKKTIIALSI AGLSLSVQAA PQSKYVLCRC ESRLGIFPDG LNQFENSTEK 
51 KGTVRNSVAY GIFGGYQITD HVAVELGSEY FGQAKGRKDK KEAKHTAQGM 
101 QLGLKASYPV LEGLDIYGRV GAALIRSNYL NVKNFENSAD GVKNTLKVSP 
151 VFAAGVEYSL PSLPELALRL EYQWVKGVGK ARKNDGKRFD YTPSIGAVTL 
201 GLSYRFGQKP VMAPEVVNKV FSLNSDVNFA FAKDTLKPEA QQTFGRCLW
G.2.2.11 Match to: gi|1332435 Score: 54
11. gj|1332435 Mass: 35003 Score: 54 Queries matched: 1
outer membrane protein [Aeromonas saimonicida]
outer membrane protein [Aeromonas saimonicida]
Nominal mass (Mr): 35003; Calculated pl value: 5.08 
NCBI BLAST search of gi| 1332435 against nr 
Taxonomy: Aeromonas saimonicida
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|1588799 from Aeromonas saimonicida
Sequence Coverage: 2%
1 MKMKMAPAL! ALAIAAMGTS TAQAADDWYT GIGAGWAYGH DLNDFGKDAD 
51 KDATALSLFG GYNFNDYYAA ELGYLYAGKA GVDFKTQGAT LSGLARLPLN 
101 DIFSVFAEGG AYFNHVNGNG NSDNGTAPLA GLGLTAKLSD LIDVQARYRY 
151 MWNLGDEQKT WETNMSVATL ELVMHPNRTS YVAPVAAPAP EPVPEPVVVD 
201 KSFALSSDVL FAFGKSTLKP EGVAALNTLY HQNVDVQPKD GSAVVVGYTD 
251 RIGSDAYNLK LSEARARTVA DFLVGKGLPA GKVAIEGRGE ASPVTGTQCD 
301 GIKAKAQLIA CLAPDRRVEV RVTGIQEVTQ
G.3 Mass spectrometry results used to determine the peak list for the 50kDa 
OMP band.
Significant hits: gi|2853240 outer membrane protein; OmpH [Pasteurella muitociddi 
gi12853242 outer membrane protein; OmpH [Pasteurella muitocidd] 
gi|12721Q89 unknown [Pasteurella m u l t o c i d a muitocida str. Pm70] 
gi|16751299 OmpH [Pasteureiia muitociddi
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gl|75431565 outer membrane protein and related peptidogiycan-associated (lipo)proteins [Actinobaciiius
succinog
gi|72121591 hypothetical protein Reut_B4426 [Raistonia eutropha JMP134] 
gi|77389887 conserved hypothetical protein [Rhodobacter sphaeroides 2.4.1] 
gi|78696479 hypotheticai protein BradDRAFT_3909 [Bradyrhlzobium sp. BTAil]
Probability Based Mowse Score
Ions score is -10*Log(P), where P is the probability that the observed match is a random event. 
Individual ions scores > 52 indicate identity or extensive homology (p<0.05).
Protein scores are derived from ions scores as a non-probabilistic basis for ranking protein hits.
(^25  4
h 20 Ii
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P rob ab ility  Based Mowse Score
G.3.1 Peptide Summary Report for 50 kDa OMP
1. gi|2853240 Mass: 35143 Score: 218 Queries matched: 6
outer membrane protein; OmpH {Pasteurella muitocidd
2. ei|2853242 Mass: 34935 Score: 190 Queries matched: 5
outer membrane protein; OmpH [Pasteurella multocidâ^
3. gi|12721089 Mass: 38122 Score: 149 Queries matched: 3
unknown [Pasteurella multocida multocida str. Pm70]
4. gi|16751299 Mass: 34993 Score: 123 Queries matched: 4
OmpH [Pasteureiia muitocida]
5. ai|75431565 Mass: 33452 Score: 69 Queries matched: 1
outer membrane protein and related peptidogiycan-associated (lipo)proteins [Actinobaciiius succinog
6. gi|72]2159l Mass: 13914 Score: 55 Queries matched: 1
hypothetical protein Reut_B4426 [Raistonia eutropha JMP134]
7. gi|77389887 Mass: 37427 Score: 55 Queries matched: 1
conserved hypothetical protein [Rhodobacter sphaeroides 2.4.1]
8. gi]78696479 Mass: 20528 Score: 53 Queries matched: 1
hypothetical protein BradDRAFT_3909 [Bradyrhlzobium sp, BTAil]
G.3.2 Amin acid sequence coverage for 50 kDa OMP
G.3,2.1 Match to: gi|2853240 Score: 218
1. gi|2853240 Mass: 35143 Score: 218 Queries matched: 6
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outer membrane protein; OmpH [Pasteurella muitocidâ] 
outer membrane protein; OmpH [Pasteurella multocldé\
Nominal mass (Mr): 35143; Calculated pl value: 8.84 
NCBI BLAST search of gl|2853240 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 24%
1 ATVYNQDGTK VDVNGSVRLI LKKEKNERGD LVDNGSRVSF KASHDLGEGL 
51 SALAYAELRF STKEKVEVKD TQNPPKVVRT YEVEKIGNDV HVKRLYAGFA 
101 YEGLGTLTFG NQLTIGDDVG VSDYTYFLGG INNLLSSGEK AINFKSAEFN 
151 GFTFGGAYVF SADADKQAPR DGRGFWAGL YNRKMGDVGF ALEAGYSQKY 
201 VTVAKQEKEK AFMVGTELSY AGLALGVDYA QSKVTNVDGK KRALEVGLNY 
251 DINDKAKVYT DLIWAKKGPK GATTRDRSII LGAGYKLHKQ VETFVEGGWG 
301 REKDANGVTT KDNVVGVGLR VHF
G.3.2.2 Match to: gi|2853242 Score: 190
2. gi|2853242 Mass: 34935 Score: 190 Queries matched: 5
outer membrane protein; OmpH [Pasteurella muitocidd]
outer membrane protein; OmpH [Pasteurella multocidd[
Nominal mass (Mr): 34935; Calculated pl value: 9.17 
NCBI BLAST search of gi|2853242 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 22%
1 ATVYNQDGTK VDVNGSVRLI LKKEKDKRGD LVDNGSRVSF KASHDLGEGL 
51 SALAYAELRF STKEEVEVTQ NQQVVRKYKV ERIGNDVHVK RLYAGFAYEG 
101 LGTLTFGNQL TIGDDVGVSD YTYFLGGINN LLSSGEKAIN FKSAEFNGFT 
151 FGGAYVFSAD ADKQAARDGR GFVVAGLYNR KMGDVGFALE AGYSQKYVTE 
201 TAKQEKEKAF MVGTELSYAG LALGVDYAQS KVTNVDGKKR ALEVGLNYDL 
251 NDKAKVYTDL IWAKKGPKGA TTRDRAIILG AGYKLHKQVE TFVEGGWGRT 
301 KNAAGVTTKD NKVGVGLRVH F
G.3.2.3 Match to: gi|12721089 Score: 149
3. ei| 12721089 Mass: 38122 Score: 149 Queries matched: 3
unknown [Pasteurella muitocida subsp. multocida str. Pm70]
unknown [Pasteurella multocida subsp. multocida str. Pm70]
Nominal mass (Mr): 38122; Calculated pl value: 9.09
NCBI BLAST search of gi|12721089 against nr
Taxonomy: P a s te u r e l la  m u lto c id a  s u b s p .  multocida str. Pm70
Links to retrieve other entries containing this sequence from NCBI Entrez:
gi|12721089 from P a s te u r e l la  m u lto c id a  s u b s p .  multocida str. Pm70
Sequence Coverage: 12%
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1 MKKTAIALTI AALAAASVAQ AAPQPNTFYV GAKAGWASFH DGLNQAKYLE 
51 APEATFGFKR NSVTYGVFGG YQITDNFAVE LGYDDFGRAK LRMAEKDQKA 
101 KDAAKHTNHG AHLSLKASYP VLDGLDIYAR VGAALIRSDY KVYDHSDPAK 
151 LPQFKRTHST QVSPVFAGGL EYAFMPELAL RVEYQWVNNV GKVKDVLGER 
201 VDYRPDIGSV TAGLSYRFGQ SVYVPEVVSK TFTLNSDVTF GFDKADLKPA 
251 AQNVLDGIYG EIAQLKSASV AVAGYTDRLG SDAYNLKLSQ RRADTVANYL 
301 VAKGVAQNAI SATGHGEANP VTGNKCDSVK GRKALIACLA DDRRVEIAVK 
351 GNK
G.3.2.4 Match to: gi|16751299 Score: 123
4. eij 16751299 Mass: 34993 Score: 123 Queries matched: 4
OmpH [Pasteurella muitocida]
OmpH [Pasteurella multoclda\
Nominal mass (Mr): 34993; Calculated pl value: 9.17 
NCBI BLAST search of gi| 16751299 against nr 
Taxonomy: P a s te u r e l la  m u lto c id a
Sequence Coverage: 18%
1 SNLANAATVY NQDGTKVDVN GSVRLILKKE KNERGDLVDN GSRVSFKASH 
51 DLGEGLSALA YAELRFSKNE KVEVKDAQNQ QVVRKYEVER IGNDVHVKRL 
101 YAGFAYEGLG TLTFGNQLTI GDDVGVSDYT YFLGGINNLL SSGEKAINFK 
151 SAEFNGFTFG GAYVFSADAD KQAPRDGRGF VVAGLYNRKM GDVGFALEAG 
201 YSQKYVTAAA KQEKEKAFMV GTELSYAGLA LGVDYHNLKS NVEGKNVLLK 
251 WLNLCIMTSK VNCLFGKKGQ RALQNRLYVG GSNLQHEPCE GLAKKFMLHK 
301 NKWVVRPFIV IKTGTCL
G.3.2.5 Match to: gi|75431565 Score: 69
5. gil7543l565 Mass: 33452 Score: 69 Queries matched: 1
outer membrane protein and related peptidogiycan-associated (lipo)protelns [Actinobaciiius succinog
outer membrane protein and related peptidogiycan-associated (llpo)proteins [Actinobaciiius 
succinog
Nominal mass (Mr): 33452; Calculated pl value: 6.53 
NCBI BLAST search of gi|75431565 against nr 
Taxonomy: Actinobaciiius succinogenes 130Z
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|74276276 from Actinobaciiius succinogenes 130Z
Sequence Coverage: 4%
1 MKKTAIALAI AGLAAASVAQ AAPQENTFYA GARVGWSAMH HGVDRIADQF 
51 VTDGGLNRNS VTYGVFGGYQ ILNQNNFGLA AELGYDFFGK TKADAAGYHA 
101 AHGASLALKP SYEIYPDLDV YGKVGVALVR NMYKAETLSA SGDAEKFNKT
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151 KASLILGAGV EYAILPELAA RLEYQWLSKA GNLDSALEDA GYNGTNARYS 
201 PDIHSVTAGL SYRFGQGAAP VAAPEVVNKT FTLNSDVTFG FNKSTLKPEA 
251 ASTLDGIYSE lAQVSSPAVA VNGYADRIGK DAANLKLSQR RAETVANYLV 
301 SKGVDSNAIT ADRLRFS
G.3.2.6 Match to; gi|72121591 Score: 55
6. gj|7212l591 Mass: 13914 Score: 55 Queries matched: 1
hypothetical protein Reut_B4426 [Raistonia eutropha JMP134] 
hypothetical protein Reut„B4426 [Raistonia eutropha JMP134]
Nominal mass (Mr): 13914; Calculated pl value: 8.39 
NCBI BLAST search of gi|72121591 against nr 
Taxonomy: Raistonia eutropha JMP134
Links to retrieve other entries containing this sequence from NCBI Entrez; 
gi|72121591 from Raistonia eutropha JMP134
Sequence Coverage: 6%
1 MVRNRSFPYN GLAPSFCHAE SLQDHSGRFI VSAIAVVPCL LCGELARRWS 
51 DRHDHVLEGR lYRCARCGGR FSVTGEAYGE IIHGNWDTTE LMTAVRQRIA 
101 TGELPRIEGI AGLPSVIAVG RQAS
G.3.2.7 Match to: gi|77389887 Score: 55
7. gi|77389887 Mass: 37427 Score: 55 Queries matched: 1
conserved hypothetical protein [Rhodobacter sphaeroides 2.4.1] 
conserved hypothetical protein [Rhodobacter sphaeroides 2.4.1]
Nominal mass (Mr): 37427; Calculated pl value: 6.02 
NCBI BLAST search of gi|77389887 against nr 
Taxonomy: Rhodobacter sphaeroides 2.4.1
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|77389887 from Rhodobacter sphaeroides 2.4.1
Sequence Coverage: 2%
1 MRIDNATPWP ATFTMAFDAA GHEQVVLVTK ASFALPRGTG PCQPTEPLPL 
51 lESDLFGADP AADAPVQEYD FAPHKPFCDV LLHGRAHAPE GRPVTELPVG 
101 LRLGGWSKRL TVRGARIWLR AAAGWRVSDP RPFTSQPIGY DHAYGGTDPD 
151 PGGGGRAAVF EENPAGLGFY PLRPDRESAP LPHTAEAGAD ATDPRGGLRP 
201 MALGPVGRTW LPRRRHAGTY DAAYFESRTP FLPLDFDPRY FQAAAEDQQI 
251 PYPKGGEPVE LVNLSPRGRI ATWLPRLQIL ATFERRSGRL TQRIANLDTV 
301 LFLPEEEVVT LTFRTRITAE RDIFEFARVL VSARQEATDG
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G.3.2.8 Match to: gi|78696479 Score: 53
8. gi|78696479 Mass; 20528 Score: 53 Queries matched: 1
hypothetical protein BradDRAFT_3909 [Bradyrhizobium sp. BTAil]
hypothetical protein BradDRAFT_3909 [Bradyrhizobium sp. BTA11]
Nominal mass (Mr): 20528; Calculated pl value: 7.88 
NCBI BLAST search of gi|78696479 against nr
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gl|78516057 from Bradyrhizobium sp. BTAil
Sequence Coverage: 3%
1 MMSLLGFDAI GRLATGQLPR SAGVNTLFAA TTSAIALSGR AASFQLVLSV 
51 PVANVNCAGL AVSTGITLPA LQAGWLTSGL SARYSFGAAA SRGEYSVAGV 
101 SAASLGNMVA AGRSYDVGAP PAVFVGALAG QSAAFQLGGY DVAYGRGFES 
151 WYPLAAVAGE WQGSASATQS WLPAPAAIPS WLDGAAPSSR WDPTSSPLPP 
201 WKSI
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